Document:

Credit Agreement dated April 18, 2006

 Exhibit 10.25 
  

 CREDIT AGREEMENT 
 Among 
 AMERICAN PHARMACEUTICAL PARTNERS,
INC., 
 to become known as Abraxis BioScience, Inc., 
 VARIOUS LENDERS 
 FROM TIME
TO TIME PARTY HERETO 
 FIFTH THIRD
BANK, an Ohio banking corporation, 
 as Agent and L/C Issuer, 
 and 
 WACHOVIA BANK, NATIONAL
ASSOCIATION, 
 as Documentation Agent, 
 and 
 HARRIS NESBITT FINANCING, INC., 

as Syndication Agent 
 DATED
AS OF APRIL 18, 2006 
  

 FIFTH THIRD BANK, AN OHIO BANKING CORPORATION, AS BOOKRUNNER
AND LEAD ARRANGER 

 TABLE OF CONTENTS 
  

					
	 SECTION
	  	 HEADING
	  	PAGE
	SECTION 1.	  	DEFINITIONS; INTERPRETATION	  	1
	 Section 1.1.
	  	Definitions	  	1
	 Section 1.2.
	  	Interpretation	  	14
	 Section 1.3.
	  	Change in Accounting Principles	  	15
			
	SECTION 2.	  	THE CREDIT FACILITIES	  	15
	 Section 2.1.
	  	Commitments	  	15
	 Section 2.2.
	  	Letters of Credit	  	15
	 Section 2.3.
	  	Applicable Interest Rates	  	18
	 Section 2.4.
	  	Manner of Borrowing Loans and Designating Applicable Interest Rates	  	19
	 Section 2.5.
	  	Minimum Borrowing Amounts; Maximum Eurodollar Loans	  	21
	 Section 2.6.
	  	Maturity of Loans	  	21
	 Section 2.7.
	  	Prepayments	  	21
	 Section 2.8.
	  	Place and Application of Payments	  	22
	 Section 2.9.
	  	Commitment Terminations	  	23
	 Section 2.10.
	  	The Notes	  	23
	 Section 2.11.
	  	Fees	  	23
	 Section 2.12.
	  	Swing Loans	  	24
			
	SECTION 3.	  	CONDITIONS PRECEDENT	  	26
	 Section 3.1.
	  	All Credit Events	  	26
	 Section 3.2.
	  	Initial Credit Event	  	26
			
	SECTION 4.	  	THE GUARANTIES	  	28
	 Section 4.1.
	  	Guaranties	  	28
	 Section 4.2.
	  	Further Assurances	  	28
	 Section 4.3.
	  	Guarantor Release	  	28
	 Section 4.4.
	  	Exclusion of Foreign Subsidiaries	  	29
			
	SECTION 5.	  	REPRESENTATIONS AND WARRANTIES	  	29
	 Section 5.1.
	  	Organization and Qualification	  	29
	 Section 5.2.
	  	Authority and Enforceability	  	29
	 Section 5.3.
	  	Financial Reports	  	29
	 Section 5.4.
	  	No Material Adverse Effect	  	30
	 Section 5.5.
	  	Litigation and other Controversies	  	30
	 Section 5.6.
	  	True and Complete Disclosure	  	30
	 Section 5.7.
	  	Use of Proceeds; Margin Stock	  	30
	 Section 5.8.
	  	Taxes	  	30
	 Section 5.9.
	  	ERISA	  	30

  

 -i- 

					
	 Section 5.10.
	  	Material Subsidiaries	  	31
	 Section 5.11.
	  	Compliance with Laws	  	31
	 Section 5.12.
	  	Environmental Matters	  	31
	 Section 5.13.
	  	Investment Company; Public Utility Holding Company	  	32
	 Section 5.14.
	  	Intellectual Property	  	32
	 Section 5.15.
	  	Good Title	  	32
	 Section 5.16.
	  	Labor Relations	  	32
	 Section 5.17.
	  	Indebtedness	  	32
	 Section 5.18.
	  	Capitalization	  	32
	 Section 5.19.
	  	Other Agreements	  	33
	 Section 5.20.
	  	Governmental Authority and Licensing	  	33
	 Section 5.21.
	  	Approvals	  	33
	 Section 5.22.
	  	Affiliate Transactions	  	33
	 Section 5.23.
	  	Solvency	  	33
	 Section 5.24.
	  	Foreign Assets Control Regulations and Anti-Money Laundering	  	33
			
	SECTION 6.	  	COVENANTS	  	34
	 Section 6.1.
	  	Information Covenants	  	34
	 Section 6.2.
	  	Inspections	  	36
	 Section 6.3.
	  	Maintenance of Property, Insurance, Environmental Matters, etc.	  	36
	 Section 6.4.
	  	Preservation of Existence	  	37
	 Section 6.5.
	  	Compliance with Laws	  	37
	 Section 6.6.
	  	ERISA	  	37
	 Section 6.7.
	  	Payment of Taxes	  	38
	 Section 6.8.
	  	Contracts With Affiliates	  	38
	 Section 6.9.
	  	No Changes in Fiscal Year	  	38
	 Section 6.10.
	  	Change in the Nature of Business	  	38
	 Section 6.11.
	  	Indebtedness	  	38
	 Section 6.12.
	  	Liens	  	39
	 Section 6.13.
	  	Consolidation, Merger, Sale of Assets, etc.	  	40
	 Section 6.14.
	  	Advances, Investments and Loans	  	41
	 Section 6.15.
	  	Limitation on Restrictions	  	43
	 Section 6.16.
	  	Notice of the Creation of Subsidiaries	  	43
	 Section 6.17.
	  	Dividends and Other Restricted Payments	  	43
	 Section 6.18.
	  	Financial Covenants	  	43
	 Section 6.19.
	  	Limitation on Non-Material Subsidiaries	  	43
			
	SECTION 7.	  	EVENTS OF DEFAULT AND REMEDIES	  	44
	 Section 7.1.
	  	Events of Default	  	44
	 Section 7.2.
	  	Non-Bankruptcy Defaults	  	46
	 Section 7.3.
	  	Bankruptcy Defaults	  	46
	 Section 7.4.
	  	Collateral for Undrawn Letters of Credit	  	46
	 Section 7.5.
	  	Notice of Default	  	47

  

 -ii- 

					
	 Section 7.6.
	  	Expenses	  	47
			
	SECTION 8.	  	CHANGE IN CIRCUMSTANCES AND CONTINGENCIES	  	47
	 Section 8.1.
	  	Funding Indemnity	  	47
	 Section 8.2.
	  	Illegality	  	48
	 Section 8.3.
	  	Unavailability of Deposits or Inability to Ascertain, or Inadequacy of, LIBOR	  	48
	 Section 8.4.
	  	Yield Protection	  	49
	 Section 8.5.
	  	Substitution of Lenders	  	50
	 Section 8.6.
	  	Lending Offices	  	50
	 Section 8.7.
	  	Discretion of Lender as to Manner of Funding	  	51
			
	SECTION 9.	  	THE AGENT	  	51
	 Section 9.1.
	  	Appointment and Authorization of Agent	  	51
	 Section 9.2.
	  	Agent and its Affiliates	  	51
	 Section 9.3.
	  	Action by Agent	  	51
	 Section 9.4.
	  	Consultation with Experts	  	52
	 Section 9.5.
	  	Liability of Agent; Credit Decision	  	52
	 Section 9.6.
	  	Indemnity	  	52
	 Section 9.7.
	  	Resignation of Agent and Successor Agent	  	53
	 Section 9.8.
	  	L/C Issuer	  	54
	 Section 9.9.
	  	Designation of Additional Agents	  	54
			
	SECTION 10.	  	MISCELLANEOUS	  	54
	 Section 10.1.
	  	Withholding Taxes	  	54
	 Section 10.2.
	  	No Waiver, Cumulative Remedies	  	55
	 Section 10.3.
	  	Non-Business Days	  	55
	 Section 10.4.
	  	Documentary Taxes	  	56
	 Section 10.5.
	  	Survival of Representations	  	56
	 Section 10.6.
	  	Survival of Indemnities	  	56
	 Section 10.7.
	  	Sharing of Set-Off	  	56
	 Section 10.8.
	  	Notices	  	56
	 Section 10.9.
	  	Counterparts	  	57
	 Section 10.10.
	  	Successors and Assigns; Assignments and Participations	  	57
	 Section 10.11.
	  	Amendments	  	60
	 Section 10.12.
	  	Headings	  	60
	 Section 10.13.
	  	Costs and Expenses; Indemnification	  	60
	 Section 10.14.
	  	Set-off	  	61
	 Section 10.15.
	  	Entire Agreement	  	61
	 Section 10.16.
	  	Governing Law	  	61
	 Section 10.17.
	  	Severability of Provisions	  	61
	 Section 10.18.
	  	Excess Interest	  	61
	 Section 10.19.
	  	Lender’s Obligations Several	  	62
	 Section 10.20.
	  	Submission to Jurisdiction; Waiver of Jury Trial	  	62

  

 -iii- 

					
	 Section 10.21.
	  	USA Patriot Act	  	62
	 Section 10.22.
	  	Confidentiality	  	62
		
	 Signature Page
	  	S-1

  

					
	 EXHIBIT A
	  	—  	  	 Notice of Payment Request

	 EXHIBIT B
	  	—  	  	 Notice of Borrowing

	 EXHIBIT C
	  	—  	  	 Notice of Continuation/Conversion

	 EXHIBIT D-1
	  	—  	  	 Revolving Note

	 EXHIBIT D-2
	  	—  	  	 Swing Note

	 EXHIBIT E
	  	—  	  	 Compliance Certificate

	 EXHIBIT F
	  	—  	  	 Assignment and Assumption

	 EXHIBIT G
	  	—  	  	 Subsidiary Guaranty Agreement

	 SCHEDULE 1
	  	—  	  	 Commitments

	 SCHEDULE 5.10
	  	—  	  	 Material Subsidiaries

	 SCHEDULE 5.17
	  	—  	  	 Existing Indebtedness

	 SCHEDULE 5.18
	  	—  	  	 Borrower Capitalization

	 SCHEDULE 6.12
	  	—  	  	 Existing Liens

	 SCHEDULE 6.14
	  	—  	  	 Existing Investments

  

 -iv- 

 CREDIT AGREEMENT 
 This Credit Agreement is entered into as of April 18, 2006, by and among AMERICAN PHARMACEUTICAL
PARTNERS, INC., a Delaware corporation to become known as Abraxis BioScience, Inc. (the “Borrower”), the various institutions from time to time party to this Agreement, as Lenders, FIFTH
THIRD BANK, an Ohio banking corporation, as Agent and L/C Issuer, WACHOVIA BANK, NATIONAL ASSOCIATION, as Documentation Agent, and HARRIS
NESBITT FINANCING, INC., as Syndication Agent. 
 The Borrower has requested, and the Lenders
have agreed to extend, certain credit facilities on the terms and conditions of this Agreement. In consideration of the mutual agreements set forth in this Agreement, the parties to this Agreement agree as follows: 
  

	SECTION 1.	DEFINITIONS; INTERPRETATION. 

 Section 1.1. Definitions. The following terms when used herein shall have the following meanings: 
 “ABI” means American BioScience, Inc., a California corporation. 
 “ABI Merger” means the merger
of ABI with and into the Borrower pursuant to the terms of the Merger Agreement. 
 “Acquired Business” means: (a) any Person,
a controlling interest in the capital stock or other equity interests of which is acquired after the date hereof by the Borrower or any of its Subsidiaries, (b) any assets constituting all or a discrete business or operating unit of the seller
acquired after the date hereof by the Borrower or any of its Subsidiaries or (c) any product or product lines acquired after the date hereof by the Borrower or any of its Subsidiaries, in each case pursuant to a Permitted Acquisition in
accordance with the terms of this Agreement. 
 “Adjusted LIBOR” means, for any Borrowing of Eurodollar Loans, a rate per
annum equal to the quotient of (i) LIBOR, divided by (ii) one minus the Reserve Percentage. 
 “Affected Lender”
is defined in Section 8.5 hereof. 
 “Agent” means Fifth Third Bank, an Ohio banking corporation, as contractual
representative for itself and the other Lenders and any successor pursuant to Section 9.7 hereof. 
 “Agent’s Quoted
Rate” is defined in Section 2.12 hereof. 
 “Affiliate” means any Person directly or indirectly controlling or
controlled by, or under direct or indirect common control with, another Person. A Person shall be deemed to control another Person for the purposes of this definition if such Person possesses, directly or indirectly, the power to direct, or cause
the direction of, the management and policies of the other Person, whether through the ownership of voting securities, common directors, trustees or officers, by contract or otherwise; provided that, in any event for purposes of this
definition, any Person that 

 
owns, directly or indirectly, 20% or more of the securities having the ordinary voting power for the election of directors or governing body of a corporation
or 20% or more of the partnership or other ownership interest of any other Person (other than as a limited partner of such other Person) will be deemed to control such corporation or other Person. 
 “Agreement” means this Credit Agreement, as the same may be amended, modified, restated or supplemented from time to time pursuant to
the terms hereof. 
 “Applicable Margin” means, with respect to Loans, Reimbursement Obligations, and the commitment fees
and letter of credit fees payable under Section 2.11 hereof, until the first Pricing Date, the rates per annum shown opposite Level I below, and thereafter from one Pricing Date to the next the Applicable Margin means the rates per annum
determined in accordance with the following schedule: 
  

												
	 LEVEL
	  	 LEVERAGE RATIO FOR SUCH
PRICING DATE
	  	APPLICABLE MARGIN FOR
BASE RATE
LOANS AND
REIMBURSEMENT
OBLIGATIONS SHALL BE:	 	 	APPLICABLE MARGIN FOR
EURODOLLAR LOANS AND
LETTER OF CREDIT
FEE
SHALL BE:	 	 	APPLICABLE
MARGIN
FOR COMMITMENT FEE
SHALL BE:	 
	 I
	  	Less than 1.00 to 1.0	  	-.50	%	 	.75	%	 	.20	%
					
	 II
	  	Less than 1.50 to 1.0, but greater than or equal to 1.00 to 1.0	  	-.50	%	 	.875	%	 	.20	%
					
	 III
	  	Less than 2.00 to 1.0, but greater than or equal to 1.50 to 1.0	  	0.00	%	 	1.00	%	 	.20	%
					
	 IV
	  	Less than 2.50 to 1.0, but greater than or equal to 2.00 to 1.0	  	0.00	%	 	1.375	%	 	.25	%
					
	 V
	  	Greater than or equal to 2.50 to 1.0	  	0.00	%	 	1.625	%	 	.30	%

 For purposes hereof, the term “Pricing Date” means, for any fiscal quarter of the Borrower ending
on or after June 30, 2006, the date on which the Agent is in receipt of the Borrower’s financial statements (and, in the case of the year-end financial statements, audit report) for the most recently ended fiscal quarter, pursuant to
Section 6.1 hereof. The Applicable Margin shall be established based on the Leverage Ratio for the most recently completed fiscal quarter and the Applicable Margin established on a Pricing Date shall remain in effect until the next Pricing
Date. If the Borrower has not delivered its financial statements by the date such financial statements (and, in the case of the year-end financial statements, audit report) are required to be delivered under Section 6.1 hereof, from the due
date of such financial statements (and, if applicable, audit report) until such financial statements (and, if applicable, audit report) are delivered, the Applicable Margin shall be raised one level from the existing Applicable Margin level. If the
Borrower subsequently delivers such financial statements before the next Pricing Date, the Applicable Margin established by such late delivered financial statements shall take effect from the date of delivery until the next Pricing Date. In all
other circumstances, the 

  

 -2- 

 
Applicable Margin established by such financial statements shall be in effect from the Pricing Date that occurs after the end of the fiscal quarter covered
by such financial statements until the next Pricing Date. Each determination of the Applicable Margin made by the Agent in accordance with the foregoing shall be presumptively correct absent manifest error. 
 “Application” is defined in Section 2.2(b) hereof. 
 “Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a
Lender. 
 “Assignment and Assumption” means an assignment and assumption entered into by a Lender and an Eligible Assignee
(with the consent of any party whose consent is required by Section 10.10), and accepted by the Agent, in substantially the form of Exhibit F or any other form approved by the Agent. 
 “Authorized Representative” means those persons shown on the list of officers provided by the Borrower pursuant to Section 3.2
hereof or on any update of any such list provided by the Borrower to the Agent, or any further or different officers of the Borrower so named by any Authorized Representative of the Borrower in a written notice to the Agent. 
 “Auto-Extension Letter of Credit” is defined in Section 2.2(g) hereof. 
 “Base Rate” means for any day the greater of: (i) the rate of interest announced by the Agent from time to time as its “prime
rate” as in effect on such day, with any change in the Base Rate resulting from a change in said prime rate to be effective as of the date of the relevant change in said prime rate (it being acknowledged that such rate may not be the
Agent’s best or lowest rate) and (ii) the sum of (x) the Federal Funds Rate, plus (y) 1/2 of 1%. 
 “Base
Rate Loan” means a Loan bearing interest at a rate specified in Section 2.3(a) hereof. 
 “Borrower” is
defined in the introductory paragraph of this Agreement. 
 “Borrowing” means the total of Loans of a single type advanced,
continued for an additional Interest Period, or converted from a different type into such type by the Lenders on a single date and, in the case of Eurodollar Loans, for a single Interest Period. Borrowings of Loans are made and maintained ratably
from each of the Lenders according to their Percentages. A Borrowing is “advanced” on the day Lenders advance funds comprising such Borrowing to the Borrower, is “continued” on the date a new Interest Period for the
same type of Loans commences for such Borrowing, and is “converted” when such Borrowing is changed from one type of Loans to the other, all as requested by the Borrower pursuant to Section 2.4(a) hereof. Borrowings of Swing
Loans are made by the Agent in accordance with the procedures set forth in Section 2.12 hereof. 
  

 -3- 

 “Business Day” means any day (other than a Saturday or Sunday) on which banks are not
authorized or required to close in Cincinnati, Ohio and Chicago, Illinois and, if the applicable Business Day relates to the advance or continuation of, or conversion into, or payment of a Eurodollar Loan, on which banks are dealing in
U.S. Dollar deposits in the interbank eurodollar market in London, England. 
 “Capital Lease” means any lease of
Property which in accordance with GAAP is required to be capitalized on the balance sheet of the lessee. 
 “Capitalized Lease
Obligation” means, for any Person, the amount of the liability shown on the balance sheet of such Person in respect of a Capital Lease determined in accordance with GAAP. 
 “Cash Equivalents” shall mean, as to any Person, Cash Equivalents, as such term is defined in the Borrower’s temporary investment
policy as approved by the Borrower’s board of directors from time to time, which temporary investment policy and any changes thereto approved by the Borrower’s board of directors shall be delivered to the Agent. 
 “CERCLA” means the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended by the Superfund Amendments
and Reauthorization Act of 1986, 42 U.S.C. §§9601 et seq., and any future amendments. 
 “Change of
Control” means either of the following, after the occurrence of the ABI Merger (a) the acquisition by any “person” or “group” (as such terms are used in sections 13(d) and 14(d) of the Securities
Exchange Act of 1934, as amended) at any time of beneficial ownership of 50% or more of the outstanding equity interests of the Borrower on a fully-diluted basis whether in a single transaction or a series of related transactions, or (b) the
failure of individuals who are members of the board of directors (or similar governing body) of the Borrower immediately after the effective date of the ABI Merger (together with any new or replacement directors whose initial nomination for election
was approved by a majority of the directors who were either directors immediately after the effective date of the ABI Merger or previously so approved) to constitute a majority of the board of directors (or similar governing body) of the Borrower.

 “Closing Date” means the date of this Agreement or such later Business Day upon which each condition described in
Section 3.2 shall be satisfied or waived in a manner acceptable to the Agent in its discretion. 
 “Code” means the
Internal Revenue Code of 1986, as amended, and any successor statute thereto. 
 “Collateral Account” is defined in
Section 7.4(b) hereof. 
 “Commitment” means, as to any Lender, the obligation of such Lender to make Revolving Loans
and to participate in Swing Loans and Letters of Credit issued for the account of the Borrower hereunder in an aggregate principal or face amount at any one time outstanding 

  

 -4- 

 
not to exceed the amount set forth opposite such Lender’s name on Schedule 1 attached hereto and made a part hereof, as the same may be reduced or
modified at any time or from time to time pursuant to the terms hereof. 
 “Contingent Obligation” shall mean as to any
Person, any obligation of such Person guaranteeing or intended to guarantee any Indebtedness, leases, dividends or other obligations (“primary obligations”) of any other Person (the “primary obligor”) in any manner,
whether directly or indirectly, including, without limitation, any obligation of such Person, whether or not contingent, (i) to purchase any such primary obligation or any Property constituting direct or indirect security therefor, (ii) to
advance or supply funds (x) for the purchase or payment of any such primary obligation or (y) to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor,
(iii) to purchase property, securities or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to make payment of such primary obligation or (iv) otherwise to assure
or hold harmless the holder of such primary obligation against loss in respect thereof; provided, however, that the term Contingent Obligation shall not include endorsements of instruments for deposit or collection in the ordinary course of
business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determinable amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the
maximum reasonably anticipated liability in respect thereof (assuming such Person is required to perform thereunder) as determined by such Person in good faith. 
 “Controlled Group” means all members of a controlled group of corporations and all trades or businesses (whether or not incorporated) under common control which, together with the Borrower, are
treated as a single employer under Section 414 of the Code. 
 “Credit Event” means the advancing of any Loan, the
continuation of or conversion into a Eurodollar Loan, or the issuance of, or extension of the expiration date or increase in the amount of, any Letter of Credit. 
 “Damages” means all damages including, without limitation, punitive damages, liabilities, costs, expenses, losses, judgments, diminutions in value, fines, penalties, demands, claims, cost recovery
actions, lawsuits, administrative proceedings, orders, response action, removal and remedial costs, compliance costs, investigation expenses, consultant fees, attorneys’ and paralegals’ fees and litigation expenses. 
 “Default” means any event or condition the occurrence of which would, with the passage of time or the giving of notice, or both,
constitute an Event of Default. 
 “Dollars” and “$” each means the lawful currency of the United States of
America. 
 “EBITDA” means, with reference to any period, Operating Income for such period plus the sum of all
amounts deducted in arriving at such Operating Income amount in respect of (a) depreciation of fixed assets and amortization of intangible assets for such period, (b) expenses incurred in connection with the ABI Merger in an aggregate
amount not to exceed $40,000,000, 

  

 -5- 

 
(c) non-cash charges associated with the amortization of merger-related charges after giving effect to the ABI Merger, (d) non-recurring costs
associated with the 2005 shutdown of the Borrower’s Melrose Park, Illinois facility and (e) non-cash charges associated with stock compensation under APB 25 or FAS 123(R). 
 “Eligible Assignee” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person
(other than a natural person) approved by (i) the Agent, (ii) the L/C Issuer, and (iii) unless an Event of Default has occurred and is continuing, the Borrower (each such approval not to be unreasonably withheld or delayed);
provided that notwithstanding the foregoing, “Eligible Assignee” shall not include the Borrower or any of the Borrower’s Affiliates or Subsidiaries. 
 “Environmental Claim” means any investigation, notice, violation, demand, allegation, action, suit, injunction, judgment, order, consent decree, penalty, fine, lien, proceeding or claim (whether
administrative, judicial or private in nature) arising (a) pursuant to, or in connection with an actual or alleged violation of, any Environmental Law, (b) in connection with a Release of Hazardous Material, (c) from any abatement,
removal, remedial, corrective or response action in connection with a Release of Hazardous Materials, Environmental Law or order of a governmental authority or (d) from any actual or alleged damage, injury, threat or harm to health, safety,
natural resources or the environment. 
 “Environmental Law” means any Legal Requirement pertaining to (a) the
protection of health, safety and the indoor or outdoor environment, (b) the conservation, management or use of natural resources and wildlife, (c) the protection or use of surface water or groundwater, (d) the manufacture, use,
generation, transportation, treatment, storage, disposal, Release, threatened Release, abatement, removal, remediation or handling of, or exposure to, any Hazardous Material or (e) any Release to air, land, surface water or groundwater, and any
amendment, rule, regulation, order or directive issued thereunder. 
 “ERISA” means the Employee Retirement Income Security
Act of 1974, as amended, or any successor statute thereto. 
 “Eurodollar Loan” means a Loan bearing interest at the rate
specified in Section 2.3(b) hereof. 
 “Event of Default” means any event or condition identified as such in
Section 7.1 hereof. 
 “Existing ABI Facility” means the credit facility extended by Merrill Lynch Professional
Clearing Corp. to ABI. 
 “Existing Credit Agreement” means the Credit Agreement dated September 2, 2004 among the
Borrower, Fifth Third Bank as agent, and the lenders party thereto, as amended. 
 “Federal Funds Rate” means for any day
the rate determined by the Agent to be the average (rounded upward, if necessary, to the next higher 1/100 of 1%) of the rates per annum quoted to the Agent at approximately 10:00 a.m. (Cincinnati time) (or as soon thereafter as is 

  

 -6- 

 
practicable) on such day (or, if such day is not a Business Day, on the immediately preceding Business Day) by two or more Federal funds brokers selected by
the Agent for sale to the Agent at face value of Federal funds in the secondary market in an amount equal or comparable to the principal amount owed to the Agent for which such rate is being determined. 
 “Fee Letter” means that letter agreement between the Agent and the Borrower dated April 18, 2006. 
 “Foreign Subsidiary” means each Subsidiary that is organized under the laws of a jurisdiction other than the United States of America or
any state thereof. 
 “Fund” means any Person (other than a natural person) that is (or will be) engaged in making,
purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business. 
 “GAAP” means generally accepted accounting principles set forth from time to time in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and
statements and pronouncements of the Financial Accounting Standards Board (or agencies with similar functions of comparable stature and authority within the U.S. accounting profession), which are applicable to the circumstances as of the date of
determination. 
 “Guaranty” and “Guaranties” each is defined in Section 4.1 hereof. 
 “Hazardous Material” means any substance, chemical, compound, product, solid, gas, liquid, waste, byproduct, pollutant, contaminant or
material which is hazardous or toxic, and includes, without limitation, (a) asbestos, polychlorinated biphenyls and petroleum (including crude oil or any fraction thereof) and (b) any material classified or regulated as
“hazardous” or “toxic” or words of like import pursuant to an Environmental Law. 
 “Hedging Agreements”
shall mean, with respect to any Person, any agreement entered into to protect such Person against fluctuations in interest rates, or currency or commodity values, including, without limitation, any interest rate swap, cap or collar agreement or
similar arrangement between such Person and one or more counterparties, any foreign currency exchange agreement, currency protection agreements, commodity purchase or option agreements or other interest or exchange rate or commodity price hedging
agreements. 
 “Hostile Acquisition” means the acquisition of the capital stock or other equity interests of a Person
through a tender offer or similar solicitation of the owners of such capital stock or other equity interests which has not been approved (prior to such acquisition) by resolutions of the Board of Directors of such Person or by similar action if such
Person is not a corporation, and as to which such approval has not been withdrawn. 
 “Indebtedness” means for any Person
(without duplication) (a) all indebtedness of such Person for borrowed money, whether current or funded, or secured or unsecured, (b) all indebtedness for the deferred purchase price of Property or services, (c) all indebtedness
created 

  

 -7- 

 
or arising under any conditional sale or other title retention agreement with respect to Property acquired by such Person (even though the rights and
remedies of the seller or lender under such agreement in the event of a default are limited to repossession or sale of such Property), (d) all indebtedness secured by a purchase money mortgage or other Lien to secure all or part of the purchase
price of Property subject to such mortgage or Lien, (e) all obligations under leases which shall have been or must be, in accordance with GAAP, recorded as Capital Leases in respect of which such Person is liable as lessee, (f) any
liability in respect of banker’s acceptances or letters of credit, (g) any indebtedness, whether or not assumed, secured by Liens on Property acquired by such Person at the time of acquisition thereof, (h) all obligations under any
so-called “synthetic lease” transaction entered into by such Person, (i) all obligations under any so-called “asset securitization” transaction entered into by such Person, and (j) all Contingent Obligations, it being
understood that the term “Indebtedness” shall not include trade payables arising in the ordinary course of business. 
 “Interest Coverage Ratio” means, as of the last day of any fiscal quarter of the Borrower, the ratio of EBITDA of the Borrower and its Subsidiaries for the period of four fiscal quarters then ended to Interest Expense of
the Borrower and its Subsidiaries for the same four fiscal quarter period. 
 “Interest Expense” means, with reference to
any period, the sum of all interest charges (including imputed interest charges with respect to Capitalized Lease Obligations and all amortization of debt discount and expense) of the Borrower and its Subsidiaries for such period determined on a
consolidated basis in accordance with GAAP. 
 “Interest Period” means the period commencing on the date a Borrowing of
Loans is advanced, continued or created by conversion and ending: (a) in the case of Base Rate Loans, on the last day of the calendar month in which such Borrowing is advanced, continued or created by conversion (or on the last day of the
following calendar month if such Loan is advanced, continued or created by conversion on the last day of a calendar month), (b) in the case of a Eurodollar Loan, 1, 2 or 3 months thereafter, as selected by Borrower in its notice delivered
pursuant to Section 2.4 hereof and (c) in the case of a Swing Loan, on the date 5 days after such Swing Loan is advanced; provided, however, that: 
 (i) any Interest Period for a Borrowing consisting of Base Rate Loans that otherwise would end after the Termination Date shall end on the
Termination Date; 
 (ii) no Interest Period with respect to any portion of the Loans shall extend beyond the Termination
Date; 
 (iii) whenever the last day of any Interest Period would otherwise be a day that is not a Business Day, the last day
of such Interest Period shall be extended to the next succeeding Business Day, provided that, if such extension would cause the last day of an Interest Period for a Borrowing of Eurodollar Loans to occur in the following calendar month, the last day
of such Interest Period shall be the immediately preceding Business Day; and 
  

 -8- 

 (iv) for purposes of determining an Interest Period for a Borrowing of Eurodollar Loans,
a month means a period starting on one day in a calendar month and ending on the numerically corresponding day in the next calendar month; provided, however, that if there is no numerically corresponding day in the month in which such an
Interest Period is to end or if such an Interest Period begins on the last Business Day of a calendar month, then such Interest Period shall end on the last Business Day of the calendar month in which such Interest Period is to end. 
 “L/C Issuer” means Fifth Third Bank, an Ohio banking corporation, or any successor issuer of Letters of Credit hereunder. 
 “L/C Obligations” means the aggregate undrawn face amounts of all outstanding Letters of Credit and all unpaid Reimbursement Obligations.

 “L/C Sublimit” means $10,000,000, as reduced pursuant to the terms hereof. 
 “Legal Requirement” means any treaty, convention, statute, law, regulation, ordinance, license, permit, governmental approval,
injunction, judgment, order, consent decree or other requirement of any governmental authority, whether federal, state, or local. 
 “Lenders” means and includes Fifth Third Bank, an Ohio banking corporation, and the other financial institutions from time to time party to this Agreement, including each assignee Lender pursuant to Section 10.10
hereof. 
 “Lending Office” is defined in Section 8.6 hereof. 
 “Letter of Credit” is defined in Section 2.2(a) hereof. 
 “Leverage Ratio” means, as of the last day of any fiscal quarter of the Borrower, the ratio of Total Funded Debt of the Borrower and its
Subsidiaries as of the last day of such fiscal quarter to EBITDA of the Borrower and its Subsidiaries for the period of four fiscal quarters then ended. 
 “LIBOR” means, for an Interest Period for a Borrowing of Eurodollar Loans, (a) the LIBOR Index Rate for such Interest Period, if such rate is available, and (b) if the LIBOR Index Rate
cannot be determined, the arithmetic average of the rates of interest per annum (rounded upwards, if necessary, to the nearest 1/100 of 1%) at which deposits in Dollars in immediately available funds are offered to the Agent at 11:00 a.m.
(London, England time) 2 Business Days before the beginning of such Interest Period by 3 or more major banks in the interbank eurodollar market selected by the Agent for delivery on the first day of and for a period equal to such Interest
Period and in an amount equal or comparable to the principal amount of the Eurodollar Loan scheduled to be made by the Agent as part of such Borrowing. 
 “LIBOR Index Rate” means, for any Interest Period, the rate per annum (rounded upwards, if necessary, to the next higher one hundred-thousandth of a percentage point) for deposits in Dollars for a
period equal to such Interest Period, which appears on the Telerate Page 

  

 -9- 

 
3750 as of 11:00 a.m. (London, England time) on the day 2 Business Days before the commencement of such Interest Period. 
 “Lien” means any mortgage, lien, security interest, pledge, charge or encumbrance of any kind in respect of any Property, including the
interests of a vendor or lessor under any conditional sale, Capital Lease or other title retention arrangement. 
 “Loan”
means any Revolving Loan or Swing Loan, whether outstanding as a Base Rate Loan or Eurodollar Loan or otherwise, each of which is a “type” of Loan hereunder. 
 “Loan Documents” means this Agreement, the Notes, the Applications, the Guaranties, and each other instrument or document to be
delivered hereunder or thereunder or otherwise in connection therewith but shall not include any Hedge Agreement with any Lender or any of its Affiliates. 
 “Material Adverse Effect” means (a) a material adverse change in, or material adverse effect upon, the operations, business, Property or condition (financial or otherwise) of the Borrower or of
the Borrower and its Subsidiaries taken as a whole, (b) a material impairment of the ability of the Borrower or any Subsidiary to perform its material obligations under any Loan Document to which it is a party or (c) a material adverse
effect upon the legality, validity, binding effect or enforceability against the Borrower or any Subsidiary of any Loan Document to which it is a party or the rights and remedies of the Agent and the Lenders thereunder. 
 “Material Subsidiary” means any Subsidiary of the Borrower for which (a) the book value of the assets of such Subsidiary exceeds
10% of the value of the consolidated assets (including intangible assets) of the Borrower and its Subsidiaries, or (b) the revenues of such Subsidiary during any fiscal year of the Borrower exceed 10% of the consolidated revenues of the
Borrower and its Subsidiaries for such year or (c) the Borrower has provided written notice to the Agent that it is designating such Subsidiary as a Material Subsidiary. 
 “Merger Agreement” means that certain Agreement and Plan of Merger dated November 27, 2005 by and between the Borrower and ABI,
filed with the SEC on March 10, 2006. 
 “Moody’s” means Moody’s Investors Service, Inc. 
 “Net Income” means, with reference to any period, the net income (or net loss) of the Borrower and its Subsidiaries for such period
computed on a consolidated basis in accordance with GAAP; provided that (other than in pro forma calculations) there shall be excluded from Net Income the net income (or net loss) of any Person accrued prior to the date it becomes a
Subsidiary of, or has merged into or consolidated with, the Borrower or another Subsidiary. 
 “Net Worth” means, at any
time the same is to be determined, total shareholder’s equity (including capital stock, additional paid-in capital, and retained earnings after deducting treasury stock, but excluding minority interests in Subsidiaries) which would appear on
the balance sheet 

  

 -10- 

 
of the Borrower and its Subsidiaries determined on a consolidated basis in accordance with GAAP. 
 “Non-Extension Notice Date” is defined in Section 2.2(g) hereof. 
 “Notes” means and includes the Revolving Notes and the Swing Note. 
 “Obligations” means all obligations of the Borrower to pay principal and interest on the Loans, all Reimbursement Obligations owing
under the Applications, all fees and charges payable hereunder, and all other payment obligations of the Borrower or any of its Subsidiaries arising under or in relation to any Loan Document, in each case whether now existing or hereafter arising,
due or to become due, direct or indirect, absolute or contingent, and howsoever evidenced, held or acquired. 
 “Operating
Income” means, with reference to any period, the operating income (or operating loss) of the Borrower and its Subsidiaries for such period computed on a consolidated basis in accordance with GAAP; provided that (other than in pro
forma calculations) there shall be excluded from Operating Income the operating income (or operating loss) of any Person accrued prior to the date it becomes a Subsidiary of, or has merged into or consolidated with, the Borrower or another
Subsidiary. 
 “Participant” is defined in Section 10.10(d) hereof. 
 “Participating Interest” is defined in Section 2.2(d) hereof. 
 “Participating Lender” is defined in Section 2.2(d) hereof. 
 “Patriot Act” is defined in Section 5.24(b) hereof. 
 “PBGC” means the Pension Benefit Guaranty Corporation or any Person succeeding to any or all of its functions under ERISA. 
 “Percentage” means, for each Lender, the percentage of the Commitments represented by such Lender’s Commitment or, if the
Commitments have been terminated, the percentage held by such Lender (including through participation interests in Reimbursement Obligations) of the aggregate principal amount of all Revolving Loans, Swing Line Loans and L/C Obligations then
outstanding. 
 “Permitted Acquisition” means any acquisition that is not a Hostile Acquisition by the Borrower or any
Subsidiary thereof of a controlling interest in the capital stock or other equity interests of, all or substantially all of the assets of, or a business, unit or division of, any Person; provided that (a) after giving pro forma
effect to such acquisition, the Borrower shall be in compliance with the covenants contained in Section 6.18, in each case recomputed as at the last day of the most recently ended fiscal quarter of the Borrower for which the relevant
information is available as if such acquisition had occurred on the first day of each relevant period for testing such compliance (as demonstrated, in a certificate of an officer of Borrower delivered to the 

  

 -11- 

 
Agent, prior to the consummation of such acquisition), and (b) no Default or Event of Default shall have occurred and be continuing, or would occur
after giving effect to such acquisition. 
 “Permitted Lien” is defined in Section 6.12 hereof. 
 “Person” means an individual, partnership, corporation, limited liability company, association, trust, unincorporated organization or
any other entity or organization, including a government or agency or political subdivision thereof. 
 “Plan” means any
employee pension benefit plan covered by Title IV of ERISA or subject to the minimum funding standards under Section 412 of the Code that either (a) is maintained by a member of the Controlled Group for employees of a member of the
Controlled Group or (b) is maintained pursuant to a collective bargaining agreement or any other arrangement under which more than one employer makes contributions and to which a member of the Controlled Group is then making or accruing an
obligation to make contributions or has within the preceding five plan years made contributions. 
 “Property” means, as to
any Person, all types of real, personal, tangible, intangible or mixed property owned by such Person whether or not included in the most recent balance sheet of such Person and its subsidiaries under GAAP. 
 “RCRA” means the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976 and Hazardous and Solid
Waste Amendments of 1984, 42 U.S.C. §§6901 et seq., and any future amendments.’ 
 “Register” is defined in Section 10.10(c) hereof. 
 “Reimbursement Obligation” is defined in
Section 2.2(c) hereof. 
 “Related Parties” means, with respect to any Person, such Person’s Affiliates and the
partners, directors, officers, employees, agents, financial advisors and consultants of such Person and of such Person’s Affiliates. 
 “Release” shall mean any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing or migration into the environment. 
 “Required Lenders” means, as of the date of determination thereof, Lenders whose aggregate Commitments constitute 51% or more of the sum
of the total Commitments, provided that if the Commitments are terminated pursuant to the terms of this Agreement, “Required Lenders” means as of the date of determination thereof, Lenders whose outstanding Loans and
interests in Swing Line Loans and Letters of Credit constitute 51% or more of the sum of the total outstanding Loans and interests in Swing Line Loans and Letters of Credit. 
 “Reserve Percentage” means, for any Borrowing of Eurodollar Loans, the daily average for the applicable Interest Period of the maximum
rate, expressed as a decimal, at which reserves (including, without limitation, any supplemental, marginal, and emergency reserves) are imposed 

  

 -12- 

 
during such Interest Period by the Board of Governors of the Federal Reserve System (or any successor) on “eurocurrency liabilities”, as
defined in such Board’s Regulation D (or in respect of any other category of liabilities that includes deposits by reference to which the interest rate on Eurodollar Loans is determined or any category of extensions of credit or other
assets that include loans by non-United States offices of any Lender to United States residents), subject to any amendments of such reserve requirement by such Board or its successor, taking into account any transitional adjustments thereto. For
purposes of this definition, the Eurodollar Loans shall be deemed to be “eurocurrency liabilities” as defined in Regulation D without benefit or credit for any prorations, exemptions or offsets under Regulation D.

 “Responsible Officer” means each of the following officers of the Borrower: president, chief executive officer, chief
financial officer and general counsel. 
 “Revolving Credit” means the credit facility for making Loans and issuing Letters
of Credit described in Sections 2.1 and 2.2 hereof. 
 “Revolving Loan” is defined in Section 2.1 hereof and, as
so defined, includes a Base Rate Loan or a Eurodollar Loan, each of which is a “type” of Loan hereunder. 
 “Revolving Note” is defined in Section 2.10 hereof. 
 “SEC” is defined in
Section 6.1(a) hereof. 
 “S&P” means Standard & Poor’s Ratings Services Group, a division of The
McGraw-Hill Companies, Inc. 
 “Subsidiary” means, as to any particular parent corporation or organization, any other
corporation or organization more than 50% of the outstanding Voting Stock of which is at the time directly or indirectly owned by such parent corporation or organization or by any one or more other entities which are themselves subsidiaries of such
parent corporation or organization. Unless otherwise expressly noted herein, the term “Subsidiary” means a Subsidiary of the Borrower or of any of its direct or indirect Subsidiaries. 
 “Swing Line” means the credit facility for making one or more Swing Loans described in Section 2.12 hereof. 
 “Swing Line Sublimit” means $20,000,000, as reduced pursuant to the terms hereof. 
 “Swing Loan” and “Swing Loans” each is defined in Section 2.12 hereof. 
 “Swing Note” is defined in Section 2.10 hereof. 
 “Taxes” is defined in Section 6.7 hereof. 
 “Telerate Page 3750”
means the display designated as “Page 3750” on the Telerate Service (or such other page as may replace Page 3750 on that service or such other service as 

  

 -13- 

 
may be nominated by the British Bankers’ Association as the information vendor for the purpose of displaying British Bankers’ Association Interest
Settlement Rates for U.S. Dollar deposits). 
 “Termination Date” means April 17, 2009, or such earlier date on
which the Commitments are terminated in whole pursuant to Section 2.9, 7.2 or 7.3 hereof. 
 “Total Commitments” means
the aggregate amount of the Commitments which shall initially be Four Hundred Fifty Million Dollars ($450,000,000); as such amount may be decreased pursuant to the provisions of (a) Section 2.9 or (b) other applicable provisions of
this Agreement. 
 “Total Funded Debt” means, at any time the same is to be determined, the aggregate of all Indebtedness of
the Borrower and its Subsidiaries at such time. 
 “Unfunded Vested Liabilities” means, for any Plan at any time, the amount
(if any) by which the present value of all vested nonforfeitable accrued benefits under such Plan exceeds the fair market value of all Plan assets allocable to such benefits, all determined as of the then most recent valuation date for such Plan,
but only to the extent that such excess represents a potential liability of a member of the Controlled Group to the PBGC or the Plan under Title IV of ERISA. 
 “Unused Commitments” means, at any time, the difference between the Commitments then in effect and the aggregate outstanding principal amount of Loans and L/C Obligations, provided that Swing
Loans outstanding from time to time shall be deemed to reduce the Unused Commitment of the Agent for purposes of computing the commitment fee under Section 2.11(a) hereof. 
 “Voting Stock” of any Person means capital stock or other equity interests of any class or classes (however designated) having ordinary
power for the election of directors or other similar governing body of such Person, other than stock or other equity interests having such power only by reason of the happening of a contingency. 
 “Welfare Plan” means a “welfare plan” as defined in Section 3(1) of ERISA. 
 “Wholly-owned Subsidiary” means a Subsidiary of which all of the issued and outstanding shares of capital stock (other than
directors’ qualifying shares as required by law) or other equity interests are owned by the Borrower and/or one or more Wholly-owned Subsidiaries within the meaning of this definition. 
 Section 1.2. Interpretation. The foregoing definitions are equally applicable to both the singular and plural forms of the terms defined. The
words “hereof”, “herein”, and “hereunder” and words of like import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. All
references to time of day herein are references to Cincinnati, Ohio, time unless otherwise specifically provided. Where the character or amount of any asset or liability or item of income or expense is required to be determined or any consolidation
or other accounting computation is required to be made for the purposes of this Agreement, it shall be done in accordance with GAAP except where such principles are 

  

 -14- 

 
inconsistent with the specific provisions of this Agreement. All terms that are used in this Agreement which are defined in the Uniform Commercial Code of
the State of Illinois as in effect from time to time (“UCC”) shall have the same meanings herein as such terms are defined in the UCC, unless this Agreement shall otherwise specifically provide. 
 Section 1.3. Change in Accounting Principles. If, after the date of this Agreement, there shall occur any change in GAAP from those used in
the preparation of the financial statements referred to in Section 5.3 hereof and such change shall result in a change in the method of calculation of any financial covenant, standard or term found in this Agreement, either the Borrower or the
Required Lenders may by notice to the Lenders and the Borrower, respectively, require that the Lenders and the Borrower negotiate in good faith to amend such covenants, standards, and term so as equitably to reflect such change in accounting
principles, with the desired result being that the criteria for evaluating the financial condition of the Borrower and its Subsidiaries shall be the same as if such change had not been made. No delay by the Borrower or the Required Lenders in
requiring such negotiation shall limit their right to so require such a negotiation at any time after such a change in accounting principles. Until any such covenant, standard, or term is amended in accordance with this Section 1.3, financial
covenants shall be computed and determined in accordance with GAAP in effect prior to such change in accounting principles. Without limiting the generality of the foregoing, the Borrower shall neither be deemed to be in compliance with any financial
covenant hereunder nor out of compliance with any financial covenant hereunder if such state of compliance or noncompliance, as the case may be, would not exist but for the occurrence of a change in accounting principles after the date hereof.

  

	SECTION 2.	THE CREDIT FACILITIES. 

 Section 2.1. Commitments. Revolving Credit Facility. Prior to the Termination Date, each Lender severally and not jointly agrees, subject to the terms and conditions hereof, to make revolving loans
(each individually a “Revolving Loan” and, collectively, the “Revolving Loans”) in Dollars to the Borrower from time to time up to the amount of such Lender’s Commitment. Each Borrowing of Revolving Loans shall
be made ratably by the Lenders in proportion to their respective Percentages. As provided in Section 2.4(a), and subject to the terms hereof, the Borrower may elect that each Borrowing of Revolving Loans be either Base Rate Loans or Eurodollar
Loans. Revolving Loans may be repaid and reborrowed before the Termination Date, subject to the terms and conditions hereof. 
 Section 2.2. Letters of Credit. (a) General Terms. Subject to the terms and conditions hereof, as part of the Revolving Credit, the L/C Issuer shall issue standby and commercial letters of credit (each a
“Letter of Credit”) for the Borrower’s account in an aggregate undrawn face amount up to the L/C Sublimit. Each Lender shall be obligated to reimburse the L/C Issuer for such Lender’s Percentage of the amount of each
drawing under a Letter of Credit and, accordingly, each Letter of Credit shall constitute usage of the Commitment of each Lender pro rata in an amount equal to its Percentage of the L/C Obligations then outstanding. 
 (b) Applications. Subject to Section 2.2(g), at any time before the Termination Date, the L/C Issuer shall, at the request of the Borrower,
issue one or more Letters of Credit in 

  

 -15- 

 
Dollars, in form and substance acceptable to the L/C Issuer, with expiration dates no later than the earlier of 12 months from the date of issuance (or which
are cancelable not later than 12 months from the date of issuance and each renewal) or 30 days prior to the Termination Date, in an aggregate face amount as set forth above, upon the receipt of a duly executed application for the relevant
Letter of Credit in the form then customarily prescribed by the L/C Issuer for the Letter of Credit requested (each an “Application”). Notwithstanding anything contained in any Application to the contrary: (i) the Borrower
shall pay fees in connection with each Letter of Credit as set forth in Section 2.11 hereof, and (ii) if the L/C Issuer is not timely reimbursed for the amount of any drawing under a Letter of Credit on the date such drawing is paid
(including pursuant to a Borrowing under Section 2.4(c) hereof), the Borrower’s obligation to reimburse the L/C Issuer for the amount of such drawing shall bear interest (which the Borrower hereby promises to pay) from and after the date
such drawing is paid at a rate per annum equal to the sum of 2% plus the Applicable Margin plus the Base Rate from time to time in effect (computed on the basis of a year of 365 or 366 days, as the case may be, and the actual number of days
elapsed). Without limiting the foregoing, the L/C Issuer’s obligation to issue, amend or extend the expiration date of a Letter of Credit is subject to the terms or conditions of this Agreement (including the conditions set forth in
Section 3.1 and the other terms of this Section 2.2). 
 (c) The Reimbursement Obligations. Subject to Section 2.2(b)
hereof, the obligation of the Borrower to reimburse the L/C Issuer for all drawings under a Letter of Credit (a “Reimbursement Obligation”) shall be governed by the Application related to such Letter of Credit, except that
reimbursement shall be made by no later than 1:00 p.m. (Cincinnati time) on the date when each drawing is to be paid if the Borrower has been informed of such drawing by the L/C Issuer on or before 11:00 a.m. (Cincinnati time) on the date
when such drawing is to be paid or, if notice of such drawing is given to the Borrower after 11:00 a.m. (Cincinnati time) on the date when such drawing is to be paid, by 11:00 a.m. (Cincinnati time) on the next day (with interest as set forth
in Section 2.2(b) above), in immediately available funds at the Agent’s principal office in Cincinnati, Ohio or such other office as the Agent may designate in writing to the Borrower, and the Agent shall thereafter cause to be distributed
to the L/C Issuer such amount(s) in like funds. If the Borrower does not make any such reimbursement payment on the date due (including with the proceeds of a Borrowing pursuant to Section 2.4 hereof) and the Participating Lenders fund their
participations in the manner set forth in Section 2.2(d) below, then all payments thereafter received by the Agent in discharge of any of the relevant Reimbursement Obligations shall be distributed in accordance with Section 2.2(d) below.

 (d) The Participating Interests. Each Lender (other than the Lender acting as L/C Issuer) severally and not jointly agrees to
purchase from the L/C Issuer, and the L/C Issuer hereby agrees to sell to each such Lender (a “Participating Lender”), an undivided participating interest (a “Participating Interest”) to the extent of its Percentage
in each Letter of Credit issued by, and each Reimbursement Obligation owed to, the L/C Issuer. Upon Borrower’s failure to pay any Reimbursement Obligation on the date and at the time required, or if the L/C Issuer is required at any time to
return to the Borrower or to a trustee, receiver, liquidator, custodian or other Person any portion of any payment of any Reimbursement Obligation, each Participating Lender shall, not later than the Business Day it receives a certificate in the
form of Exhibit A hereto from the L/C Issuer (with a copy to the Agent) to such effect, if such certificate is received before 1:00 p.m. (Cincinnati time), or not later than 1:00 p.m. (Cincinnati time) the following Business 

  

 -16- 

 
Day, if such certificate is received after such time, pay to the Agent for the account of the L/C Issuer an amount equal to such Participating Lender’s
Percentage of such unpaid Reimbursement Obligation together with interest on such amount accrued from the date the L/C Issuer made the related payment to the date of such payment by such Participating Lender at a rate per annum equal to:
(i) from the date the L/C Issuer made the related payment to the date 2 Business Days after payment by such Participating Lender is due hereunder, the Federal Funds Rate for each such day and (ii) from the date 2 Business Days
after the date such payment is due from such Participating Lender to the date such payment is made by such Participating Lender, the Base Rate in effect for each such day. Each such Participating Lender shall, after making its appropriate payment,
be entitled to receive its Percentage of each payment received in respect of the relevant Reimbursement Obligation and of interest paid thereon, with the L/C Issuer retaining its Percentage thereof as a Lender hereunder. 
 The several obligations of the Participating Lenders to the L/C Issuer under this Section 2.2 shall be absolute, irrevocable and unconditional under
any and all circumstances and shall not be subject to any set-off, counterclaim or defense to payment which any Participating Lender may have or has had against the Borrower, the L/C Issuer, the Agent, any Lender or any other Person. Without
limiting the generality of the foregoing, such obligations shall not be affected by any Default or Event of Default or by any reduction or termination of the Commitment of any Lender, and each payment by a Participating Lender under this
Section 2.2 shall be made without any offset, abatement, withholding or reduction whatsoever. 
 (e) Indemnification. The
Participating Lenders shall, to the extent of their respective Percentages, indemnify the L/C Issuer (to the extent not reimbursed by the Borrower) against any cost, expense (including reasonable counsel fees and disbursements), claim, demand,
action, loss or liability (except such as result from the L/C Issuer’s gross negligence or willful misconduct) that the L/C Issuer may suffer or incur in connection with any Letter of Credit issued by it. The obligations of the Participating
Lenders under this Section 2.2(e) and all other parts of this Section 2.2 shall survive termination of this Agreement and of all Applications, Letters of Credit, and all drafts and other documents presented in connection with drawings
thereunder. 
 (f) Manner of Requesting a Letter of Credit. The Borrower shall provide at least 3 Business Days’ advance
written notice to the Agent of each request for the issuance of a Letter of Credit, each such notice to be accompanied by a properly completed and executed Application for the requested Letter of Credit and, in the case of an extension or an
increase in the amount of a Letter of Credit, a written request therefor, in a form acceptable to the Agent and the L/C Issuer, in each case, together with the fees called for by this Agreement. The Agent shall promptly notify the L/C Issuer of the
Agent’s receipt of each such notice and the L/C Issuer shall promptly notify the Agent and the Lenders of the issuance of a Letter of Credit. 
 (g) Auto-Extension Letters of Credit. If the Borrower requests in an Application a Letter of Credit that has automatic extension provisions with respect to such Letters of Credit’s expiration date (each, an
“Auto-Extension Letter of Credit”), the L/C Issuer shall, subject to the terms and conditions hereof, issue such an Auto-Extension Letter of Credit; provided that any such Auto-Extension Letter of Credit must permit the L/C
Issuer to prevent any such extension at least once in each twelve-month period (commencing with the date of issuance of such Letter of 

  

 -17- 

 
Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Non-Extension Notice Date”) in each such twelve-month
period to be determined at the time such Letter of Credit is issued. Unless otherwise directed by the L/C Issuer, the Borrower shall not be required to make a specific request to the L/C Issuer for any such extension of an Auto-Extension Letter of
Credit. Once an Auto-Extension Letter of Credit has been issued, the Lenders shall be deemed to have authorized (but may not require) the L/C Issuer to permit the extension of such Letter of Credit pursuant to the terms of such Letter of Credit;
provided, however, that the L/C Issuer shall not permit any such extension if (A) the L/C Issuer has determined that it would not be permitted, or would have no obligation, at such time to issue such Letter of Credit in its
revised form (as extended) under the terms hereof, or (B) the L/C Issuer has received notice (which may be by telephone or in writing) on or before the day that is five Business Days before the Non-Extension Notice Date (1) from the Agent
that the Required Lenders have elected not to permit such extension or (2) from the Agent, any Lender or the Borrower that one or more of the applicable conditions specified in Section 3.1 is not then satisfied, and in each such case
directing the L/C Issuer not to permit such extension. 
 Section 2.3. Applicable Interest Rates. (a) Base Rate
Loans. Each Base Rate Loan made or maintained by a Lender shall bear interest during each Interest Period it is outstanding (computed on the basis of a year of 365 or 366 days, as the case may be, and the actual days elapsed) on the unpaid
principal amount thereof from the date such Loan is advanced, continued or created by conversion from a Eurodollar Loan until maturity (whether by acceleration or otherwise) at a rate per annum equal to the sum of the Applicable Margin plus the Base
Rate from time to time in effect, payable on the last day of its Interest Period and at maturity (whether by acceleration or otherwise). 
 (b) Eurodollar Loans. Each Eurodollar Loan made or maintained by a Lender shall bear interest during each Interest Period it is outstanding (computed on the basis of a year of 360 days and actual days elapsed) on the unpaid
principal amount thereof from the date such Loan is advanced, continued or created by conversion from a Base Rate Loan until maturity (whether by acceleration or otherwise) at a rate per annum equal to the sum of the Applicable Margin plus the
Adjusted LIBOR applicable for such Interest Period, payable on the last day of the Interest Period and at maturity (whether by acceleration or otherwise). 
 (c) Default Rate. While any Event of Default exists or after acceleration, the Borrower shall pay interest (after as well as before entry of judgment thereon to the extent permitted by law) on the principal
amount of all Loans owing by it at a rate per annum equal to: 
 (i) for any Base Rate Loan or any Swing Loan bearing interest
based on the Base Rate, the sum of 2.0% per annum plus the Applicable Margin plus the Base Rate from time to time in effect; and 
 (ii) for any Eurodollar Loan or any Swing Loan bearing interest at the Agent’s Quoted Rate, the sum of 2.0% per annum plus the rate of interest in effect thereon at the time of such default until the end of
the Interest Period applicable thereto and, thereafter, at a rate per annum equal to the sum of 2.0% plus the 

  

 -18- 

 
Applicable Margin for Base Rate Loans plus the Base Rate from time to time in effect; 
 provided, however, that in the absence of acceleration, any adjustments pursuant to this Section shall be made at the election of the Agent, acting at the request or with the consent of the Required Lenders,
with written notice to the Borrower. While any Event of Default exists or after acceleration, interest shall be paid on demand of the Agent at the request or with the consent of the Required Lenders. 
 (d) Rate Determinations. The Agent shall determine each interest rate applicable to the Loans and the Reimbursement Obligations hereunder, and its
determination thereof shall be presumptively correct, except in the case of manifest error. 
 Section 2.4. Manner of Borrowing Loans
and Designating Applicable Interest Rates. (a) Notice to the Agent. The Borrower shall give notice to the Agent by no later than 12:00 noon (Cincinnati time): (i) at least 3 Business Days before the date on which the Borrower
requests the Lenders to advance a Borrowing of Eurodollar Loans and (ii) on the date the Borrower requests the Lenders to advance a Borrowing of Base Rate Loans. The Loans included in each Borrowing shall bear interest initially at the type of
rate specified in such notice. Thereafter, the Borrower may from time to time elect to change or continue the type of interest rate borne by each Borrowing or, subject to Section 2.5 hereof, a portion thereof, as follows: (i) if such
Borrowing is of Eurodollar Loans, on the last day of the Interest Period applicable thereto, the Borrower may continue part or all of such Borrowing as Eurodollar Loans or convert part or all of such Borrowing into Base Rate Loans or (ii) if
such Borrowing is of Base Rate Loans, on any Business Day, the Borrower may convert all or part of such Borrowing into Eurodollar Loans for an Interest Period or Interest Periods specified by the Borrower. The Borrower shall give all such notices
requesting the advance, continuation or conversion of a Borrowing to the Agent by telephone or telecopy (which notice shall be irrevocable once given and, if by telephone, shall be promptly confirmed in writing), substantially in the form attached
hereto as Exhibit B (Notice of Borrowing) or Exhibit C (Notice of Continuation/Conversion), as applicable, or in such other form acceptable to the Agent. Notice of the continuation of a Borrowing of Eurodollar Loans for an additional
Interest Period or of the conversion of part or all of a Borrowing of Base Rate Loans into Eurodollar Loans must be given by no later than 12:00 noon (Cincinnati time) at least 3 Business Days before the date of the requested continuation
or conversion. All notices concerning the advance, continuation or conversion of a Borrowing shall specify the date of the requested advance, continuation or conversion of a Borrowing (which shall be a Business Day), the amount of the requested
Borrowing to be advanced, continued or converted, the type of Loans to comprise such new, continued or converted Borrowing and, if such Borrowing is to be comprised of Eurodollar Loans, the Interest Period applicable thereto. The Borrower agrees
that the Agent may rely on any such telephonic or telecopy notice given by any person the Agent in good faith believes is an Authorized Representative without the necessity of independent investigation and, in the event any such notice by telephone
conflicts with any written confirmation, such telephonic notice shall govern if the Agent has acted in reliance thereon. 
 (b) Notice to
the Lenders. The Agent shall give prompt telephonic or telecopy notice to each Lender of any notice from the Borrower received pursuant to Section 2.4(a) above and, if 

  

 -19- 

 
such notice requests the Lenders to make Eurodollar Loans, the Agent shall give notice to the Borrower and each Lender of the interest rate applicable
thereto promptly after the Agent has made such determination. 
 (c) Borrower’s Failure to Notify; Automatic Continuations and
Conversions. Any outstanding Borrowing of Base Rate Loans shall automatically be continued for an additional Interest Period on the last day of its then current Interest Period unless the Borrower has properly notified the Agent that the
Borrower intends to convert such Borrowing, subject to Section 3.1 hereof, into a Borrowing of Eurodollar Loans or such Borrowing is prepaid in accordance with Section 2.7(a). If the Borrower fails to give proper notice of the continuation
or conversion of any outstanding Borrowing of Eurodollar Loans before the last day of its then current Interest Period within the period required by Section 2.4(a) or, whether or not such notice has been given, one or more of the conditions set
forth in Section 3.1 for the continuation or conversion of a Borrowing of Eurodollar Loans would not be satisfied, and such Borrowing is not prepaid in accordance with Section 2.7(a), such Borrowing shall automatically be converted into a
Borrowing of Base Rate Loans. In the event the Borrower fails to give notice pursuant to Section 2.4(a) of a Borrowing equal to the amount of a Reimbursement Obligation and has not notified the Agent by 1:00 p.m. (Cincinnati time) on the
day such Reimbursement Obligation becomes due that it intends to repay such Reimbursement Obligation through funds not borrowed under this Agreement, the Borrower shall be deemed to have requested a Borrowing of Base Rate Loans under the Revolving
Credit (or, at the option of the Agent, under the Swing Line) on such day in the amount of the Reimbursement Obligation then due, which Borrowing shall be applied to pay the Reimbursement Obligation then due. 
 (d) Disbursement of Loans. Not later than 1:00 p.m. (Cincinnati time) on the date of any requested advance of a new Borrowing, subject to
Section 3 hereof, each Lender shall make available its Loan comprising part of such Borrowing in funds immediately available at the principal office of the Agent in Cincinnati, Ohio. The Agent shall make the proceeds of each new Borrowing
available to the Borrower at the Agent’s principal office in Cincinnati, Ohio. 
 (e) Agent Reliance on Lender Funding. Unless
the Agent shall have been notified by a Lender prior to (or, in the case of a Borrowing of Base Rate Loans, by 1:00 p.m. (Cincinnati time) on) the date on which such Lender is scheduled to make payment to the Agent of the proceeds of a Loan
(which notice shall be effective upon receipt) that such Lender does not intend to make such payment, the Agent may assume that such Lender has made such payment when due and the Agent, in reliance upon such assumption may (but shall not be required
to) make available to the Borrower the proceeds of the Loan to be made by such Lender and, if any Lender has not in fact made such payment to the Agent, such Lender shall, on demand, pay to the Agent the amount made available to the Borrower
attributable to such Lender together with interest thereon in respect of each day during the period commencing on the date such amount was made available to the Borrower and ending on (but excluding) the date such Lender pays such amount to the
Agent at a rate per annum equal to: (i) from the date the related advance was made by the Agent to the date 2 Business Days after payment by such Lender is due hereunder, the Federal Funds Rate for each such day and (ii) from the date
2 Business Days after the date such payment is due from such Lender to the date such payment is made by such Lender, the Base Rate in effect for each such day. If such amount is not received from such Lender by the 

  

 -20- 

 
Agent immediately upon demand, the Borrower will, on demand, repay to the Agent the proceeds of the Loan attributable to such Lender with interest thereon at
a rate per annum equal to the interest rate applicable to the relevant Loan, but without such payment being considered a payment or prepayment of a Loan under Section 8.1 hereof so that the Borrower will have no liability under such Section
with respect to such payment. 
 Section 2.5. Minimum Borrowing Amounts; Maximum Eurodollar Loans. Each Borrowing of Base Rate
Loans shall be in an amount not less than $500,000. Each Borrowing of Eurodollar Loans shall be in an amount equal to $1,000,000 or such greater amount that is an integral multiple of $100,000. Without the Agent’s consent, there shall not be
more than 5 Borrowings of Eurodollar Loans outstanding at any one time; provided that, without the Required Lenders’ consent, there shall not be more than 10 such Borrowings outstanding at any one time. 
 Section 2.6. Maturity of Loans. Each Loan, both for principal and interest, shall mature and become due and payable by the Borrower on the
Termination Date. 
 Section 2.7. Prepayments. (a) Optional. The Borrower may prepay without premium or penalty
(except as set forth in Section 8.1 below) and in whole or in part any Borrowing of Eurodollar Loans at any time upon 3 Business Days prior notice by the Borrower to the Agent or, in the case of a Borrowing of Base Rate Loans, notice
delivered by the Borrower to the Agent no later than 10:00 a.m. (Cincinnati time) on the date of prepayment, such prepayment to be made by the payment of the principal amount to be prepaid and, in the case of any Eurodollar Loans or Swing
Loans, accrued interest thereon to the date fixed for prepayment plus any amounts due the Lenders under Section 8.1; provided, however, the Borrower may not partially repay a Borrowing (i) if such Borrowing is of Base Rate Loans, in
a principal amount less than $500,000, (ii) if such Borrowing is of Eurodollar Loans, in a principal amount less than $1,000,000, and (iii) in each case, unless it is in an amount such that the minimum amount required for a Borrowing
pursuant to Section 2.5 remains outstanding. 
 (b) Mandatory. The Borrower shall, on each date the Commitments are reduced
pursuant to Section 2.9, prepay the Loans and, if necessary, prefund the L/C Obligations by the amount, if any, necessary to reduce the sum of the aggregate principal amount of Loans and L/C Obligations then outstanding to the amount
to which the Commitments have been so reduced. Unless the Borrower otherwise directs, prepayments of Loans under this Section 2.7(b) shall be applied first to Borrowings of Base Rate Loans and Swing Line Loans payable at the Agent’s Quoted
Rate until payment in full thereof with any balance applied to Borrowings of Eurodollar Loans in the order in which their Interest Periods expire. Each prepayment of Loans under this Section 2.7(b) shall be made by the payment of the principal
amount to be prepaid and, in the case of any Eurodollar Loans, accrued interest thereon to the date of prepayment together with any amounts due the Lenders under Section 8.1. Each prefunding of L/C Obligations shall be made in accordance
with Section 7.4. 
 (c) The Agent will promptly advise each Lender of any notice of prepayment it receives from the Borrower, and in
the case of any partial prepayment, such prepayment shall be applied first to Borrowings of Base Rate Loans and Swing Line Loans payable at the Agent’s Quoted 

  

 -21- 

 
Rate until payment in full thereof with any balance applied to Borrowings of Eurodollar Loans in the order in which their Interest Periods expire.

 Section 2.8. Place and Application of Payments. All payments of principal of and interest on the Loans and the Reimbursement
Obligations, and of all other Obligations payable by the Borrower under this Agreement and the other Loan Documents, shall be made by the Borrower to the Agent by no later than 12:00 Noon (Cincinnati time) on the due date thereof at the office
of the Agent in Cincinnati, Ohio (or such other location as the Agent may designate to the Borrower) for the benefit of the Lender or Lenders entitled thereto. Any payments received after such time shall be deemed to have been received by the Agent
on the next Business Day. All such payments shall be made in Dollars, in immediately available funds at the place of payment, in each case without set-off or counterclaim. The Agent will promptly thereafter cause to be distributed like funds
relating to the payment of principal or interest on Loans and on Reimbursement Obligations in which the Lenders have purchased Participating Interests ratably to the Lenders and like funds relating to the payment of any other amount payable to any
Lender to such Lender, in each case to be applied in accordance with the terms of this Agreement. 
 Anything contained herein to the
contrary notwithstanding, (x) pursuant to the exercise of remedies under Sections 7.2 and 7.3 hereof or (y) after written instruction by the Required Lenders after the occurrence and during the continuation of an Event of Default, all
payments and collections received in respect of the Obligations by the Agent or any of the Lenders shall be remitted to the Agent and distributed as follows: 
 (a) first, to the payment of any outstanding costs and expenses incurred by the Agent, and any trustee therefor, in protecting, preserving
or enforcing rights under the Loan Documents, and in any event all costs and expenses of a character which the Borrower has agreed to pay the Agent under Section 10.13 hereof (such funds to be retained by the Agent for its own account unless it
has previously been reimbursed for such costs and expenses by the Lenders, in which event such amounts shall be remitted to the Lenders to reimburse them for payments theretofore made to the Agent); 
 (b) second, to the payment of any outstanding interest and fees due under the Loan Documents to be allocated pro rata in accordance with
the aggregate unpaid amounts owing to each holder thereof; 
 (c) third, to the payment of principal on the Notes, unpaid
Reimbursement Obligations, together with amounts to be held by the Agent as collateral security for any outstanding L/C Obligations pursuant to Section 7.4 hereof (until the Agent is holding an amount of cash equal to the then outstanding
amount of all such L/C Obligations), the aggregate amount paid to, or held as collateral security for, the Lenders to be allocated pro rata in accordance with the aggregate unpaid amounts owing to each holder thereof; 
 (d) fourth, to the payment of all other unpaid Obligations to be allocated pro rata in accordance with the aggregate unpaid amounts owing
to each holder thereof; and 
 (e) fifth, to the Borrower or whoever else may be lawfully entitled thereto. 
  

 -22- 

 Section 2.9. Commitment Terminations. The Borrower shall have the right at any time and from
time to time, upon 3 Business Days prior written notice to the Agent, to terminate the Commitments in whole or in part, any partial termination to be (i) in an amount not less than $1,000,000 or such greater amount that is an integral
multiple of $100,000 and (ii) allocated ratably among the Lenders in proportion to their respective Percentages, provided that the Commitments may not be reduced to an amount less than the sum of the aggregate principal amount of Loans
and of L/C Obligations then outstanding. Any termination of the Commitments below the L/C Sublimit or the Swing Line Sublimit then in effect shall reduce the L/C Sublimit and the Swing Line Sublimit, as applicable, by a like amount.
The Agent shall give prompt notice to each Lender of any such termination of the Commitments. Any termination of the Commitments pursuant to this Section 2.9 may not be reinstated. 
 Section 2.10. The Notes. (a) The Revolving Loans made to the Borrower by a Lender shall be evidenced by a single promissory note of the
Borrower issued to such Lender in the form of Exhibit D-1 hereto. Each such promissory note is hereinafter referred to as a “Revolving Note” and collectively such promissory notes are referred to as the “Revolving
Notes.” 
 (b) The Swing Loans made to the Borrower by the Agent shall be evidenced by a single promissory note of the Borrower
issued to the Agent in the form of Exhibit D-2 hereto. Such promissory note is hereinafter referred to as the “Swing Note.” 
 (c) Each Lender shall record on its books and records or on a schedule to its appropriate Note the amount and type of each Loan advanced, continued or converted by it, all payments of principal and interest and the principal balance from
time to time outstanding thereon, and, for any Eurodollar Loan, the Interest Period and the interest rate applicable thereto. The Lender’s record thereof, whether shown on its books and records or on a schedule to the relevant Note, shall be
prima facie evidence as to all such matters; provided, however, that the failure of any Lender to record any of the foregoing or any error in any such record shall not limit or otherwise affect the obligation of the Borrower to repay
all Loans made to it together with accrued interest thereon. At the request of any Lender and upon such Lender tendering to the Borrower the appropriate Note to be replaced, the Borrower shall furnish a new Note to such Lender to replace any
outstanding Note, and at such time the first notation appearing on a schedule on the reverse side of, or attached to, such new Note shall set forth the aggregate unpaid principal amount of all Loans, if any, then outstanding thereon. 
 Section 2.11. Fees. (a) Commitment Fee. The Borrower shall pay to the Agent for the ratable account of the Lenders according to
their Percentages a commitment fee at the rate per annum equal to the Applicable Margin (computed on the basis of a year of 360 days and the actual number of days elapsed) on the average daily Unused Commitments. Such commitment fee shall be
payable quarterly in arrears on the last day of each March, June, September, and December in each year (commencing on the first such date occurring after the date hereof) and on the Termination Date, unless the Commitments are terminated in whole on
an earlier date, in which event the commitment fee for the period to the date of such termination in whole shall be paid on the date of such termination. 
  

 -23- 

 (b) Letter of Credit Fees. On the date of issuance or extension, or increase in the amount, of any
Letter of Credit pursuant to Section 2.2 hereof, the Borrower shall pay to the L/C Issuer for its own account an issuance fee equal to .125% of the face amount of (or of the increase in the face amount of) such Letter of Credit. Quarterly
in arrears, on the last day of each March, June, September, and December, commencing on the first such date occurring after the date the first Letter of Credit is issued hereunder, the Borrower shall pay to the Agent, for the ratable benefit of the
Lenders according to their Percentages, a letter of credit fee at a rate per annum equal to the Applicable Margin (computed on the basis of a year of 360 days and the actual number of days elapsed) in effect during each day of such quarter
applied to the daily average face amount of Letters of Credit outstanding during such quarter. In addition, the Borrower shall pay to the L/C Issuer for its own account the L/C Issuer’s standard drawing, negotiation, amendment, transfer and
other administrative fees for each Letter of Credit. Such standard fees referred to in the preceding sentence may be established by the L/C Issuer from time to time. 
 (c) Agent Fees. The Borrower shall pay to the Agent, for its own use and benefit, the fees agreed to between the Agent and the Borrower in the Fee Letter. 
 Section 2.12. Swing Loans. (a) Generally. Subject to the terms and conditions hereof, as part of the Revolving Credit, the Agent
agrees to make loans to the Borrower under the Swing Line (individually a “Swing Loan” and collectively the “Swing Loans”) which shall not in the aggregate at any time outstanding exceed the Swing Line Sublimit. The
Swing Loans may be availed of the Borrower from time to time and borrowings thereunder may be repaid and used again during the period ending on the Termination Date; provided that each Swing Loan must be repaid on the last day of the Interest
Period applicable thereto. Each Swing Loan shall be in a minimum amount of $250,000 or such greater amount which is an integral multiple of $100,000. 
 (b) Interest on Swing Loans. Each Swing Loan shall bear interest until maturity (whether by acceleration or otherwise) at a rate per annum equal to (i) the sum of the Base Rate plus the Applicable Margin
for Base Rate Loans under the Revolving Credit as from time to time in effect (computed on the basis of a year of 365 or 366 days, as the case may be, for the actual number of days elapsed) or (ii) the Agent’s Quoted Rate (computed on the
basis of a year of 360 days for the actual number of days elapsed). Interest on each Swing Loan shall be due and payable on the last day of each Interest Period applicable thereto and at maturity (whether by acceleration or otherwise).

 (c) Requests for Swing Loans. The Borrower shall give the Agent prior notice (which may be written or oral) no later than
12:00 Noon (Cincinnati time) on the date upon which a Borrower requests that any Swing Loan be made, of the amount and date of such Swing Loan, and the Interest Period requested therefor. Within 30 minutes after receiving such notice, the
Agent shall in its discretion quote an interest rate to the Borrower at which the Agent would be willing to make such Swing Loan available to the Borrower for the Interest Period so requested (the rate so quoted for a given Interest Period being
herein referred to as “Agent’s Quoted Rate”). The Borrower acknowledges and agrees that the interest rate quote is given for immediate and irrevocable acceptance. If the Borrower does not so immediately accept the Agent’s
Quoted Rate for the full amount requested by the Borrower for such Swing Loan, the 

  

 -24- 

 
Agent’s Quoted Rate shall be deemed immediately withdrawn and such Swing Loan shall bear interest at the rate per annum determined by adding the
Applicable Margin for Base Rate Loans under the Revolving Credit to the Base Rate as from time to time in effect. Subject to the terms and conditions hereof, the proceeds of such Swing Loan shall be made available to the Borrower on the date so
requested at the offices of the Agent in Cincinnati, Ohio. Anything contained in the foregoing to the contrary notwithstanding (i) the obligation of the Agent to make Swing Loans shall be subject to all of the terms and conditions of this
Agreement and (ii) the Agent shall not be obligated to make more than one Swing Loan during any one day. 
 (d) Refunding of Swing
Loans. In its sole and absolute discretion, the Agent may at any time, on behalf of the Borrower (which hereby irrevocably authorizes the Agent to act on its behalf for such purpose) and with notice to the Borrower, request each Lender to make a
Revolving Loan in the form of a Base Rate Loan in an amount equal to such Lender’s Percentage of the amount of the Swing Loans outstanding on the date such notice is given. Unless an Event of Default described in Section 7.1(j) or 7.1(k)
exists with respect to the Borrower, regardless of the existence of any other Event of Default, each Lender shall make the proceeds of its requested Revolving Loan available to the Agent, in immediately available funds, at the Agent’s principal
office in Cincinnati, Ohio, before 12:00 Noon (Cincinnati time) on the Business Day following the day such notice is given. The proceeds of such Borrowing of Revolving Loans shall be immediately applied to repay the outstanding Swing Loans.

 (e) Participations. If any Lender refuses or otherwise fails to make a Revolving Loan when requested by the Agent pursuant to
Section 2.12(d) above (because an Event of Default described in Section 7.1(j) or 7.1(k) exists with respect to the Borrower or otherwise), such Lender will, by the time and in the manner such Revolving Loan was to have been funded to the
Agent, purchase from the Agent an undivided participating interest in the outstanding Swing Loans in an amount equal to its Percentage of the aggregate principal amount of Swing Loans that were to have been repaid with such Revolving Loans. Each
Lender that so purchases a participation in a Swing Loan shall thereafter be entitled to receive its Percentage of each payment of principal received on the Swing Loan and of interest received thereon accruing from the date such Lender funded to the
Agent its participation in such Loan. The several obligations of the Lenders under this Section shall be absolute, irrevocable and unconditional under any and all circumstances whatsoever and shall not be subject to any set-off, counterclaim or
defense to payment which any Lender may have or have had against the Borrower, any other Lender or any other Person whatever. Without limiting the generality of the foregoing, such obligations shall not be affected by any Default or Event of Default
or by any reduction or termination of the Commitments of any Lender, and each payment made by a Lender under this Section shall be made without any offset, abatement, withholding or reduction whatsoever; provided that, notwithstanding
anything to the contrary in this Section, a Lender shall not have any obligation to acquire a participation in a Swing Loan pursuant to this paragraph if a Default or an Event of Default shall have occurred and be continuing at the time such Swing
Loan was made and such Lender shall have notified the Agent in writing, at least one Business Day prior to the time such Swing Loan was made, that such Default or Event of Default has occurred, whether such Lender has knowledge of such Default or
Event of Default as a result of a notice received pursuant to Section 9.3 or otherwise, and that such Lender will not acquire participations in Swing Loans made while such Default or Event of Default is continuing. 
  

 -25- 

 SECTION 3. CONDITIONS PRECEDENT. 
 The obligation of each Lender to advance, continue or convert any Loan (other than the continuation of, or conversion into, a Base Rate Loan) or of the
L/C Issuer to issue, extend the expiration date (including by not giving notice of non-renewal) of or increase the amount of any Letter of Credit under this Agreement, shall be subject to the following conditions precedent: 
 Section 3.1. All Credit Events. At the time of each Credit Event hereunder: 
 (a) each of the representations and warranties set forth herein shall be and remain true and correct in all material respects as of said
time, except to the extent the same expressly relate to an earlier date, which representations and warranties shall continue to be true and correct in all material respects as of such earlier date; 
 (b) the Borrower and each Subsidiary shall be in compliance with all of the terms and conditions hereof and of the other Loan Documents to
which it is a party, and no Default or Event of Default shall have occurred and be continuing or would occur as a result of such Credit Event; 
 (c) in the case of a Borrowing the Agent shall have received the notice required by Section 2.4 hereof, in the case of the issuance of any Letter of Credit the L/C Issuer shall have received a duly completed
Application together with any fees called for by Section 2.11 hereof, and, in the case of an extension or increase in the amount of a Letter of Credit, a written request therefor in a form acceptable to the L/C Issuer together with fees
called for by Section 2.11 hereof; and 
 (d) such Credit Event shall not violate any order, judgment or decree of any
court or other authority or any provision of law or regulation applicable to the Agent or any Lender (including, without limitation, Regulation U of the Board of Governors of the Federal Reserve System) as then in effect. 
 Each request for a Borrowing hereunder and each request for the issuance of, increase in the amount of, or extension of the expiration date of, a Letter
of Credit shall be deemed to be a representation and warranty by the Borrower on the date of such Credit Event as to the facts specified in subsections (a) through (c), both inclusive, of this Section. 
 Section 3.2. Initial Credit Event. Before or concurrently with the initial Credit Event: 
 (a) the Agent shall have received for each Lender such Lender’s duly executed Notes of the Borrower dated the date hereof and
otherwise in compliance with the provisions of Section 2.10 hereof; 
 (b) intentionally left blank; 

 

 -26- 

 (c) the Agent shall have received for each Lender copies of the Borrower’s articles
of incorporation and bylaws (or comparable organizational documents) and any amendments thereto, certified in each instance by its Secretary or Assistant Secretary; 
 (d) the Agent shall have received for each Lender copies of resolutions of the Borrower’s Board of Directors (or similar governing
body) authorizing the execution, delivery and performance of this Agreement and the other Loan Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby, together with specimen signatures of the
persons authorized to execute such documents on the Borrower’s behalf, all certified in each instance by its Secretary or Assistant Secretary; 
 (e) the Agent shall have received for each Lender copies of the certificates of good standing for the Borrower (dated no earlier than 45 days prior to the date hereof) from the office of the secretary of state or
other appropriate governmental department or agency of the state of its incorporation or organization and of each state in which it is qualified to do business as a foreign corporation or organization; 
 (f) the Agent shall have received for each Lender a list of the Borrower’s Authorized Representatives; 
 (g) the Agent shall have received for itself and for the Lenders the initial fees called for by Section 2.11 hereof; 
 (h) each Lender shall have received such evaluations and certifications as it may reasonably require in order to satisfy itself as to the
financial condition of the Borrower, and the lack of material contingent liabilities of the Borrower; 
 (i) the Agent shall
have received financing statement, tax, and judgment lien search results against the Property of the Borrower and ABI evidencing the absence of Liens on its Property except for Permitted Liens and Liens on the assets of ABI under the Existing ABI
Facility (which Liens shall be released in connection with the initial Credit Event); 
 (j) the Agent shall have received a
pay-off letter from Merrill Lynch Professional Clearing Corp. setting forth, among other things, the total amount of indebtedness outstanding and owing under the Existing ABI Facility (and outstanding letters of credit issued for the account of
ABI), which pay-off letter shall include a general release of all collateral securing such Existing ABI Facility upon the repayment of such indebtedness with the proceeds of the initial Credit Event, and shall otherwise be in form and substance
acceptable to the Agent; 
 (k) the Existing Credit Agreement shall have been terminated and all amounts owing thereunder
(including all principal, interest and accrued fees) shall have been paid (or shall contemporaneously be paid) in full; 
  

 -27- 

 (l) intentionally left blank; 
 (m) all conditions precedent to the ABI Merger shall have been satisfied (or waived in writing pursuant to the terms of the Merger
Agreement) and the Agent shall have received evidence satisfactory to it of the foregoing; 
 (n) the Agent shall have
received a solvency certificate and a pro forma balance sheet of the Borrower and its Subsidiaries (after giving effect to the ABI Merger) and the same shall be satisfactory to the Agent; 
 (o) the Agent shall have received for each Lender the favorable written opinion of counsel to the Borrower (which may be the in house
counsel of the Borrower), in form and substance satisfactory to the Agent; 
 (p) the Agent shall have received a copy of the
Borrower’s temporary investment policy, as approved by the Borrower’s board of directors, certified by an officer of the Borrower acceptable to the Agent; and 
 (q) the Agent shall have received for the account of the Lenders such other agreements, instruments, documents, certificates, and opinions
as the Agent may reasonably request. 
 By execution of this Agreement, each of the Lenders that is a lender under the Existing Credit
Agreement hereby waives any requirement set forth in the Existing Credit Agreement of prior notice of the termination of the commitments thereunder. 
  

	SECTION 4.	THE GUARANTIES. 

 Section 4.1. Guaranties. The payment and performance of the Obligations shall at all times be guaranteed by each direct and indirect Material Subsidiary of the Borrower pursuant to one or more guaranty agreements in the form
attached hereto as Exhibit G, as the same may be amended, modified or supplemented from time to time (individually a “Guaranty” and collectively the “Guaranties”). 
 Section 4.2. Further Assurances. In the event the Borrower or any Material Subsidiary forms or acquires any other Material Subsidiary after
the date hereof, the Borrower shall promptly upon such formation or acquisition cause such newly formed or acquired Material Subsidiary to execute a Guaranty. In the event that any Subsidiary that has not previously executed a Guaranty becomes a
Material Subsidiary after the date hereof, the Borrower shall promptly cause such Material Subsidiary to execute a Guaranty. 
 Section 4.3. Guarantor Release. So long as no Default or Event of Default exists or would arise as a result of a release under this Section, in the event that any Subsidiary that was a Material Subsidiary and had executed a
Guaranty ceases to be a Material Subsidiary, such Subsidiary shall be deemed to be released from its Guaranty until such time as such Subsidiary again becomes a Material Subsidiary. 
  

 -28- 

 Section 4.4. Exclusion of Foreign Subsidiaries. Notwithstanding anything in this
Section 4 to the contrary, unless otherwise required by the Agent or the Required Lenders during the existence of any Event of Default, a Foreign Subsidiary shall not be required to provide a Guaranty. 
  

	SECTION 5.	REPRESENTATIONS AND WARRANTIES. 

 The Borrower represents and warrants to each Lender and the Agent, and agrees, that: 
 Section 5.1.
Organization and Qualification. The Borrower and each of its Material Subsidiaries (i) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, (ii) has the power and authority to
own its property and to transact the business in which it is engaged and proposes to engage and (iii) is duly qualified and in good standing in each jurisdiction where the ownership, leasing or operation of property or the conduct of its
business requires such qualification, except where the failure to be so qualified and in good standing could not reasonably be expected to have a Material Adverse Effect. 
 Section 5.2. Authority and Enforceability. The Borrower has full right and authority to enter into this Agreement and the other Loan Documents executed by it, to make the borrowings herein provided for, to
issue its Notes in evidence thereof, and to perform all of its obligations hereunder and under the other Loan Documents executed by it. Each Material Subsidiary has full right and authority to enter into the Loan Documents executed by it, to
guarantee the Obligations, and to perform all of its obligations under the Loan Documents executed by it. The Loan Documents delivered by the Borrower and by each Material Subsidiary have been duly authorized, executed, and delivered by such Person
and constitute valid and binding obligations of such Person enforceable against it in accordance with their terms, except as enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance or similar laws affecting creditors’
rights generally and general principles of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law); and this Agreement and the other Loan Documents do not, nor does the performance or
observance by the Borrower or any Material Subsidiary of any of the matters and things herein or therein provided for, (a) contravene or constitute a default under any provision of law or any judgment, injunction, order or decree binding upon
the Borrower or any Material Subsidiary or any provision of the organizational documents (e.g., charter, articles of incorporation or bylaws, articles of association or operating agreement, partnership agreement or other similar document) of
the Borrower or any Material Subsidiary, in each case where such contravention or default, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect, (b) contravene or constitute a default under any
covenant, indenture or agreement of or affecting the Borrower or any Material Subsidiary or any of its Property, in each case where such contravention or default, individually or in the aggregate, could reasonably be expected to have a Material
Adverse Effect or (c) result in the creation or imposition of any Lien on any Property of the Borrower or any Material Subsidiary. 
 Section 5.3. Financial Reports. The audited consolidated financial statements of the Borrower and its Subsidiaries as at December 31, 2005, heretofore furnished to the Agent, fairly and adequately present the consolidated
financial condition of the Borrower and its Subsidiaries 

  

 -29- 

 
as at said dates and the consolidated results of their operations and cash flows for the periods then ended in conformity with GAAP applied on a consistent
basis. Except as disclosed to the Agent and the Lenders in writing, neither the Borrower nor any Material Subsidiary has contingent liabilities or judgments, orders or injunctions against it that are material to it other than as indicated on such
financial statements or, with respect to future periods, on the financial statements furnished pursuant to Section 6.1 hereof. 
 Section 5.4. No Material Adverse Effect. Since December 31, 2005, there has been no Material Adverse Effect. 
 Section 5.5. Litigation and other Controversies. There is no litigation, arbitration or governmental proceeding pending or, to the knowledge of the Borrower and its Material Subsidiaries, threatened against the Borrower or any
of its Material Subsidiaries that could reasonably be expected to have a Material Adverse Effect. 
 Section 5.6. True and Complete
Disclosure. All information furnished by or on behalf of the Borrower or any of its Material Subsidiaries in writing to the Agent or any Lender for purposes of or in connection with this Agreement, or any transaction contemplated herein, is true
and accurate in all material respects and not incomplete by omitting to state any fact necessary to make such information (taken as a whole) not misleading in light of the circumstances under which such information was provided. 
 Section 5.7. Use of Proceeds; Margin Stock. (a) All proceeds of Loans shall be used by the Borrower to repay all indebtedness under the
Existing ABI Facility and the Existing Credit Agreement and for working capital purposes and other general corporate purposes of the Borrower and its Subsidiaries. No part of the proceeds of any Loan or other extension of credit hereunder will be
used by the Borrower or any Subsidiary thereof to purchase or carry any margin stock (within the meaning of Regulation U of the Board of Governors of the Federal Reserve System) or to extend credit to others for the purpose of purchasing or
carrying any margin stock. Neither the making of any Loan or other extension of credit hereunder nor the use of the proceeds thereof will violate or be inconsistent with the provisions of Regulations T, U or X of the Board of Governors of the
Federal Reserve System and any successor to all or any portion of such regulations. Margin Stock (as defined above) constitutes less than 25% of the value of those assets of the Borrower and its Subsidiaries that are subject to any limitation on
sale, pledge or other restriction hereunder. 
 Section 5.8. Taxes. The Borrower and each of its Subsidiaries has timely filed or
caused to be timely filed all tax returns required to be filed by the Borrower and/or any of its Subsidiaries. The Borrower and each of its Subsidiaries has paid all Taxes other than Taxes which are not delinquent, and other than those contested in
good faith and for which adequate reserves have been established in accordance with GAAP and as to which no Lien exists, except for Permitted Liens. 
 Section 5.9. ERISA. The Borrower and each other member of its Controlled Group has fulfilled its obligations under the minimum funding standards of, and is in compliance in all material respects with,
ERISA and the Code to the extent applicable to it and, other than a 

  

 -30- 

 
liability for premiums under Section 4007 of ERISA, has not incurred any liability to the PBGC or a Plan (other than a “multiemployer plan” as
defined under Section 3(37) of ERISA) under Title IV of ERISA. The Borrower and its Subsidiaries have no contingent liabilities with respect to any post-retirement benefits under a welfare plan, as defined in Section 3(l) of ERISA,
other than liability for continuation coverage described in article 6 of Title 1 of ERISA and applicable state law. 
 Section 5.10. Material Subsidiaries. Schedule 5.10 correctly sets forth each Material Subsidiary of the Borrower, its respective jurisdiction of organization and the percentage ownership (direct and indirect) of the
Borrower in each class of capital stock or other equity interests of each of its Material Subsidiaries and also identifies the direct owner thereof. The Borrower shall provide the Agent with a supplement to Schedule 5.10 at any time a new
Material Subsidiary is added or at any time a Subsidiary ceases to be a Material Subsidiary. 
 Section 5.11. Compliance with
Laws. The Borrower and each of its Material Subsidiaries is in compliance with all applicable statutes, regulations and orders of, and all applicable restrictions imposed by, all governmental authority, or any subdivision thereof, in respect of
the conduct of their businesses and the ownership of their property, except such noncompliances as could not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. 
 Section 5.12. Environmental Matters. The Borrower and each of its Subsidiaries is in compliance with all applicable Environmental Laws and
the requirements of any permits issued under such Environmental Laws, except to the extent that the aggregate effect of all noncompliances could not reasonably be expected to have a Material Adverse Effect. There are no pending or, to the best
knowledge of the Borrower and its Subsidiaries after due inquiry, threatened Environmental Claims, including any such claims (regardless of materiality) for liabilities under CERCLA relating to the disposal of Hazardous Materials, against the
Borrower or any of its Subsidiaries or any real property, including leaseholds, owned or operated by the Borrower or any of its Subsidiaries, except to the extent that the aggregate effect of all noncompliances could not reasonably be expected to
have a Material Adverse Effect. There are no facts, circumstances, conditions or occurrences on any real property, including leaseholds, owned or operated by the Borrower or any of its Subsidiaries that, to the best knowledge of the Borrower and its
Subsidiaries after due inquiry, could reasonably be expected (i) to form the basis of an Environmental Claim against the Borrower or any of its Subsidiaries or any such real property, or (ii) to cause any such real property to be subject
to any restrictions on the ownership, occupancy, use or transferability of such real property by the Borrower or any of its Subsidiaries under any applicable Environmental Law, expect such restrictions as could not reasonably be expected to have,
either individually or in the aggregate, a Material Adverse Effect. Hazardous Materials have not been Released on or from any real property arising from or relating to the operations of the Borrower or any of its Subsidiaries, including leaseholds,
owned or operated by the Borrower or any of its Subsidiaries where such Release, individually, may reasonably be expected to require in excess of $500,000 in response costs under any applicable Environmental Law. 
  

 -31- 

 Section 5.13. Investment Company; Public Utility Holding Company. Neither the Borrower nor
any Subsidiary is an “investment company” or a company “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as amended, or a “public utility holding company” within
the meaning of the Public Utility Holding Company Act of 1935, as amended. 
 Section 5.14. Intellectual Property. The Borrower
and each of its Material Subsidiaries owns all the patents, trademarks, permits, service marks, trade names, copyrights, franchises and formulas, or rights with respect to the foregoing, or each has obtained licenses of all other rights of whatever
nature necessary for the present conduct of its businesses, in each case without any known conflict with the rights of others which, or the failure to obtain which, as the case may be, could reasonably be expected to result in a Material Adverse
Effect. 
 Section 5.15. Good Title. The Borrower and its Material Subsidiaries have good and marketable title, or valid
leasehold interests, to their assets as reflected on the Borrower’s most recent consolidated balance sheet provided to the Agent, except for sales of assets in the ordinary course of business and other sales of assets not prohibited by this
Agreement, subject to no Liens, other than Permitted Liens and the Liens under the Existing ABI Facility, which Liens under the Existing ABI Facility shall be released upon the repayment of indebtedness thereunder in connection with the initial
Credit Extension. 
 Section 5.16. Labor Relations. To the best knowledge of the Borrower, neither the Borrower nor any of its
Material Subsidiaries is engaged in any unfair labor practice that could reasonably be expected to have a Material Adverse Effect. There is (i) no strike, labor dispute, slowdown or stoppage pending against the Borrower or any of its
Subsidiaries or, to the best knowledge of the Borrower and its Material Subsidiaries, threatened in writing against the Borrower or any of its Material Subsidiaries and (ii) to the best knowledge of the Borrower and its Material Subsidiaries,
no union representation proceeding is pending with respect to the employees of the Borrower or any of its Material Subsidiaries and no union organizing activities are taking place, except (with respect to any matter specified in clause (i) or
(ii) above, either individually or in the aggregate) such as could not reasonably be expected to have a Material Adverse Effect. 
 Section 5.17. Indebtedness. Schedule 5.17 sets forth a true and complete list of all Indebtedness of the Borrower and its Material Subsidiaries as of the Closing Date, in each case showing the aggregate principal amount
thereof and the name of the respective borrower and any guarantor. 
 Section 5.18. Capitalization. All outstanding shares of
capital stock or other equity interests of the Borrower and its Material Subsidiaries have been duly authorized and validly issued, and are fully paid and nonassessable, and as of the Closing Date, except as disclosed on Schedule 5.18, there are no
outstanding commitments or other obligations of the Borrower or any Material Subsidiary to issue, and no rights of any Person to acquire, any shares of any capital stock or other equity interests of any Material Subsidiary. Schedule 5.18 also
sets forth the capitalization of the Borrower after giving effect to the ABI Merger. 
  

 -32- 

 Section 5.19. Other Agreements. Neither the Borrower nor any Material Subsidiary is in
default under the terms of any covenant, indenture or agreement of or affecting the Borrower, any Material Subsidiary or any of their Property, which default if uncured could reasonably be expected to have a Material Adverse Effect. 
 Section 5.20. Governmental Authority and Licensing. The Borrower and its Material Subsidiaries have received all licenses, permits, and
approvals of all federal, state, local, and foreign governmental authorities, if any, necessary to conduct their businesses, in each case where the failure to obtain or maintain the same could reasonably be expected to have a Material Adverse
Effect. No investigation or proceeding that, if adversely determined, could reasonably be expected to result in revocation or denial of any material license, permit or approval is pending or, to the knowledge of the Borrower, threatened, in each
case, where the revocation or denial of such license, permit or approval could reasonably be expected to have a Material Adverse Effect. 
 Section 5.21. Approvals. No authorization, consent, license or exemption from, or filing or registration with, any court or governmental department, agency or instrumentality, nor any approval or consent of any other Person, is
or will be necessary to the valid execution, delivery or performance by the Borrower or any Material Subsidiary of any Loan Document, except for such approvals which have been obtained prior to the date of this Agreement and remain in full force and
effect. 
 Section 5.22. Affiliate Transactions. Neither the Borrower nor any Subsidiary is a party to any contracts or
agreements with any of its Affiliates (other than with Wholly-owned Subsidiaries) on terms and conditions which are less favorable to the Borrower or such Subsidiary than would be usual and customary in similar contracts or agreements between
Persons not affiliated with each other. 
 Section 5.23. Solvency. The Borrower and its Material Subsidiaries are solvent, able
to pay their debts as they become due, and have sufficient capital to carry on their business and all businesses in which they are about to engage. 
 Section 5.24. Foreign Assets Control Regulations and Anti-Money Laundering. (a) OFAC. The Borrower is not (i) a person whose property or interest in property is blocked or subject to blocking pursuant to
Section 1 of Executive Order 13224 of September 23, 2001 Blocking Party and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism (66 Fed. Reg. 49079 (2001)), (ii) a person who engages in any
dealings or transactions prohibited by Section 2 of such executive order, or is otherwise associated with any such person in any manner violative of Section 2, or (iii) a person on the list of Specially Designated Nationals and
Blocked Persons or subject to the limitations or prohibitions under any other U.S. Department of Treasury’s Office of Foreign Assets Control regulation or executive order. 
 (b) Patriot Act. The Borrower is in compliance, in all material respects, with the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law
October 26, 2001)) (the “Patriot Act”). No part of the proceeds of the Loans will be used, directly or indirectly, for any payments to any 

  

 -33- 

 
governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official
capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as Amended. 
  

	SECTION 6.	COVENANTS. 

 The Borrower covenants
and agrees that, so long as any Loans or Letters of Credit are available to the Borrower under the Revolving Credit and until all Obligations are paid in full: 
 Section 6.1. Information Covenants. The Borrower will furnish to the Agent, with sufficient copies for each Lender: 
 (a) Quarterly Statements. Within 45 days after the close of each quarterly accounting period in each fiscal year of the Borrower
or, if earlier, within 10 days of the date the Borrower is required to file its Form 10-Q with the Securities and Exchange Commission or any governmental agencies substituted therefor (the “SEC”), the Borrower’s consolidated
balance sheet as at the end of such quarterly accounting period and the related consolidated statements of income and retained earnings and of cash flows for such quarterly accounting period and for the elapsed portion of the fiscal year ended with
the last day of such quarterly accounting period, in each case setting forth comparative figures for the related periods in the prior fiscal year, all of which shall be in reasonable detail, prepared by the Borrower in accordance with GAAP, and
certified by the chief financial officer or other officer of the Borrower reasonably acceptable to the Agent that they fairly present in all material respects in accordance with GAAP the financial condition of the Borrower and its Subsidiaries as of
the dates indicated and the results of their operations and changes in their cash flows for the periods indicated, subject to normal year-end audit adjustments and the absence of footnotes. 
 (b) Annual Statements. Within 120 days after the close of each fiscal year of the Borrower or, if earlier, within 10 days of the
date the Borrower is required to file its Form 10-K with the SEC, a copy of the Borrower’s consolidated balance sheet as of the last day of the fiscal year then ended and the Borrower’s consolidated statements of income, retained earnings,
and cash flows for the fiscal year then ended, and accompanying notes thereto, each in reasonable detail showing in comparative form the figures for the previous fiscal year, which consolidated balance sheet and income statement shall be accompanied
by an unqualified opinion of a firm of independent public accountants of recognized national standing, selected by the Borrower and reasonably acceptable to the Agent, to the effect that such consolidated financial statements have been prepared in
accordance with GAAP and present fairly in accordance with GAAP the consolidated financial condition of the Borrower and its Subsidiaries as of the close of such fiscal year and the results of their operations and cash flows for the fiscal year then
ended and that an examination of such accounts in connection with such financial statements has been made in accordance with generally accepted auditing standards. 
  

 -34- 

 (c) Officer’s Certificates. At the time of the delivery of the financial
statements provided for in Section 6.1(a) and (b), a certificate of the chief financial officer or other officer of the Borrower reasonably acceptable to Agent in the form of Exhibit E (x) stating no Default or Event of Default has
occurred during the period covered by such statements of, if a Default or Event of Default exists, a detailed description of the Default or Event of Default and all actions the Borrower is taking with respect to such Default or Event of Default,
(y) confirming that the representations and warranties stated in Section 5 remain true and correct in all material respects (except to the extent such representations and warranties relate to an earlier date, in which case they are true
and correct as of such date), and (z) showing the Borrower’s compliance with the covenants set forth in Section 6.18. 
 (d) Budgets. (i) As soon as available, but in any event at least 30 days prior to the first day of each fiscal year of the Borrower, a draft budget in form reasonably satisfactory to the Agent (including, without limitation, a
breakdown of the projected results of each line of business of the Borrower and its Material Subsidiaries, and budgeted consolidated statements of income, and sources and uses of cash and balance sheets for the Borrower and its Material
Subsidiaries) of the Borrower and its Material Subsidiaries in reasonable detail reasonably satisfactory to the Agent for each fiscal month and, with appropriate discussion, the principal assumptions upon which such budget is based. 
 (ii) Within 30 days after the approval of the draft budget described in this Section 6.1(d) by the Borrower’s board of
directors, the final budget in form reasonably satisfactory to the Agent (including, without limitation, a breakdown of the projected results of each line of business of the Borrower and its Material Subsidiaries, and budgeted consolidated
statements of income, and sources and uses of cash and balance sheets for the Borrower and its Material Subsidiaries) of the Borrower and its Material Subsidiaries in reasonable detail reasonably satisfactory to the Agent for each fiscal month and,
with appropriate discussion, the principal assumptions upon which such budget is based. 
 (e) Notice of Default or
Litigation. Promptly, and in any event within three Business Days after any Responsible Officer obtains knowledge thereof, notice of (i) the occurrence of any event which constitutes a Default or an Event of Default or any other event which
could reasonably be expected to have a Material Adverse Effect, which notice shall specify the nature thereof, the period of existence thereof and what action the Borrower proposes to take with respect thereto, (ii) the commencement of, or
threat of, or any significant development in, any litigation, labor controversy, arbitration or governmental proceeding pending against the Borrower or any of its Material Subsidiaries which, if adversely determined, could reasonably be expected to
have a Material Adverse Effect. 
 (f) Management Letters. Promptly after the Borrower’s receipt thereof, a copy
of each report or any “management letter” submitted to the Borrower or any of its 

  

 -35- 

 
Material Subsidiaries by its certified public accountants and the management’s responses thereto. 
 (g) Other Reports and Filings. Promptly, copies of all material financial information, proxy materials and other material
information, certificates, reports, statements and completed forms, if any, which the Borrower or any of its Material Subsidiaries (x) has filed with the SEC or any comparable agency outside of the United States, or (y) has furnished to
the shareholders of the Borrower. 
 (h) Other Information. From time to time, such other information or documents
(financial or otherwise) as the Agent or any Lender may reasonably request. 
 Any items required to be delivered under Section 6.1(a), (b) or
(g) need not to be separately delivered to the Agent if such items are publicly available through the SEC; provided that such items are filed with the SEC within the time allotted in such Sections and, with respect to each such item
other than a Form 10-K or a Form 10-Q, the Borrower furnishes to the Agent within the time allotted in such Sections a written notice of such filing. 
 Section 6.2. Inspections. The Borrower will, and will cause each Subsidiary to, permit officers, representatives and agents of the Agent or any Lender, to visit and inspect any Property of the Borrower or
such Subsidiary, and to examine the books of account of the Borrower or such Subsidiary and discuss the affairs, finances and accounts of the Borrower or such Subsidiary with its and their officers and independent accountants, all at such reasonable
times during normal business hours as the Agent or any Lender may request. Notwithstanding the foregoing, so long as no Default or Event of Default shall have occurred and be continuing, Borrower shall not be responsible for the charges incurred in
connection with inspections to the extent that such inspections (i) are done more frequently than one time during any fiscal year or (ii) are incurred for any inspection of any Subsidiary that is not a Material Subsidiary. 
 Section 6.3. Maintenance of Property, Insurance, Environmental Matters, etc. (a) The Borrower will, and will cause each of its Material
Subsidiaries to, (i) keep its property, plant and equipment necessary to its business and operations in good repair, working order and condition, normal wear and tear excepted, and shall from time to time make to all needful and proper repairs,
renewals, replacements, extensions, additions, betterments and improvements thereto so that at all times such property, plant and equipment are reasonably preserved and maintained and (ii) maintain in full force and effect with financially
sound and reputable insurance companies insurance which provides substantially the same (or greater) coverage and against at least such risks as is in accordance with industry practice, and shall furnish to the Agent upon request full information as
to the insurance so carried. 
 (b) Without limiting the generality of Section 6.3(a), the Borrower and its Material Subsidiaries:
(i) shall comply with, and maintain all real property in compliance with, any applicable Environmental Laws, except to the extent that the aggregate affect of all noncompliance could not reasonably be expected to have a Material Adverse Effect;
(ii) shall obtain and maintain in full force and effect all governmental approvals required for its operations at or on its properties by any applicable Environmental Laws; (iii) shall cure as soon as 

  

 -36- 

 
reasonably practicable any violation of applicable Environmental Laws with respect to any of its properties which individually or in the aggregate may
reasonably be expected to have a Material Adverse Effect; (iv) shall not, and shall not permit any other Person to, own or operate on any of its properties any landfill or dump or hazardous waste treatment, storage or disposal facility as
defined pursuant to the RCRA, or any comparable state law; and (v) shall not use, generate, treat, store, release or dispose of Hazardous Materials at or on any of the real property except in the ordinary course of its business and in
compliance with all Environmental Laws. With respect to any Release of Hazardous Materials, the Borrower and its Material Subsidiaries shall conduct any necessary or required investigation, study, sampling and testing, and undertake any cleanup,
removal, remedial or other response action necessary to remove, cleanup or abate any material quantity of Hazardous Materials released at or on any of its properties as required by any governmental authority pursuant to any applicable Environmental
Law. 
 Section 6.4. Preservation of Existence. The Borrower will, and will cause each of its Material Subsidiaries to, do or
cause to be done, all things necessary to preserve and keep in full force and effect its existence and, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect, its franchises, authority to do business,
licenses, patents, trademarks, copyrights and other proprietary rights; provided, however, that nothing in this Section 6.4 shall prevent, to the extent permitted by Section 6.13, sales of assets by the Borrower or any of its
Subsidiaries, the dissolution or liquidation of any Subsidiary of the Borrower, or the merger or consolidation between or among the Subsidiaries of the Borrower. 
 Section 6.5. Compliance with Laws. The Borrower shall, and shall cause each Material Subsidiary to, comply in all respects with the requirements of all federal, state, local, and foreign laws, rules,
regulations, ordinances and orders applicable to its property or business operations, where any such non-compliance, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or result in a Lien upon any of its
Property, other than a Permitted Lien. 
 Section 6.6. ERISA. The Borrower shall, and shall cause each Subsidiary to, promptly
pay and discharge all obligations and liabilities arising under ERISA of a character which if unpaid or unperformed could reasonably be expected to have a Material Adverse Effect or result in a Lien upon any of its Property. The Borrower shall, and
shall cause each Subsidiary to, promptly notify the Agent and each Lender of: (a) the occurrence of any reportable event (as defined in Section 4043 of ERISA, excluding, however, such events as to which the PBGC by regulation has waived
the notice requirements under Section 4043(a) except for waivers with respect to the occurrence of the disqualification of a Plan or the failure to meet the minimum funding standards under Section 412 of the Code or Section 302 of
ERISA) with respect to a Plan, (b) receipt of any notice from the PBGC of its intention to seek termination of any Plan or appointment of a trustee therefor, (c) its intention to terminate or withdraw from any Plan, and (d) the
occurrence of any event with respect to any Plan which would result in the incurrence by the Borrower or any Subsidiary of any material liability, fine or penalty, or any material increase in the contingent liability of the Borrower or any
Subsidiary with respect to any post-retirement Welfare Plan benefit. 
  

 -37- 

 Section 6.7. Payment of Taxes. The Borrower will, and will cause each of its Material
Subsidiaries to, pay and discharge, all taxes, assessments, fees and other governmental charges imposed upon it or any of its Property (collectively, “Taxes”), before becoming delinquent and before any penalties accrue thereon,
unless and to the extent that the same are being contested in good faith and by proper proceedings and as to which appropriate reserves are provided therefor, unless and until any Lien or Liens resulting from Taxes aggregating in excess of
$10,000,000 attaches to any of its Property and any such Lien is unbonded and any proceeding relating to the enforcement of any such Lien is not stayed. 
 Section 6.8. Contracts With Affiliates. The Borrower shall not, nor shall it permit any Subsidiary to, enter into any contract, agreement or business arrangement with any of its Affiliates on terms and
conditions which are less favorable to the Borrower or such Subsidiary than would be usual and customary in similar contracts, agreements or business arrangements between Persons not affiliated with each other. 
 Section 6.9. No Changes in Fiscal Year. The Borrower shall not, nor shall it permit any Subsidiary to, change its fiscal year from its
present basis. 
 Section 6.10. Change in the Nature of Business. The Borrower shall not, nor shall it permit any Material
Subsidiary to, engage in any business or activity if as a result the general nature of the business of the Borrower or any Material Subsidiary would be changed in any material respect from the general nature of the business engaged in by the
Borrower or any Subsidiary as of the Closing Date. For the purpose of this Section, any business reasonably related to the business of the Borrower, the Subsidiaries and ABI as of the Closing Date shall be presumptively deemed to not be a change in
the nature of the Borrower’s business. 
 Section 6.11. Indebtedness. The Borrower will not, and will not permit any of its
Subsidiaries to, contract, create, incur, assume or suffer to exist any Indebtedness, except; 
 (a) the Obligations of the
Borrower and its Subsidiaries owing to the Agent and the Lenders; 
 (b) intercompany Indebtedness among the Borrower and its
Subsidiaries to the extent permitted by Section 6.14; 
 (c) purchase money Indebtedness and Capitalized Lease
Obligations of the Borrower and its Subsidiaries in an amount not to exceed $10,000,000 in the aggregate at any one time outstanding; 
 (d) Indebtedness and obligations owing under Hedging Agreements entered into to manage existing or anticipated interest rate, currency or commodity risks and not for speculative purposes; and 
 (e) the Existing ABI Facility which shall be paid in full substantially concurrently with the initial Credit Extension. 
  

 -38- 

 Section 6.12. Liens. The Borrower will not, and will not permit any of its Subsidiaries to,
create, incur or suffer to exist any Lien on any of its Property; provided that the foregoing shall not prevent the following (the Liens described below, the “Permitted Liens”): 
 (a) inchoate Liens for the payment of Taxes which are not yet due and payable or the payment of which is not required by Section 6.7;

 (b) Liens arising by statute in connection with worker’s compensation, unemployment insurance, old age benefits,
social security obligations, taxes, assessments, statutory obligations or other similar charges (other than Liens arising under ERISA), good faith cash deposits in connection with tenders, contracts or leases to which the Borrower or any Subsidiary
is a party or other cash deposits required to be made in the ordinary course of business, provided in each case that the obligation is not for borrowed money and that the obligation secured is not overdue or, if overdue, is being contested in good
faith by appropriate proceedings which prevent enforcement of the matter under contest and adequate reserves have been established therefor; 
 (c) mechanics’, workmen’s, materialmen’s, landlords’, carriers’ or other similar Liens arising in the ordinary course of business with respect to obligations which are not due or which are
being contested in good faith by appropriate proceedings which prevent enforcement of the matter under contest; 
 (d) Liens
created by or pursuant to this Agreement; 
 (e) any interest or title of a lessor under any operating lease or Capital Lease;
and 
 (f) Liens on property of the Borrower or any Subsidiary created solely for the purpose of securing indebtedness
permitted by Section 6.11(c) hereof, representing or incurred to finance the purchase price of Property, provided that no such Lien shall extend to or cover other Property of the Borrower or such Subsidiary other than the respective Property so
acquired, and the principal amount of indebtedness secured by any such Lien shall at no time exceed the purchase price of such Property, as reduced by repayments of principal thereon; 
 (g) cash deposits to secure performance bonds and other obligations of a like nature (in each case, other than for Indebtedness) incurred
in the ordinary course of business for obligations not yet due or which are being contested in good faith by appropriate proceedings which prevent enforcement of the matter under contest and adequate reserves have been established therefore;

 (h) easements, rights-of-way, zoning and similar restrictions, building codes, reservations, covenants, conditions,
waivers, survey exceptions and other similar encumbrances or title defects and, with respect to any interests in real property held or leased by the Borrower or any of its Subsidiaries, mortgages, deeds of trust and other encumbrances incurred,
created, assumed or permitted to exist and arising by, through or 

  

 -39- 

 
under a landlord or owner of such property encumbering solely such landlord’s or owner’s interest in such real property, with or without the
consent of the lessee; 
 (i) Liens in existence on the date hereof listed on Schedule 6.12; and 
 (j) any interest of a licensor under a license entered into in the ordinary course of the Borrower’s or the applicable
Subsidiary’s business. 
 Section 6.13. Consolidation, Merger, Sale of Assets, etc. The Borrower will not, and will not
permit any of its Material Subsidiaries to, wind up, liquidate or dissolve its affairs or agree to any merger or consolidation, or convey, sell, lease or otherwise dispose of all or any part of its property, including any disposition as part of any
sale-leaseback transactions except that this Section shall not prevent: 
 (a) the sale and lease of inventory in the ordinary
course of business; 
 (b) the sale, transfer or other disposition of any tangible personal property that, in the reasonable
judgment of the Borrower or its Subsidiaries, has become uneconomic, obsolete or worn out or is not used or useful in its business; 
 (c) the sale, transfer, lease, or other disposition of Property of the Borrower and its Material Subsidiaries to one another; 
 (d) the merger of any Subsidiary with and into the Borrower or any other Subsidiary, provided that, in the case of any merger involving the Borrower, the Borrower is the legal entity surviving the merger;

 (e) the merger of Borrower or any Subsidiary with an Affiliate incorporated for the purposes of incorporating the Borrower
or any Subsidiary in another jurisdiction to realize tax or other benefits; provided that in the case of any merger involving the Borrower, the Borrower is the legal entity surviving the merger and in the case of any merger involving the
Borrower or a Material Subsidiary, the surviving entity must be incorporated or otherwise organized under the laws of a jurisdiction within the United States of America. 
 (f) the liquidation or sale of any Subsidiary or its assets if, in the Borrower’s reasonable judgment, such Subsidiary is not
profitable; 
 (g) the sale or issuance of capital stock of a Subsidiary to the Borrower or any Subsidiary; 
 (h) the disposition of the stock or assets of any Subsidiary that is organized under the laws of a jurisdiction outside of the United
States; 
 (i) the ABI Merger; and 
  

 -40- 

 (j) the sale, transfer, lease, or other disposition of other Property of the Borrower or
any Subsidiary (including any disposition of Property as part of a sale and leaseback transaction, but excluding any sale and leaseback transaction, fee in lieu of tax transaction or other similar transaction intended primarily for tax relief and
other tax incentive purposes) aggregating for the Borrower and its Subsidiaries not more than $20,000,000 during any fiscal year of the Borrower. 
 Section 6.14. Advances, Investments and Loans. The Borrower will not, and will not permit any of its Subsidiaries to, directly or indirectly, make loans or advances to or make, retain or have outstanding any investments (whether
through purchase of equity interests or obligations or otherwise) in, any Person or enter into any partnerships or joint ventures, or purchase or own a futures contract or otherwise become liable for the purchase or sale of currency or other
commodities at a future date in the nature of a futures contract, except that this Section shall not prevent: 
 (a)
receivables created in the ordinary course of business and payable or dischargeable in accordance with customary trade terms; 
 (b) investments in Cash Equivalents; 
 (c) investments (including debt obligations) received in connection with the
bankruptcy or reorganization of suppliers and customers and in settlement of delinquent obligations of, and other disputes with, customers and suppliers arising in the ordinary course of business; 
 (d) the Borrower’s investments from time to time in its Subsidiaries, now existing or hereafter acquired or created, and investments
made from time to time by a Subsidiary in or more of its Subsidiaries; 
 (e) intercompany advances made from time to time
from the Borrower to any one or more Subsidiaries in the ordinary course of business; 
 (f) investments existing on the
Closing Date and set forth on Schedule 6.14; 
 (g) extensions of trade credit in the ordinary course of business;

 (h) Indebtedness permitted by Section 6.11; 
 (i) investments in Affiliates and non-related entities conducting business with the Borrower or any Subsidiary, or acting as a supplier or
distributor to the Borrower or any Subsidiary in an aggregate amount not to exceed $20,000,000 in any fiscal year; 
 (j)
investments received in connection with the licensing to non-related entities to market and sell Abraxane; provided, that in each case (i) no Default or Event of Default shall have occurred and be continuing, or would be reasonably
likely to occur after giving effect to such investment and (ii) after giving pro forma effect to such 

  

 -41- 

 
investment, the Borrower shall be in compliance with the the covenants contained in Section 6.18 and the Borrower shall demonstrate such compliance in a
certificate of an officer of Borrower delivered to the Agent prior to the consummation of such investment and such covenants shall be recomputed as at the last day of the most recently ended fiscal quarter of the Borrower for which the relevant
information is available as if such investment had occurred on the first day of each relevant period for testing such compliance; 
 (k) Permitted Acquisitions; 
 (l) those loans existing on the Closing Date made by the Borrower to ABI in an
aggregate principal amount not to exceed $23,000,000; 
 (m) payroll, travel, housing and similar advances to cover matters
that are expected at the time of such advances ultimately to be treated as expenses for accounting purposes and that are made in the ordinary course of business; 
 (n) investments by the Borrower or any Subsidiary in prepaid expenses, negotiable instruments held for collection or lease, workers’
compensation, performance and other similar deposits provided to third parties in the ordinary course of business; 
 (o)
investments in bonds, notes, debentures, capital stock, or other securities that are issued solely as partial consideration of an asset sale permitted pursuant to Section 6.13; provided that such sales shall be made at fair market value;

 (p) investments in the capital stock or other equity interests, or the assets of, or a business, unit or division of, any
Person; provided that in each case (i) such investments are in a Person (or are of assets of a Person) that is in the same or similar business as the business of the Borrower or any Subsidiary or a business related to any such business,
such as that of a supplier to the Borrower, (ii) such investment shall not constitute a Hostile Acquisition, (iii) no Default or Event of Default shall have occurred and be continuing, or could occur after giving effect to such investment
and (iv) after giving pro forma effect to such investment, the Borrower shall be in compliance with the covenants contained in Section 6.18 (with respect to each investment that is in an amount equal to or greater than $10,000,000,
the Borrower shall demonstrate such compliance in a certificate of an officer of Borrower delivered to the Agent prior to the consummation of such investment and such covenants shall be recomputed as at the last day of the most recently ended fiscal
quarter of the Borrower for which the relevant information is available as if such investment had occurred on the first day of each relevant period for testing such compliance); and 
 (q) other investments, loans and advances in addition to those otherwise permitted by this Section in an amount not to exceed $10,000,000
in the aggregate at any one time outstanding. 
  

 -42- 

 Section 6.15. Limitation on Restrictions. The Borrower will not, and it will not permit any
of its Material Subsidiaries to, directly or indirectly, create or otherwise cause or suffer to exist or become effective any restriction on the ability of any such Material Subsidiary to (a) pay dividends or make any other distributions on its
capital stock or other equity interests owned by the Borrower or any other Subsidiary, (b) pay or repay any Indebtedness owed to the Borrower or any other Subsidiary, (c) make loans or advances to the Borrower or any other Subsidiary,
(d) transfer any of its Property to the Borrower or any other Subsidiary, (e) encumber or pledge any of its assets to or for the benefit of the Agent or (f) guaranty the Obligations. 
 Section 6.16. Notice of the Creation of Subsidiaries. The Borrower will provide the Agent with timely notice of the creation or acquisition
of any Subsidiary occurring after the Closing Date. 
 Section 6.17. Dividends and Other Restricted Payments. The Borrower shall
not declare or pay any dividends on or make any other distributions in respect of any of its capital stock or other equity interests. 
 Section 6.18. Financial Covenants. 
 (a) Minimum Net Worth. The Borrower shall not, as of the last day of each
fiscal quarter of the Borrower, permit Net Worth to be less than the sum of (i) 85% of the Net Worth on June 30, 2006, plus (ii) 50% of Net Income for each fiscal quarter of the Borrower (commencing with the fiscal quarter
ending September 30, 2006) for which Net Income is a positive amount (i.e. there shall be no reduction to the minimum amount of Net Worth required to be maintained hereunder for any fiscal quarter in which Net Income is less than zero).

 (b) Leverage Ratio. The Borrower shall not, as of the last day of each fiscal quarter of the Borrower, permit the Leverage Ratio to
be more than 2.75 to 1.00. 
 (c) Interest Coverage Ratio. The Borrower shall not, as of the date day of each fiscal quarter of the
Borrower, permit the Interest Coverage Ratio to be less than 3.00 to 1.00. 
 Section 6.19. Limitation on Non-Material
Subsidiaries. The Borrower shall not permit (i) at any time, the aggregate book value of the assets of all Subsidiaries that are not Material Subsidiaries to exceed 20% of the value of the consolidated assets (including intangible assets)
of the Borrower and its Subsidiaries or (ii) as of the last day of each fiscal quarter of the Borrower, the aggregate revenues of all Subsidiaries that are not Material Subsidiaries during any fiscal year of the Borrower to exceed 20% of the
consolidated revenues of the Borrower and its Subsidiaries during such year. 
  

 -43- 

	SECTION 7.	EVENTS OF DEFAULT AND REMEDIES. 

 Section 7.1. Events of Default. Any one or more of the following shall constitute an “Event of Default” hereunder:

 (a) default in the payment when due (whether at the stated maturity thereof or at any other time provided for in this
Agreement) of all or any part of the principal of any Note or any other Obligation payable hereunder or under any other Loan Document or five days after default in the payment when due of all or any part of the interest on any Note or any other
Obligation payable hereunder or under any other Loan Document; 
 (b) default in the observance or performance of any covenant
set forth in Sections 6.1(e), 6.13 or 6.18 hereof; 
 (c) default in the observance or performance of Section 6.1
(other than subsection (e) thereof), 6.4, 6.11, 6.12, 6.14, 6.15 6.16 or 6.17 hereof which is not remedied within 15 days after the earlier of (i) the date on which such failure shall first become known to any Responsible Officer or
(ii) written notice thereof is given to the Borrower by the Agent or default in the observance or performance of any other provision hereof or of any other Loan Document which is not remedied within 30 days after the earlier of
(i) the date on which such failure shall first become known to any Responsible Officer or (ii) written notice thereof is given to the Borrower by the Agent; 
 (d) any representation or warranty made herein or in any other Loan Document or in any certificate delivered to the Agent or the Lenders
pursuant hereto or thereto or in connection with any transaction contemplated hereby or thereby proves untrue in any material respect as of the date of the issuance or making or deemed making thereof; 
 (e) any event occurs or condition exists (other than those described in subsections (a) through (d) above) which is specified as
an event of default under any of the other Loan Documents, or any of the Loan Documents shall for any reason not be or shall cease to be in full force and effect or is declared to be null and void, or any Subsidiary takes any action for the purpose
of terminating, repudiating or rescinding any Loan Document executed by it or any of its obligations thereunder; 
 (f)
default shall occur under any Indebtedness, or in respect of obligations under one or more Hedging Agreements, of the Borrower or any Subsidiary aggregating in excess of $10,000,000, or under any indenture, agreement or other instrument under which
such Indebtedness may be issued, and, with respect to Indebtedness, such default shall continue for a period of time sufficient to permit the acceleration of the maturity of any such Indebtedness (whether or not such maturity is in fact
accelerated), unless, in all instances, such default is subject to a waiver or forbearance (provided that, for purposes of determining the amount of the obligations of the Borrower or any Subsidiary in respect of any Hedging Agreements at any
time shall be the maximum aggregate amount (giving 

  

 -44- 

 
effect to any netting agreements) that the Borrower or such Subsidiary would be required to pay if such Hedging Agreements were terminated at such time).

 (g) any judgment or judgments, writ or writs or warrant or warrants of attachment, or any similar process or processes,
shall be entered or filed against the Borrower or any Subsidiary, or against any of its Property, in an aggregate amount in excess of $10,000,000 (except to the extent covered by insurance (subject to customary deductibles) pursuant to which the
insurer has accepted liability therefor in writing), and which remains undischarged, unvacated, unbonded or unstayed for a period of 60 days; 
 (h) (i) the Borrower or any Subsidiary, or any member of its Controlled Group, shall fail to pay when due an amount or amounts aggregating in excess of $5,000,0000 which it shall have become liable to pay to the
PBGC or to a Plan under Title IV of ERISA; or (ii) notice of intent to terminate a Plan or Plans (other than a “multiemployer plan” as defined under Section 3(37) of ERISA) having aggregate Unfunded Vested Liabilities in
excess of $5,000,000 (collectively, a “Material Plan”) shall be filed under Title IV of ERISA by the Borrower or any Subsidiary, or any other member of its Controlled Group, any plan administrator or any combination of the
foregoing; or (iii) the PBGC shall institute proceedings under Title IV of ERISA to terminate or to cause a trustee to be appointed to administer any Material Plan; or (iv) a proceeding shall be instituted by a fiduciary of any Plan
that is a “multiemployer plan” under Section 3(37) of ERISA against the Borrower or any Subsidiary, or any member of its Controlled Group, to enforce Section 515 or 4219(c)(5) of ERISA, with respect to which the liability of the
Borrower, any Subsidiary or any member of its Controlled Group is in excess of $5,000,000, and such proceeding shall not have been dismissed within 30 days thereafter; or (v) a condition shall exist by reason of which the PBGC would be entitled
to obtain a decree adjudicating that any Material Plan must be terminated; 
 (i) any Change of Control shall occur;

 (j) the Borrower or any Material Subsidiary shall (i) have entered involuntarily against it an order for relief under
the United States Bankruptcy Code, as amended, (ii) not pay, or admit in writing its inability to pay, its debts generally as they become due, (iii) make an assignment for the benefit of creditors, (iv) apply for, seek, consent to or
acquiesce in, the appointment of a receiver, custodian, trustee, examiner, liquidator or similar official for it or any substantial part of its Property, (v) institute any proceeding seeking to have entered against it an order for relief under
the United States Bankruptcy Code, as amended, to adjudicate it insolvent, or seeking dissolution, winding up, liquidation, reorganization, arrangement, adjustment or composition of it or its debts under any law relating to bankruptcy, insolvency or
reorganization or relief of debtors or fail to file an answer or other pleading denying the material allegations of any such proceeding filed against it, (vi) take any corporate action in furtherance of any matter described in parts (i)
through (v) above, or (vii) fail to contest in good faith any appointment or proceeding described in Section 7.1(k) hereof; or 
  

 -45- 

 (k) a custodian, receiver, trustee, examiner, liquidator or similar official shall be
appointed for the Borrower or any Material Subsidiary, or any substantial part of any of its Property, or a proceeding described in Section 7.1(j)(v) shall be instituted against the Borrower or any Material Subsidiary, and such appointment
continues undischarged or such proceeding continues undismissed or unstayed for a period of 60 days. 
 Section 7.2.
Non-Bankruptcy Defaults. - When any Event of Default other than those described in subsection (j) or (k) of Section 7.1 hereof has occurred and is continuing with respect to the Borrower, the Agent shall, by written notice to the
Borrower: (a) if so directed by the Required Lenders, terminate the remaining Commitments and all other obligations of the Lenders hereunder on the date stated in such notice (which may be the date thereof); (b) if so directed by the
Required Lenders, declare the principal of and the accrued interest on all outstanding Notes to be forthwith due and payable and thereupon all outstanding Notes, including both principal and interest thereon, shall be and become immediately due and
payable together with all other amounts payable under the Loan Documents without further demand, presentment, protest or notice of any kind; and (c) if so directed by the Required Lenders, demand that the Borrower immediately pay to the Agent
the full amount then available for drawing under each or any Letter of Credit, and the Borrower agrees to immediately make such payment and acknowledges and agrees that the Lenders would not have an adequate remedy at law for failure by the Borrower
to honor any such demand and that the Agent, for the benefit of the Lenders, shall have the right to require the Borrower to specifically perform such undertaking whether or not any drawings or other demands for payment have been made under any
Letter of Credit. The Agent, after giving notice to the Borrower pursuant to Section 7.1(c) or this Section 7.2, shall also promptly send a copy of such notice to the other Lenders, but the failure to do so shall not impair or annul the
effect of such notice. 
 Section 7.3. Bankruptcy Defaults. When any Event of Default described in subsections (j) or
(k) of Section 7.1 hereof has occurred and is continuing, then all outstanding Notes shall immediately become due and payable together with all other amounts payable under the Loan Documents without presentment, demand, protest or notice
of any kind, the obligation of the Lenders to extend further credit pursuant to any of the terms hereof shall immediately terminate and the Borrower shall immediately pay to the Agent the full amount then available for drawing under all outstanding
Letters of Credit, the Borrower acknowledging and agreeing that the Lenders would not have an adequate remedy at law for failure by the Borrower to honor any such demand and that the Lenders, and the Agent on their behalf, shall have the right to
require the Borrower to specifically perform such undertaking whether or not any draws or other demands for payment have been made under any of the Letters of Credit. 
 Section 7.4. Collateral for Undrawn Letters of Credit. (a) If the prepayment of the amount available for drawing under any or all outstanding Letters of Credit is required under Section 2.7(b) or
under Section 7.2 or 7.3 above, the Borrower shall forthwith pay the amount required to be so prepaid, to be held by the Agent as provided in subsection (b) below. 
 (b) All amounts prepaid pursuant to subsection (a) above shall be held by the Agent in one or more separate collateral accounts (each such account,
and the credit balances, properties, and any investments from time to time held therein, and any substitutions for such 

  

 -46- 

 
account, any certificate of deposit or other instrument evidencing any of the foregoing and all proceeds of and earnings on any of the foregoing being
collectively called the “Collateral Account”) as security for, and for application by the Agent (to the extent available) to, the reimbursement of any payment under any Letter of Credit then or thereafter made by the Agent, and to
the payment of the unpaid balance of any other Obligations. The Collateral Account shall be held in the name of and subject to the exclusive dominion and control of the Agent for the benefit of the Agent, the Lenders, and the L/C Issuer. If and when
requested by the Borrower, the Agent shall invest funds held in the Collateral Account from time to time in direct obligations of, or obligations the principal of and interest on which are unconditionally guaranteed by, the United States of America
with a remaining maturity of one year or less, provided that the Agent is irrevocably authorized to sell investments held in the Collateral Account when and as required to make payments out of the Collateral Account for application to amounts
due and owing from the Borrower to the L/C Issuer, the Agent or the Lenders; provided, however, that if (i) the Borrower shall have made payment of all such obligations referred to in subsection (a) above, (ii) all relevant
preference or other disgorgement periods relating to the receipt of such payments have passed, and (iii) no Letters of Credit, Commitments, Loans or other Obligations remain outstanding hereunder, then the Agent shall release to the Borrower
any remaining amounts held in the Collateral Account. 
 Section 7.5. Notice of Default. The Agent shall give notice to the
Borrower under Section 7.1(c) hereof promptly upon being requested to do so by any Lender and shall thereupon notify all the Lenders thereof. 
 Section 7.6. Expenses. The Borrower agrees to pay to the Agent and each Lender, and any other holder of any Note outstanding hereunder, all costs and expenses reasonably incurred or paid by the Agent and such Lender or any such
holder, including reasonable attorneys’ fees and court costs, in connection with any Default or Event of Default by the Borrower hereunder or in connection with the enforcement of any of the Loan Documents (including all such costs and expenses
incurred in connection with any proceeding under the United States Bankruptcy Code involving the Borrower or any Subsidiary as a debtor thereunder). 
  

	SECTION 8.	CHANGE IN CIRCUMSTANCES AND CONTINGENCIES. 

 Section 8.1. Funding Indemnity. If any Lender shall incur any loss, cost or expense (excluding loss of the respective Applicable Margin but
including, without limitation, any loss, cost or expense incurred by reason of the liquidation or re-employment of deposits or other funds acquired by such Lender to fund or maintain any Eurodollar Loan or Swing Loan or the relending or reinvesting
of such deposits or amounts paid or prepaid to such Lender or by reason of breakage of interest rate swap agreements or the liquidation of other hedging contracts or agreements) as a result of: 
 (a) any payment, prepayment or conversion of a Eurodollar Loan or Swing Loan on a date other than the last day of its Interest Period,

 (b) any failure (because of a failure to meet the conditions of Section 3 or otherwise) by the Borrower to borrow or
continue a Eurodollar Loan or Swing 

  

 -47- 

 
Loan, or to convert a Base Rate Loan into a Eurodollar Loan or Swing Loan, on the date specified in a notice given pursuant to Section 2.4(a) or
Section 2.12 hereof, 
 (c) any failure by the Borrower to make any payment of principal on any Eurodollar Loan or Swing
Loan when due (whether by acceleration or otherwise), or 
 (d) any acceleration of the maturity of a Eurodollar Loan or Swing
Loan as a result of the occurrence of any Event of Default hereunder, 
 then, upon the demand of such Lender, the Borrower shall pay to such Lender such
amount as will reimburse such Lender for such loss, cost or expense. If any Lender makes such a claim for compensation, it shall provide to the Borrower, with a copy to the Agent, a certificate setting forth the amount of such loss, cost or expense
in reasonable detail (including an explanation of the basis for and the computation of such loss, cost or expense) and the amounts shown on such certificate shall be presumptively correct absent manifest error. 
 Section 8.2. Illegality. Notwithstanding any other provisions of this Agreement or any Note, if at any time any change in applicable law,
rule or regulation or in the interpretation thereof makes it unlawful for any Lender to make or continue to maintain any Eurodollar Loans or to perform its obligations as contemplated hereby, such Lender shall promptly give notice thereof to the
Borrower and the Agent and such Lender’s obligations to make or maintain Eurodollar Loans under this Agreement shall be suspended until it is no longer unlawful for such Lender to make or maintain Eurodollar Loans. The Borrower shall prepay on
demand the outstanding principal amount of any such affected Eurodollar Loans, together with all interest accrued thereon and all other amounts then due and payable to such Lender under this Agreement; provided, however, subject to all of the
terms and conditions of this Agreement, the Borrower may then elect to borrow the principal amount of the affected Eurodollar Loans from such Lender by means of Base Rate Loans from such Lender, which Base Rate Loans shall not be made ratably by the
Lenders but only from such affected Lender. 
 Section 8.3. Unavailability of Deposits or Inability to Ascertain, or Inadequacy of,
LIBOR. If on or prior to the first day of any Interest Period for any Borrowing of Eurodollar Loans: 
 (a) the Agent
determines that deposits in Dollars (in the applicable amounts) are not being offered to it in the interbank eurodollar market for such Interest Period, or that by reason of circumstances affecting the interbank eurodollar market adequate and
reasonable means do not exist for ascertaining the applicable LIBOR, or 
 (b) the Required Lenders advise the Agent that
(i) LIBOR as determined by the Agent will not adequately and fairly reflect the cost to such Lenders of funding their Eurodollar Loans for such Interest Period or (ii) that the making or funding of Eurodollar Loans become impracticable,

  

 -48- 

 then the Agent shall forthwith give notice thereof to the Borrower and the Lenders, whereupon until the Agent notifies
the Borrower that the circumstances giving rise to such suspension no longer exist, the obligations of the Lenders to make Eurodollar Loans shall be suspended. 
 Section 8.4. Yield Protection. (a) If, on or after the date hereof, the adoption of any applicable law, rule or regulation, or any change therein, or any change in the interpretation or administration
thereof by any governmental authority, central bank or comparable agency charged with the interpretation or administration thereof, or compliance by any Lender (or its Lending Office) with any request or directive (whether or not having the force of
law) of any such authority, central bank or comparable agency: 
 (i) shall subject any Lender (or its Lending Office) to any
tax, duty or other charge with respect to its Eurodollar Loans, its Notes, its Letter(s) of Credit, or its participation in any thereof, any Reimbursement Obligations owed to it or its obligation to make Eurodollar Loans, issue a Letter of Credit,
or to participate therein, or shall change the basis of taxation of payments to any Lender (or its Lending Office) of the principal of or interest on its Eurodollar Loans, Letter(s) of Credit, or participations therein or any other amounts due under
this Agreement or any other Loan Document in respect of its Eurodollar Loans, Letter(s) of Credit, any participation therein, any Reimbursement Obligations owed to it, or its obligation to make Eurodollar Loans, or issue a Letter of Credit, or
acquire participations therein (except for changes in the rate of tax on the overall net income of such Lender or its Lending Office imposed by the jurisdiction in which such Lender’s principal executive office or Lending Office is located); or

 (ii) shall impose, modify or deem applicable any reserve, special deposit or similar requirement (including, without
limitation, any such requirement imposed by the Board of Governors of the Federal Reserve System, but excluding with respect to any Eurodollar Loans any such requirement included in an applicable Reserve Percentage) against assets of, deposits with
or for the account of, or credit extended by, any Lender (or its Lending Office) or shall impose on any Lender (or its Lending Office) or on the interbank market any other condition affecting its Eurodollar Loans, its Notes, its Letter(s) of Credit,
or its participation in any thereof, any Reimbursement Obligation owed to it, or its obligation to make Eurodollar Loans, or to issue a Letter of Credit, or to participate therein; 
 and the result of any of the foregoing is to increase the cost to such Lender (or its Lending Office) of making or maintaining any Eurodollar Loan, issuing or maintaining a Letter of Credit, or participating therein,
or to reduce the amount of any sum received or receivable by such Lender (or its Lending Office) under this Agreement or under any other Loan Document with respect thereto, by an amount deemed by such Lender to be material, then, within 15 days
after demand by such Lender (with a copy to the Agent), the Borrower shall be obligated to pay to such Lender such additional amount or amounts as will compensate such Lender for such increased cost or reduction. 
  

 -49- 

 (b) If, after the date hereof, any Lender or the Agent shall have determined that the adoption of any
applicable law, rule or regulation regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any governmental authority, central bank or comparable agency charged with the interpretation or
administration thereof, or compliance by any Lender (or its Lending Office) or any corporation controlling such Lender with any request or directive regarding capital adequacy (whether or not having the force of law) of any such authority, central
bank or comparable agency, has had the effect of reducing the rate of return on such Lender’s or such corporation’s capital as a consequence of its obligations hereunder to a level below that which such Lender or such corporation could
have achieved but for such adoption, change or compliance (taking into consideration such Lender’s or such corporation’s policies with respect to capital adequacy) by an amount deemed by such Lender to be material, then from time to time,
within 15 days after demand by such Lender (with a copy to the Agent), the Borrower shall pay to such Lender such additional amount or amounts as will compensate such Lender for such reduction. 
 (c) A certificate of a Lender claiming compensation under this Section 8.4 and setting forth the additional amount or amounts to be paid to it
hereunder shall be presumptively correct, absent manifest error. In determining such amount, such Lender may use any reasonable averaging and attribution methods. 
 Section 8.5. Substitution of Lenders. Upon the receipt by the Borrower of (a) a claim from any Lender for compensation under Section 8.4 or 10.1 hereof, (b) notice by any Lender to the
Borrower of any illegality pursuant to Section 8.2 hereof or (c) in the event any Lender is in default in any material respect with respect to its obligations under the Loan Documents (any such Lender referred to in clause (a),
(b) or (c) above being hereinafter referred to as an “Affected Lender”), the Borrower may, in addition to any other rights the Borrower may have hereunder or under applicable law, require, at its expense, any such Affected
Lender to assign, at par plus accrued interest and fees, without recourse, all of its interest, rights, and obligations hereunder (including all of its Commitments and the Loans and participation interests in Letters of Credit and other amounts at
any time owing to it hereunder and the other Loan Documents) to a bank or other institutional lender specified by the Borrower, provided that (i) such assignment shall not conflict with or violate any law, rule or regulation or order of
any court or other governmental authority, (ii) the Borrower shall have received the written consent of the Agent and the L/C Issuer, which consents shall not be unreasonably withheld, to such assignment, (iii) the Borrower shall have paid
to the Affected Lender all monies (together with amounts due such Affected Lender under Section 8.1 hereof as if the Loans owing to it were prepaid rather than assigned) other than principal owing to it hereunder, and (iv) the assignment
is entered into in accordance with the other requirements of Section 10.10 hereof. 
 Section 8.6. Lending Offices. Each
Lender may, at its option, elect to make its Loans hereunder at the branch, office or affiliate specified on the appropriate signature page hereof (each a “Lending Office”) for each type of Loan available hereunder or at such other
of its branches, offices or affiliates as it may from time to time elect and designate in a written notice to the Borrower and the Agent. To the extent reasonably possible, a Lender shall designate an alternative branch or funding office with
respect to its Eurodollar Loans to reduce any liability of the Borrower to such Lender under Section 8.4 or Section 10.1 hereof or to avoid the 

  

 -50- 

 
unavailability of Eurodollar Loans under Section 8.3 hereof, so long as such designation is not materially disadvantageous to the Lender. 
 Section 8.7. Discretion of Lender as to Manner of Funding. Notwithstanding any other provision of this Agreement, each Lender shall be
entitled to fund and maintain its funding of all or any part of its Loans in any manner it sees fit, it being understood, however, that for the purposes of this Agreement all determinations hereunder with respect to Eurodollar Loans shall be made as
if each Lender had actually funded and maintained each Eurodollar Loan through the purchase of deposits in the interbank eurodollar market having a maturity corresponding to such Loan’s Interest Period, and bearing an interest rate equal to
LIBOR for such Interest Period. 
  

	SECTION 9.	THE AGENT. 

 Section 9.1. Appointment and Authorization of Agent. Each Lender hereby appoints Fifth Third Bank, an Ohio banking corporation, as the Agent under the Loan Documents and hereby authorizes the Agent to take such action as Agent
on its behalf and to exercise such powers under the Loan Documents as are delegated to the Agent by the terms thereof, together with such powers as are reasonably incidental thereto. Notwithstanding the use of the word “Agent” as a defined
term, the Lenders expressly agree that the Agent is not acting as a fiduciary of any Lender in respect of the Loan Documents, the Borrower or otherwise, and nothing herein or in any of the other Loan Documents shall result in any duties or
obligations on the Agent or any of the Lenders except as expressly set forth herein. 
 Section 9.2. Agent and its Affiliates.
The Agent shall have the same rights and powers under this Agreement and the other Loan Documents as any other Lender and may exercise or refrain from exercising such rights and power as though it were not the Agent, and the Agent and its affiliates
may accept deposits from, lend money to, and generally engage in any kind of business with the Borrower or any Affiliate of the Borrower as if it were not the Agent under the Loan Documents. The term “Lender” as used herein and in
all other Loan Documents, unless the context otherwise clearly requires, includes the Agent in its individual capacity as a Lender. References in Section 2 hereof to the Agent’s Loans, or to the amount owing to the Agent for which an
interest rate is being determined, refer to the Agent in its individual capacity as a Lender. 
 Section 9.3. Action by Agent. If
the Agent receives from the Borrower a written notice of an Event of Default pursuant to Section 6.1 hereof, the Agent shall promptly give each of the Lenders written notice thereof. Without limiting the generality of the foregoing, the Agent
shall not be required to take any action hereunder with respect to any Default or Event of Default, except as expressly provided in Sections 7.2 and 7.5. Unless and until the Required Lenders give such direction, the Agent may (but shall not be
obligated to) take or refrain from taking such actions as it deems appropriate and in the best interest of all the Lenders. In no event, however, shall the Agent be required to take any action in violation of applicable law or of any provision of
any Loan Document, and the Agent shall in all cases be fully justified in failing or refusing to act hereunder or under any other Loan Document unless it first receives any further assurances of its indemnification from the Lenders that it may
require, including prepayment of any related expenses and any other protection it requires against any and all costs, expense, and liability 

  

 -51- 

 
which may be incurred by it by reason of taking or continuing to take any such action. The Agent shall be entitled to assume that no Default or Event of
Default exists unless notified in writing to the contrary by a Lender or the Borrower. In all cases in which the Loan Documents do not require the Agent to take specific action, the Agent shall be fully justified in using its discretion in failing
to take or in taking any action thereunder. Any instructions of the Required Lenders, or of any other group of Lenders called for under the specific provisions of the Loan Documents, shall be binding upon all the Lenders and the holders of the
Obligations. 
 Section 9.4. Consultation with Experts. The Agent may consult with legal counsel, independent public accountants,
and other experts selected by it and shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the advice of such counsel, accountants or experts. 
 Section 9.5. Liability of Agent; Credit Decision. Neither the Agent nor any of its directors, officers, agents or employees shall be liable
for any action taken or not taken by it in connection with the Loan Documents: (i) with the consent or at the request of the Required Lenders or (ii) in the absence of its own gross negligence or willful misconduct. Neither the Agent nor
any of its directors, officers, agents or employees shall be responsible for or have any duty to ascertain, inquire into or verify: (i) any statement, warranty or representation made in connection with this Agreement, any other Loan Document or
any Credit Event; (ii) the performance or observance of any of the covenants or agreements of the Borrower or any Subsidiary contained herein or in any other Loan Document; (iii) the satisfaction of any condition specified in
Section 3 hereof, except receipt of items required to be delivered to the Agent; or (iv) the validity, effectiveness, genuineness, enforceability, perfection, value, worth or collectibility hereof or of any other Loan Document or of any
other documents or writing furnished in connection with any Loan Document; and the Agent makes no representation of any kind or character with respect to any such matter mentioned in this sentence. The Agent may execute any of its duties under any
of the Loan Documents by or through employees, agents, and attorneys-in-fact and shall not be answerable to the Lenders, the Borrower, or any other Person for the default or misconduct of any such agents or attorneys-in-fact selected with reasonable
care. The Agent shall not incur any liability by acting in reliance upon any notice, consent, certificate, other document or statement (whether written or oral) believed by it to be genuine or to be sent by the proper party or parties. In particular
and without limiting any of the foregoing, the Agent shall have no responsibility for confirming the accuracy of any compliance certificate or other document or instrument received by it under the Loan Documents. The Agent may treat the payee of any
Note as the holder thereof until written notice of transfer shall have been filed with the Agent signed by such payee in form satisfactory to the Agent. Each Lender acknowledges that it has independently and without reliance on the Agent or any
other Lender, and based upon such information, investigations and inquiries as it deems appropriate, made its own credit analysis and decision to extend credit to the Borrower in the manner set forth in the Loan Documents. It shall be the
responsibility of each Lender to keep itself informed as to the creditworthiness of the Borrower and its Subsidiaries, and the Agent shall have no liability to any Lender with respect thereto. 
 Section 9.6. Indemnity. The Lenders shall ratably, in accordance with their respective Percentages, indemnify and hold the Agent, and its
directors, officers, employees, agents, and 

  

 -52- 

 
representatives harmless from and against any liabilities, losses, costs or expenses suffered or incurred by it under any Loan Document or in connection with
the transactions contemplated thereby, regardless of when asserted or arising, except to the extent they are promptly reimbursed for the same by the Borrower and except to the extent that any event giving rise to a claim was caused by the gross
negligence or willful misconduct of the party seeking to be indemnified; provided that, in the event that the Borrower pays the Agent any amounts due after any Lender has paid the Agent under this Section in respect of such amounts, the Agent
shall reimburse such Lender its share of such Borrower payment. The obligations of the Lenders under this Section shall survive termination of this Agreement. The Agent shall be entitled to offset amounts received for the account of a Lender under
this Agreement against unpaid amounts due from such Lender to the Agent hereunder (whether as fundings of participations, indemnities or otherwise), but shall not be entitled to offset against amounts owed to the Agent by any Lender arising outside
of this Agreement and the other Loan Documents. 
 Section 9.7. Resignation of Agent and Successor Agent. The Agent may resign at
any time by giving written notice thereof to the Lenders and the Borrower. Upon any such resignation of the Agent, the Required Lenders shall have the right to appoint a successor Agent which, so long as no Default or Event of Default has occurred
and is continuing, shall be subject to the Borrower’s approval. If no successor Agent shall have been so appointed by the Required Lenders, and shall have accepted such appointment, within 30 days after the retiring Agent’s giving of
notice of resignation then the retiring Agent may, on behalf of the Lenders and, so long as no Default or Event of Default has occurred and is continuing, subject to the Borrower’s approval, appoint a successor Agent, which may be any Lender
hereunder or any commercial bank organized under the laws of the United States of America or of any State thereof and having a combined capital and surplus of at least $200,000,000. Upon the acceptance of its appointment as the Agent hereunder, such
successor Agent shall thereupon succeed to and become vested with all the rights and duties of the retiring Agent under the Loan Documents, and the retiring Agent shall be discharged from its duties and obligations thereunder. After any retiring
Agent’s resignation hereunder as Agent, the provisions of this Section 9 and all protective provisions of the other Loan Documents shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Agent, but no
successor Agent shall in any event be liable or responsible for any actions of its predecessor. If the Agent resigns and no successor is appointed, the rights and obligations of such Agent shall be automatically assumed by the Required Lenders and
the Borrower shall be directed to make all payments due each Lender hereunder directly to such Lender. 
 Any resignation by the Agent
pursuant to this Section shall also constitute its resignation as L/C Issuer. Upon the acceptance of a successor’s appointment as Agent hereunder, (a) such successor shall succeed to and become vested with all of the rights, powers,
privileges and duties of the retiring L/C Issuer, (b) the retiring L/C Issuer shall be discharged from all of its respective duties and obligations hereunder or under the other Loan Documents, and (c) the successor L/C Issuer shall issue
letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangement satisfactory to the retiring L/C Issuer to effectively assume the obligations of the retiring L/C Issuer with
respect to such Letters of Credit. 
  

 -53- 

 Section 9.8. L/C Issuer. The L/C Issuer shall act on behalf of the Lenders with respect
to any Letters of Credit issued by it and the documents associated therewith. The L/C Issuer shall have all of the benefits and immunities (i) provided to the Agent in this Section 9 with respect to any acts taken or omissions
suffered by the L/C Issuer in connection with Letters of Credit issued by it or proposed to be issued by it and the Applications pertaining to such Letters of Credit as fully as if the term “Agent”, as used in this Section 9,
included the L/C Issuer with respect to such acts or omissions and (ii) as additionally provided in this Agreement with respect to such L/C Issuer. 
 Section 9.9. Designation of Additional Agents. The Agent shall have the continuing right, for purposes hereof, at any time and from time to time to designate one or more of the Lenders (and/or its or their
Affiliates) as “syndication agents,” “documentation agents,” “bookrunners,” “arrangers” or other designations for purposes hereto, but such designation shall have no substantive effect, and such Lenders and
their Affiliates shall have no additional powers, duties or responsibilities as a result thereof. 
  

	SECTION 10.	MISCELLANEOUS. 

 Section 10.1. Withholding Taxes. (a) Payments Free of Withholding. Except as otherwise required by law and subject to Section 10.1(b) hereof, each payment by the Borrower under this Agreement or the other Loan
Documents shall be made without withholding for or on account of any present or future taxes (other than overall net income taxes on the recipient imposed by the jurisdiction in which its principal executive office or Lending Office is located)
imposed by or within the jurisdiction in which the Borrower is domiciled, any jurisdiction from which the Borrower makes any payment, or (in each case) any political subdivision or taxing authority thereof or therein. If any such withholding is so
required, the Borrower shall make the withholding, pay the amount withheld to the appropriate governmental authority before penalties attach thereto or interest accrues thereon and (if the Lender shall have complied with Section 10.1(b) hereof)
forthwith pay such additional amount as may be necessary to ensure that the net amount actually received by each Lender and the Agent free and clear of such taxes (including such taxes on such additional amount) is equal to the amount which that
Lender or the Agent (as the case may be) would have received had such withholding not been made. If the Borrower shall have paid an additional amount as described in the preceding sentence to any Lender that has not complied with
Section 10.1(b) hereof, such Lender shall promptly return such amount to Borrower. If the Agent or any Lender that has complied with Section 10.1(b) hereof, pays any amount in respect of any such taxes, penalties or interest, the Borrower
shall reimburse the Agent or such Lender for that payment on demand in Dollars. If the Borrower pays any such taxes, penalties or interest, it shall deliver official tax receipts evidencing that payment or certified copies thereof to the Lender or
Agent on whose account such withholding was made (with a copy to the Agent if not the recipient of the original) on or before the thirtieth day after payment. 
 (b) U.S. Withholding Tax Exemptions. Each Lender that is not a United States person (as such term is defined in Section 7701(a)(30) of the Code) shall submit to the Borrower and the Agent on or before the
date the initial Credit Event is made hereunder or, if later, the date such financial institution becomes a Lender hereunder, two duly completed and signed copies of (i) either Form W-8 BEN (relating to such Lender and entitling it to a
complete exemption from 

  

 -54- 

 
withholding under the Code on all amounts to be received by such Lender, including fees, pursuant to the Loan Documents and the Obligations) or Form
W-8 ECI (relating to all amounts to be received by such Lender, including fees, pursuant to the Loan Documents and the Obligations) of the United States Internal Revenue Service or (ii) solely if such Lender is claiming exemption from
United States withholding tax under Section 871(h) or 881(c) of the Code with respect to payments of “portfolio interest”, a Form W-8 BEN, or any successor form prescribed by the Internal Revenue Service, and a certificate
representing that such Lender is not a bank for purposes of Section 881(c) of the Code, is not a 10-percent shareholder (within the meaning of Section 871(h)(3)(B) of the Code) of the Borrower and is not a controlled foreign corporation
related to the Borrower (within the meaning of Section 864(d)(4) of the Code). Thereafter and from time to time, each Lender shall submit to the Borrower and the Agent such additional duly completed and signed copies of one or the other of such
Forms (or such successor forms as shall be adopted from time to time by the relevant United States taxing authorities) and such other certificates as may be (i) requested by the Borrower in a written notice, directly or through the Agent,
to such Lender and (ii) required under then-current United States law or regulations to avoid United States withholding taxes on payments in respect of all amounts to be received by such Lender, including fees, pursuant to the Loan Documents or
the Obligations. Upon the request of the Borrower or the Agent, each Lender that is a United States person (as such term is defined in Section 7701(a)(30) of the Code) shall submit to the Borrower and the Agent a certificate to the effect that
it is such a United States person. 
 (c) Inability of Lender to Submit Forms. If any Lender determines, as a result of any change in
applicable law, regulation or treaty, or in any official application or interpretation thereof, occurring after the Closing Date, that it is unable to submit to the Borrower or the Agent any form or certificate that such Lender is obligated to
submit pursuant to subsection (b) of this Section 10.1 or that such Lender is required to withdraw or cancel any such form or certificate previously submitted or any such form or certificate otherwise becomes ineffective or inaccurate,
such Lender shall promptly notify the Borrower and Agent of such fact and the Lender shall to that extent not be obligated to provide any such form or certificate and will be entitled to withdraw or cancel any affected form or certificate, as
applicable. 
 Section 10.2. No Waiver, Cumulative Remedies. No delay or failure on the part of the Agent or any Lender or on the
part of the holder or holders of any of the Obligations in the exercise of any power or right under any Loan Document shall operate as a waiver thereof or as an acquiescence in any default, nor shall any single or partial exercise of any power or
right preclude any other or further exercise thereof or the exercise of any other power or right. The rights and remedies hereunder of the Agent, the Lenders and of the holder or holders of any of the Obligations are cumulative to, and not exclusive
of, any rights or remedies which any of them would otherwise have. 
 Section 10.3. Non-Business Days. If any payment hereunder
becomes due and payable on a day which is not a Business Day, the due date of such payment shall be extended to the next succeeding Business Day on which date such payment shall be due and payable. In the case of any payment of principal falling due
on a day which is not a Business Day, interest on such principal amount shall continue to accrue during such extension at the rate per annum then in 

  

 -55- 

 
effect, which accrued amount shall be due and payable on the next scheduled date for the payment of interest. 
 Section 10.4. Documentary Taxes. The Borrower agrees to pay on demand any documentary, stamp or similar taxes payable in respect of this
Agreement or any other Loan Document, including interest and penalties, in the event any such taxes are assessed, irrespective of when such assessment is made and whether or not any credit is then in use or available hereunder. 
 Section 10.5. Survival of Representations. All representations and warranties made herein or in any other Loan Document or in certificates
given pursuant hereto or thereto shall survive the execution and delivery of this Agreement and the other Loan Documents, and shall continue in full force and effect with respect to the date as of which they were made as long as any credit is in use
or available hereunder. 
 Section 10.6. Survival of Indemnities. All indemnities and other provisions relative to reimbursement
to the Lenders of amounts sufficient to protect the yield of the Lenders with respect to the Loans and Letters of Credit, including, but not limited to, Sections 8.1, 8.4, and 10.13 hereof, shall survive the termination of this Agreement and the
other Loan Documents and the payment of the Obligations. 
 Section 10.7. Sharing of Set-Off. Each Lender agrees with each other
Lender a party hereto that if such Lender shall receive and retain any payment, whether by set-off or application of deposit balances or otherwise, on any of the Loans or Reimbursement Obligations in excess of its ratable share of payments on all
such Obligations then outstanding to the Lenders, then such Lender shall purchase for cash at face value, but without recourse, ratably from each of the other Lenders such amount of the Loans or Reimbursement Obligations, or participations therein,
held by each such other Lenders (or interest therein) as shall be necessary to cause such Lender to share such excess payment ratably with all the other Lenders; provided, however, that if any such purchase is made by any Lender, and if such
excess payment or part thereof is thereafter recovered from such purchasing Lender, the related purchases from the other Lenders shall be rescinded ratably and the purchase price restored as to the portion of such excess payment so recovered, but
without interest. For purposes of this Section, amounts owed to or recovered by the L/C Issuer in connection with Reimbursement Obligations in which Lenders have been required to fund their participation shall be treated as amounts owed to or
recovered by the L/C Issuer as a Lender hereunder. 
 Section 10.8. Notices. Except as otherwise specified herein, all notices
hereunder and under the other Loan Documents shall be in writing (including, without limitation, notice by telecopy) and shall be given to the relevant party at its address or telecopier number set forth below, or such other address or telecopier
number as such party may hereafter specify by notice to the Agent and the Borrower given by courier, by United States certified or registered mail, by telecopy or by other telecommunication device capable of creating a written record of such notice
and its receipt. Notices under the Loan Documents to the Lenders and the Agent shall be addressed to their respective addresses or telecopier numbers set forth on the signature pages hereof, and to the Borrower to: 
  

					
		 	American Pharmaceutical Partners, Inc.
		 	1501 East Woodfield Road, Suite 300 East
		 	Schaumburg, Illinois 60173
		 	 Attention:
	 	Vice President & Treasurer
		 	 Telephone:
	 	(847) 330-1248
		 	 Telecopy:
	 	(847) 517-3347

  

 -56- 

 Each such notice, request or other communication shall be effective (i) if given by telecopier, when such telecopy
is transmitted to the telecopier number specified in this Section or on the signature pages hereof and a confirmation of such telecopy has been received by the sender, (ii) if given by mail, 5 days after such communication is deposited in
the mail, certified or registered with return receipt requested, addressed as aforesaid or (iii) if given by any other means, when delivered at the addresses specified in this Section or on the signature pages hereof; provided that any notice
given pursuant to Section 2 hereof shall be effective only upon receipt. 
 Section 10.9. Counterparts. This Agreement may
be executed in any number of counterparts, and by the different parties hereto on separate counterpart signature pages, and all such counterparts taken together shall be deemed to constitute one and the same instrument. 
 Section 10.10. Successors and Assigns; Assignments and Participations. (a) Successors and Assigns Generally. The provisions of
this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that the Borrower may not assign or otherwise transfer any of its rights or obligations under
any Loan Document without the prior written consent of the Agent and each Lender (which consent shall not be unreasonably withheld or delayed), and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except
(i) to an Eligible Assignee in accordance with the provisions of paragraph (b) of this Section, (ii) by way of participation in accordance with the provisions of paragraph (d) of this Section or (iii) by way of pledge or
assignment of a security interest subject to the restrictions of paragraph (f) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall
be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in paragraph (d) of this Section and, to the extent expressly contemplated
hereby, the Related Parties of each of the Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. 
 (b) Assignments by Lenders. Any Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment
and the Loans at the time owing to it); provided that 
 (i) except in the case of an assignment of the entire
remaining amount of the assigning Lender’s Commitment and the Loans at the time owing to it or in the case of an assignment to a Lender or an Affiliate of a Lender or an Approved Fund with respect to a Lender, the aggregate amount of the
Commitment (which for this purpose includes Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the Loans of the assigning Lender subject to each such 

  

 -57- 

 
assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if
“Trade Date” is specified in the Assignment and Assumption, as of the Trade Date) shall not be less than $5,000,000 unless each of the Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise
consent (each such consent not to be unreasonably withheld or delayed); 
 (ii) each partial assignment shall be made as an
assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement with respect to the Loan or the Commitment assigned; 
 (iii) any assignment of a Commitment must be approved by the Agent and the L/C Issuer and the Borrower (unless an Event of Default
has occurred and is continuing), unless the Person that is the proposed assignee is itself a Lender with a Commitment (whether or not the proposed assignee would otherwise qualify as an Eligible Assignee); and 
 (iv) the parties to each assignment shall execute and deliver to the Agent an Assignment and Assumption, together with a processing and
recordation fee of $3,500, and the Eligible Assignee, if it shall not be a Lender, shall deliver to the Agent an administrative questionnaire in the form prescribed by the Agent. 
 Subject to acceptance and recording thereof by the Agent pursuant to paragraph (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the Eligible Assignee thereunder
shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the
interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement,
such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 8.4 and 10.13 with respect to facts and circumstances occurring prior to the effective date of such assignment. Any assignment or
transfer by a Lender of rights or obligations under this Agreement that does not comply with this paragraph shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with
paragraph (d) of this Section. 
 (c) Register. The Agent, acting solely for this purpose as an agent of the Borrower, shall
maintain a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitment of, and principal amounts of the Loans owing to, each Lender pursuant to the terms
hereof from time to time (the “Register”). The entries in the Register shall be conclusive, and the Borrower, the Agent and the Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a
Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.

  

 -58- 

 (d) Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower
or the Agent, sell participations to any Person (other than a natural person or the Borrower or any of the Borrower’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or
obligations under this Agreement (including all or a portion of its Commitment and/or the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall
remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Agent and the Lenders and L/C Issuer shall continue to deal solely and directly with such Lender in connection with
such Lender’s rights and obligations under this Agreement. 
 Any agreement or instrument pursuant to which a Lender sells such a
participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide
that such Lender will not, without the consent of the Participant, agree to any amendment or waiver described in Section 10.11(i)(B) that affects such Participant. Subject to paragraph (e) of this Section, the Borrower agrees that each
Participant shall be entitled to the benefits of Sections 8.1 and 8.4 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section. To the extent permitted by law, each
Participant also shall be entitled to the benefits of Section 10.14 as though it were a Lender, provided the Borrower is notified of the participation sold to such Participant and such Participant agrees to be subject to Section 10.7 as
though it were a Lender. 
 (e) Limitations upon Participant Rights. A Participant shall not be entitled to receive any greater
payment under Section 8.1, 8.4 or 10.1 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the
Borrower’s prior written consent. A Participant that is not a United States person (as such term is defined in Section 7701(a)(30) of the Code) if it were a Lender shall not be entitled to the benefits of Section 10.1(a) unless the
Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to comply with Section 10.1(b) as though it were a Lender. 
 (f) Certain Pledges. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to
secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute
any such pledgee or assignee for such Lender as a party hereto. 
 (g) Electronic Execution of Assignments. The words
“execution,” “signed,” “signature,” and words of like import in any Assignment and Assumption shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the
same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures
in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. 
  

 -59- 

 Section 10.11. Amendments. Any provision of this Agreement or the other Loan Documents may be
amended or waived if, but only if, such amendment or waiver is in writing and is signed by (a) the Borrower, (b) the Required Lenders, and (c) if the rights or duties of the Agent are affected thereby, the Agent; provided that:

 (i) no amendment or waiver pursuant to this Section 10.11 shall (A) increase any Commitment of any Lender without
the consent of such Lender or (B) reduce the amount of or postpone the date for any scheduled payment of any principal of or interest on any Loan or of any Reimbursement Obligation or of any fee payable hereunder without the consent of the
Lender to which such payment is owing or which has committed to make such Loan or Letter of Credit (or participate therein) hereunder; 
 (ii) no amendment or waiver pursuant to this Section 10.11 shall amend Section 2.8 or 10.7 in a manner that would alter the ratable distribution of, and sharing of, payments received pursuant to such
Sections; and 
 (iii) no amendment or waiver pursuant to this Section 10.11 shall, unless signed by each Lender,
increase the aggregate Commitments of the Lenders, change the definitions of Termination Date or Required Lenders, change the provisions of this Section 10.11, release any material guarantor (except as otherwise provided for in the Loan
Documents), or affect the number of Lenders required to take any action hereunder or under any other Loan Document. 
 Section 10.12.
Headings. Section headings used in this Agreement are for reference only and shall not affect the construction of this Agreement. 
 Section 10.13. Costs and Expenses; Indemnification. The Borrower agrees to pay all reasonable costs and expenses of the Agent in connection with the preparation, negotiation, syndication, and administration of the Loan
Documents, including, without limitation, the reasonable fees and disbursements of counsel to the Agent, in connection with the preparation and execution of the Loan Documents, and any amendment, waiver or consent related thereto, whether or not the
transactions contemplated herein are consummated. The Borrower further agrees to indemnify the Agent, each Lender, and their respective directors, officers, employees, agents, financial advisors, and consultants against all Damages (including,
without limitation, all expenses of litigation or preparation therefor, whether or not the indemnified Person is a party thereto, or any settlement arrangement arising from or relating to any such litigation) which any of them may pay or incur
arising out of or relating to any Loan Document or any of the transactions contemplated thereby or the direct or indirect application or proposed application of the proceeds of any Loan or Letter of Credit, other than those which arise from the
gross negligence or willful misconduct of the party claiming indemnification. The Borrower, upon demand by the Agent or a Lender at any time, shall reimburse the Agent or such Lender for any legal or other expenses incurred in connection with
investigating or defending against any of the foregoing (including any settlement costs relating to the foregoing) except if the same is directly due to the gross negligence or willful misconduct of the party to be indemnified. The obligations of
the Borrower under this Section shall survive the termination of this Agreement. 
  

 -60- 

 Section 10.14. Set-off. In addition to any rights now or hereafter granted under applicable
law and not by way of limitation of any such rights, upon the occurrence of any Event of Default, each Lender and each subsequent holder of any Obligation is hereby authorized by the Borrower at any time or from time to time, upon notice to the
Borrower or to any other Person, to set-off and to appropriate and to apply any and all deposits (general or special, including, but not limited to, indebtedness evidenced by certificates of deposit, whether matured or unmatured, but not including
trust or payroll accounts, and in whatever currency denominated) and any other indebtedness at any time held or owing by that Lender or that subsequent holder to or for the credit or the account of the Borrower, whether or not matured, against and
on account of the Obligations of the Borrower to that Lender or that subsequent holder under the Loan Documents, including, but not limited to, all claims of any nature or description arising out of or connected with the Loan Documents, irrespective
of whether or not (a) that Lender or that subsequent holder shall have made any demand hereunder or (b) the principal of or the interest on the Loans or Notes and other amounts due hereunder shall have become due and payable pursuant to
Section 7 and although said obligations and liabilities, or any of them, may be contingent or unmatured. 
 Section 10.15.
Entire Agreement. The Loan Documents constitute the entire understanding of the parties thereto with respect to the subject matter thereof and any prior agreements, whether written or oral, with respect thereto are superseded hereby. 

Section 10.16. Governing Law. This Agreement and the other Loan Documents, and the rights and duties of the parties hereto, shall be
construed and determined in accordance with the internal laws of the State of Illinois. 
 Section 10.17. Severability of Provisions.
Any provision of any Loan Document which is unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such unenforceability without invalidating the remaining provisions hereof or affecting the validity or
enforceability of such provision in any other jurisdiction. All rights, remedies and powers provided in this Agreement and the other Loan Documents may be exercised only to the extent that the exercise thereof does not violate any applicable
mandatory provisions of law, and all the provisions of this Agreement and other Loan Documents are intended to be subject to all applicable mandatory provisions of law which may be controlling and to be limited to the extent necessary so that they
will not render this Agreement or the other Loan Documents invalid or unenforceable. 
 Section 10.18. Excess Interest.
Notwithstanding any provision to the contrary contained herein or in any other Loan Document, no such provision shall require the payment or permit the collection of any amount of interest in excess of the maximum amount of interest permitted by
applicable law to be charged for the use or detention, or the forbearance in the collection, of all or any portion of the Loans or other obligations outstanding under this Agreement or any other Loan Document (“Excess Interest”). If
any Excess Interest is provided for, or is adjudicated to be provided for, herein or in any other Loan Document, then in such event (a) the provisions of this Section shall govern and control, (b) neither the Borrower nor any guarantor or
endorser shall be obligated to pay any Excess Interest, (c) any Excess Interest that the Agent or any Lender may have received hereunder shall, at the option of the Agent, be (i) applied as a credit against the 

  

 -61- 

 
then outstanding principal amount of Obligations hereunder and accrued and unpaid interest thereon (not to exceed the maximum amount permitted by applicable
law), (ii) refunded to the Borrower, or (iii) any combination of the foregoing, (d) the interest rate payable hereunder or under any other Loan Document shall be automatically subject to reduction to the maximum lawful contract rate
allowed under applicable usury laws (the “Maximum Rate”), and this Agreement and the other Loan Documents shall be deemed to have been, and shall be, reformed and modified to reflect such reduction in the relevant interest rate, and
(e) neither the Borrower nor any guarantor or endorser shall have any action against the Agent or any Lender for any Damages whatsoever arising out of the payment or collection of any Excess Interest. Notwithstanding the foregoing, if for any
period of time interest on any of Borrower’s Obligations is calculated at the Maximum Rate rather than the applicable rate under this Agreement, and thereafter such applicable rate becomes less than the Maximum Rate, the rate of interest
payable on the Borrower’s Obligations shall remain at the Maximum Rate until the Lenders have received the amount of interest which such Lenders would have received during such period on the Borrower’s Obligations had the rate of interest
not been limited to the Maximum Rate during such period. 
 Section 10.19. Lender’s Obligations Several. The obligations of
the Lenders hereunder are several and not joint. Nothing contained in this Agreement and no action taken by the Lenders pursuant hereto shall be deemed to constitute the Lenders a partnership, association, joint venture or other entity. 

Section 10.20. Submission to Jurisdiction; Waiver of Jury Trial. The Borrower hereby submits to the nonexclusive jurisdiction of the
United States District Court for the Northern District of Illinois and of any Illinois State court sitting in the City of Chicago for purposes of all legal proceedings arising out of or relating to this Agreement, the other Loan Documents or the
transactions contemplated hereby or thereby. The Borrower irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any
claim that any such proceeding brought in such a court has been brought in an inconvenient forum. THE BORROWER, THE AGENT, AND THE LENDERS HEREBY IRREVOCABLY WAIVE ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING
TO ANY LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED THEREBY. 
 Section 10.21. USA Patriot Act. Each Lender hereby notifies the
Borrower that pursuant to the requirements of the Patriot Act it is required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow
such Lender to identify the Borrower in accordance with the Patriot Act. 
 Section 10.22. Confidentiality. The Agent and each
Lender agree to keep confidential all non-public information provided to it by any Borrower or any of its Subsidiaries or Affiliates pursuant to this Agreement; provided that nothing herein shall prevent the Agent or any Lender from
disclosing any such information (a) to the Agent, any other Lender, (b) subject to an agreement to comply with the provisions of this Section, to any actual or prospective assignee or participant, (c) upon the demand of any
governmental authority, (d) in response to any order of 

  

 -62- 

 
any court or other governmental authority or as may otherwise be required pursuant to any Legal Requirement, (e) if required to do so in connection with
any litigation or similar proceeding, (f) that has been publicly disclosed, or (i) in connection with the exercise of any remedy hereunder, if and to the extent necessary to exercise such remedy. The Agent and each Lender acknowledge and
agree that the Borrower may, in response to any request that the Agent or a Lender disclose information (by deposition, interrogatories, requests for information or documents in legal proceedings, subpoena, or other similar process), seek a
protective order to enforce compliance with this Section, and the Agent and each Lender agree to cooperate with any such request. 
 [SIGNATURE PAGES TO FOLLOW] 
  

 -63- 

 This Agreement is entered into between us for the uses and purposes hereinabove set forth as of the date
first above written. 
  

					
	 AMERICAN PHARMACEUTICAL PARTNERS, INC.

		
	 By
	 	 /s/ Nicole S. Williams

		 	 Name:
	 	 Nicole S. Williams

		 	 Title:
	 	 Executive Vice President and
 Chief Financial Officer

  

 S-1 

					
	 “LENDERS”

	
	 FIFTH THIRD BANK, an Ohio banking
corporation, as a Lender, as L/C Issuer,
and
as Agent

		
	 By
	 	 /s/ Gregory D. Aromoso

		 	 Name
	 	 Gregory D. Aromoso

		 	 Title
	 	 Vice President

  

	
	 Address:

	
	 Fifth Third Center
 MD 109047
 Cincinnati, Ohio 45263
 Attention: Loan Syndications

  

 -2- 

					
	 WACHOVIA BANK, NATIONAL ASSOCIATION

		
	 By
	 	 /s/ Kirk Tesch

		 	 Name
	 	 Kirk Tesch

		 	 Title
	 	 Vice President

  

	
	 Address:

	
	 301 S. College Street, TW15
 NC5562
 Charlotte, NC 28288
 Attention: Kirk Tesch

  

 -3- 

					
	 HARRIS NESBITT FINANCING, INC.

		
	 By
	 	 /s/ Todd M. Kostelnik

		 	 Name
	 	 Todd M. Kostelnik

		 	 Title
	 	 Vice President

  

	
	 Address:

	
	 111 W. Monroe
 10th Floor East
 Chicago, IL 60603
 Attention: Gregory F. Tomczyk

  

 -4- 

					
	 LASALLE BANK NATIONAL ASSOCIATION

		
	 By
	 	 /s/ Tom Estey

		 	 Name
	 	 Tom Estey

		 	 Title
	 	 Senior Vice President

  

	
	 Address:

	
	 LaSalle Bank N.A.
 135 S/ LaSalle, #1127
 Chicago, IL 60603
 Attention: Susan Shitrin

  

 -5- 

					
	 CHARTER ONE BANK, N.A.

		
	By	 	 /s/ Michael Dolson

		 	 Name
	 	 Michael Dolson

		 	 Title
	 	 Vice President

  

	
	 Address:

	
	 71 S. Wacker Drive
 Chicago, IL 60606
 Attention: Jim Berry

  

 -6- 

					
	 U.S. BANK NATIONAL ASSOCIATION

		
	By	 	 /s/ James N. DeVries

		 	 Name
	 	 James N. DeVries

		 	 Title
	 	 Senior Vice President

  

	
	 Address:

	 209 South LaSalle Street
 Chicago, IL 60604
 Attention: J.
DeVries/Corp. Banking

  

 -7- 

					
	 THE GOVERNOR AND COMPANY OF THE
BANK OF IRELAND

		
	By	 	 /s/ Gwen Evans

		 	 Name
	 	 Gwen Evans

		 	 Title
	 	 Authorised Signatory

		
	By	 	 /s/ Iain Donovan

		 	 Name
	 	 Iain Donovan

		 	 Title
	 	 Authorised Signatory

  

	
	 Address:

	
	 Bank of Ireland Head Office (B2)
 Lower Baggot
Street
 Dublin 2 Ireland
 Attention: Ciaran
Doyle

  

 -8- 

					
	 NATIONAL CITY BANK

		
	By	 	 /s/ Rachel M. Williamson

		 	 Name
	 	 Rachel M. Williamson

		 	 Title
	 	 Assistant Vice President

  

	
	 Address:

	
	 One North Franklin
 20th Floor
 Chicago, IL 60606
 Attention: Rachel Williamson

  

 -9- 

					
	 COMERICA BANK

		
	By	 	 /s/ Tamara J. Miller

		 	 Name
	 	 Tamara J. Miller

		 	 Title
	 	 Vice President

  

	
	 Address:

	
	 500 Woodward Avenue
 MC 3269
 Detroit, MI 48266
 Attention: Tamara Miller

  

 -10- 

					
	 BRANCH BANKING AND TRUST CO.

		
	By	 	 /s/ Robert M. Searson

		 	 Name
	 	 Robert M. Searson

		 	 Title
	 	 Senior Vice President

  

	
	 Address:

	
	 200 West Second Street
 Winston Salem, NC 27104
 Mailcode: 001-16-16-20
 Attention: Robert M. Searson

  

 -11-Purchase and Sale Agreement, dated April 24, 2006

 Exhibit 10.26 
 PURCHASE AND SALE AGREEMENT 
 dated as of 
 April 24, 2006 
 between 
 PFIZER INC. 
 and 
 ABRAXIS BIOSCIENCE, INC. 

 Table of Contents 
  

					
	 	  	 	  	Page
	 ARTICLE I DEFINITIONS AND TERMS
	  	1
	 Section 1.1.
	  	Definitions	  	1
	 Section 1.2.
	  	Other Definitional Provisions	  	9
		
	 ARTICLE II PURCHASE AND SALE
	  	10
	 Section 2.1.
	  	Purchase and Sale of Assets of the Facility	  	10
	 Section 2.2.
	  	Consents	  	11
	 Section 2.3.
	  	Excluded Assets	  	12
	 Section 2.4.
	  	Assumption of Certain Liabilities	  	13
	 Section 2.5.
	  	Retained Liabilities	  	13
	 Section 2.6.
	  	Purchase Price	  	14
	 Section 2.7.
	  	Deposit	  	14
	 Section 2.8.
	  	Allocation of the Purchase Price	  	14
	 Section 2.9.
	  	Risk of Loss	  	15
		
	 ARTICLE III CLOSING
	  	15
	 Section 3.1.
	  	 Closing
	  	15
		
	 ARTICLE IV CONDITIONS TO CLOSING
	  	16
	 Section 4.1.
	  	Conditions to the Obligations of ABS and Pfizer	  	16
	 Section 4.2.
	  	Conditions to the Obligations of ABS	  	16
	 Section 4.3.
	  	Conditions to the Obligations of Pfizer	  	17
	 Section 4.4
	  	Reasonable Efforts	  	18
		
	 ARTICLE V REPRESENTATIONS AND WARRANTIES OF PFIZER
	  	18
	 Section 5.1.
	  	Organization	  	18
	 Section 5.2.
	  	Authority; Binding Effect	  	18
	 Section 5.3.
	  	Non-Contravention	  	19
	 Section 5.4.
	  	Consents	  	18
	 Section 5.5.
	  	Licenses and Permits	  	19
	 Section 5.6.
	  	Governmental Authorization	  	19
	 Section 5.7.
	  	Conduct of Business	  	19
	 Section 5.8.
	  	No Litigation	  	20
	 Section 5.9.
	  	Compliance with Laws	  	20
	 Section 5.10.
	  	Environmental Matters	  	20
	 Section 5.11.
	  	Material Contracts	  	22
	 Section 5.12.
	  	Real Property	  	22
	 Section 5.13.
	  	INTENTIONALLY OMMITTED	  	23
	 Section 5.14.
	  	Taxes	  	23
	 Section 5.15.
	  	Title to the Purchased Assets	  	23
	 Section 5.16.
	  	Brokers	  	23
	 Section 5.17
	  	Disclaimer.	  	23
		
	 ARTICLE VI REPRESENTATIONS AND WARRANTIES OF PURCHASER
	  	24
	 Section 6.1.
	  	Organization	  	24
	 Section 6.2.
	  	Authority; Binding Effect	  	24
	 Section 6.3.
	  	Non-Contravention	  	24
	 Section 6.4.
	  	Governmental Authorization	  	24

					
	 Section 6.5.
	  	Litigation	  	25
	 Section 6.6.
	  	Financial Capability	  	25
	 Section 6.7.
	  	Brokers	  	25
		
	 ARTICLE VII COVENANTS
	  	25
	 Section 7.1.
	  	Information and Documents; Confidentiality	  	25
	 Section 7.2.
	  	Conduct of Business	  	24
	 Section 7.3.
	  	Reasonable Best Efforts; Certain Governmental Matters	  	26
	 Section 7.4.
	  	Tax Matters	  	27
	 Section 7.5.
	  	Employees	  	29
	 Section 7.6.
	  	Storm Water UIC Project	  	29
	 Section 7.7.
	  	Fire Protection Tanks	  	30
	 Section 7.8.
	  	API Building Pipe Rack Sprinklers	  	30
	 Section 7.9.
	  	Waste Water Treatment Plant Liner	  	30
	 Section 7.10.
	  	Insurance	  	30
	 Section 7.11.
	  	Notification of Certain Matters	  	30
	 Section 7.12.
	  	.Bulk Sales Laws	  	30
	 Section 7.13.
	  	Intentionally Omitted	  	30
	 Section 7.14.
	  	Lease Agreement	  	31
	 Section 7.15.
	  	Compliance with WARN, Etc.	  	31
	 Section 7.16.
	  	Further Assurances and Cooperation	  	31
	 Section 7.17.
	  	Post-Closing Access	  	31
	 Section 7.18.
	  	Return of Excluded Assets	  	31
		
	 ARTICLE VIII INDEMNIFICATION
	  	31
	 Section 8.1.
	  	Indemnification by Sellers	  	31
	 Section 8.2.
	  	Indemnification by Purchaser Group	  	32
	 Section 8.3.
	  	Notice of Claims	  	33
	 Section 8.4.
	  	Third Party Claims	  	34
	 Section 8.5.
	  	Expiration	  	34
	 Section 8.6.
	  	Certain Limitations	  	35
	 Section 8.7.
	  	Losses Net of Insurance, Other Indemnities, Etc.	  	35
	 Section 8.8.
	  	Other Limitations	  	36
	 Section 8.9.
	  	Sole/Remedy/Waiver	  	36
	 Section 8.10.
	  	Indemnification Procedures for Remedial Actions on Purchased Assets	  	36
	 Section 8.11.
	  	Limitation on Indemnification for Third Party Claims for Remedial Action	  	38
	 Section 8.12.
	  	No Consequential Damages	  	39
		
	 ARTICLE IX TERMINATION
	  	39
	 Section 9.1.
	  	Termination	  	39
	 Section 9.2.
	  	Effect of Termination	  	39
		
	 ARTICLE X MISCELLANEOUS
	  	40
	 Section 10.1.
	  	Notices	  	40
	 Section 10.2.
	  	Amendment; Waiver	  	41
	 Section 10.3.
	  	Assignment	  	41
	 Section 10.4.
	  	Entire Agreement	  	41
	 Section 10.5.
	  	Fulfillment of Obligations	  	41

					
	 Section 10.6.
	  	Parties in Interest	  	41
	 Section 10.7.
	  	Public Disclosure	  	41
	 Section 10.8.
	  	Return of Information	  	42
	 Section 10.9.
	  	Expenses	  	42
	 Section 10.10.
	  	Schedules; Supplemental Disclosure	  	42
	 Section 10.11.
	  	Governing Law; Jurisdiction	  	43
	 Section 10.12.
	  	Counterparts	  	43
	 Section 10.13.
	  	Headings	  	43
	 Section 10.14.
	  	Severability	  	43
	 Section 10.15
	  	No Joint Venture or Partnership	  	43

 List of Schedules 
  

			
	 1.1(a)
	  	Knowledge of Pfizer
		
	 2.1(b)
	  	Equipment
		
	 2.1(c)
	  	Assumed Contracts
		
	 2.3 (j)
	  	API Equipment
		
	 2.4(d)
	  	Liabilities to Suppliers
		
	 4.2(c)
	  	Permits Required for Closing
		
	 5.4
	  	Consents
		
	 5.5
	  	Permits
		
	 5.6
	  	Governmental Authorization (Pfizer)
		
	 5.7
	  	Conduct of Business
		
	 5.8(a)
	  	Pending Litigation
		
	 5.9
	  	Compliance with Laws
		
	 5.10
	  	Environmental Matters
		
	 5.11
	  	Material Contracts
		
	 5.12(e)
	  	Real Property – Exceptions to Compliance with Law
		
	 5.16
	  	Brokers
		
	 6.7
	  	Purchasers Brokers

 List of Exhibits 
  

			
	 A.
	  	API Building
		
	 B.
	  	Form of Bill of Sale and Assumption Agreement
		
	 C.
	  	Form of Deed
		
	 D.
	  	Description of Land
		
	 E.
	  	Form of Lease Agreement
		
	 F.
	  	List of instruments and documents to be provided by Pfizer to Purchaser
		
	 G.
	  	List of instruments and documents to be provided by Purchaser to Pfizer
		
	 H.
	  	Wire Transfer Instructions
		
	 I.
	  	Plot Plan
		
	 J.
	  	Retained API Equipment

 PURCHASE AND SALE AGREEMENT 
 This Purchase and Sale Agreement is made and entered into as of April 24, 2006 between Pfizer Inc., a Delaware corporation
(“Pfizer”) and Abraxis BioScience, Inc. a Delaware corporation (“ABS). 
 W I T N E S E T H: 
 WHEREAS, Pfizer, through Selling LLC (as defined below), is engaged in the operation of the Facility (as defined below); 
 WHEREAS, Pfizer is the indirect beneficial owner of all of the issued and outstanding membership interests in the Selling LLC (as defined below);

 WHEREAS, the Selling LLC owns all of the Purchased Assets (as defined below); 
 WHEREAS, on February 1, 2006, Pfizer and American Pharmaceutical Partners, Inc. (“APP”) entered into a Letter of Intent, as amended from
time to time (the “Letter of Intent”), with respect to the transactions contemplated under this Agreement (as such term is defined below); 
 WHEREAS, as of April 18, 2006 APP merged with American BioScience, Inc. adopting the name Abraxis BioScience, Inc. and assuming the obligations of APP under the Letter of Intent; 
 WHEREAS, ABS is the direct beneficial owner of all of the issued and outstanding ownership interests of Abraxis BioScience Manufacturing, LLC, a Puerto
Rico limited liability company (the “Purchasing Entity”); and 
 WHEREAS, the parties hereto desire that, at the Closing,
Pfizer shall cause the Selling LLC to sell and transfer to the Purchasing Entity, and ABS shall cause the Purchasing Entity to purchase and accept from the Selling LLC, all of the Purchased Assets and assume from the Selling LLC all of the Assumed
Liabilities (as defined below), upon the terms and conditions set forth herein. 
 NOW THEREFORE, in consideration of the foregoing and the
representations, warranties, covenants and agreements contained herein, the parties hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS AND TERMS 
 Section 1.1. Definitions. As used in this Agreement, the following terms shall have the meanings set forth or as referenced below: 
 “Affiliate(s)” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with, such Person at any time during the 

  

 1 

 
period for which the determination of affiliation is being made. For purposes of this definition, “control” shall be presumed to exist if one of
the following conditions is met: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. 
 “Agreement” means this Purchase and Sale Agreement and the schedules and exhibits hereto, as the same may be amended or supplemented
from time to time in accordance with the terms hereof. 
 “Allocation” has the meaning set forth in Section 2.8 hereof.

 “API” means the active pharmaceutical ingredient known as “celecoxib” currently manufactured at the API
Building. 
 “API Building” means the building with a total construction area of Ninety Thousand Square Feet
(90,000) Square Feet as illustrated in the site plan (#15 on the Plot Plan) attached hereto as Exhibit A. 
 “API Building Pipe
Rack Sprinklers Project” means the project described in Section 7.8. 
 “API Equipment” means the equipment
(including the three (3) distillation columns), machinery, furniture and fixtures (including, without limitation, all trade fixtures), reactor trains and piping, including all property of a similar nature and all other items (including, without
limitation, drug product, API, supplies, spare parts, utilities and tools) necessary for the continued API Operations of Selling LLC and including, without limitation, those items more particularly described on Schedule 2.3(j). Prior to
Closing, Seller Group may amend, supplement or modify Schedule 2.3(j) by adding or removing API Equipment from the list described therein upon prior written notice to the Purchaser Group. 
 “API Operations” means any and all business operations in any way relating to the API Building and Support Facilities, including, but
not limited to, use, occupancy, and possession of the API Building and the handling of API. 
 “ABS” has the meaning
set forth in the preamble hereof. 
 “Applicable Remedial Action Standard” means the least stringent, most cost-effective
standard required by applicable Environmental Law and consistent with the industrial/commercial use of the Facility or a standard pursuant to applicable Environmental Laws acceptable to the relevant Governmental Authorities. 
 “As Is” means the condition and state of repair of the Purchased Assets existing on the Closing Date. 
 “Assumed Contracts” has the meaning set forth in Section 2.1(c) hereof. 
  

 2 

 “Assumed Liabilities” has the meaning set forth in Section 2.4 hereof. 

“Assumption Agreement” shall mean the agreement substantially in the form attached as Exhibit B to be entered into by the Purchaser
and the Selling LLC. 
 “Best Efforts” means the commercially reasonable efforts that a prudent person desirous of achieving
a result would use in similar circumstances to assure that such result is achieved as expeditiously as possible. 
 “Bill of
Sale” shall mean the bill of sale for the Purchased Assets substantially in the form attached as Exhibit B to be executed by the Purchaser and the Selling LLC. 
 “Business Day” means any day other than a Saturday, a Sunday or a day on which banks in New York, New York are authorized or obligated by law or executive order to close. 
 “Cash Equivalents” means cash, checks, money orders, marketable securities, short-term instruments and other cash equivalents, funds in
time and demand deposits or similar accounts, and any evidence of indebtedness issued or guaranteed by any Person. 
 “Closing” means the closing of the transactions contemplated by this Agreement. 
 “Closing Date”
has the meaning set forth in Section 3.1(a) hereof. 
 “Collateral Source” has the meaning set forth in
Section 8.7 hereof. 
 “Code” means the Internal Revenue Code of 1986, as amended. 
 “Commonwealth” means the Commonwealth of Puerto Rico, including the Municipality of Barceloneta. 
 “Confidentiality Agreement” means the Confidentiality Agreement between Pfizer and APP dated August 9, 2005. 
 “Consents” has the meaning set forth in Section 5.4 hereof. 
 “Deed” shall mean the public instrument substantially in the form attached as Exhibit C whereby title to the Real Property is
transferred from the Selling LLC to the Purchasing Entity. 
 “Deposit” has the meaning set forth in Section 2.7
hereof. 
 “Drug Product Building” means the drug product building consisting of approximately One Hundred Seventy Two
Thousand (172,000) Square Feet. 
 “Environmental Law” means any applicable federal, state, municipal or Commonwealth
Laws, binding administrative or judicial, regulations, Governmental Orders, and ordinances, as same may be amended from time to time, relating to (i) the protection of the environment (including air, water vapor, surface water, groundwater,
drinking water supply, surface or subsurface land); or (ii) the exposure to or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, Release or disposal of Hazardous Substances. 
  

 3 

 “Environmental Liability” means all Liabilities and Losses resulting from
(i) failure to comply with any requirement of an Environmental Law; (ii) failure to obtain or comply with any required Environmental Permit; (iii) Remedial Actions; or (iv) harm or injury to any real property, to any Person, to
public health, or to any natural resource (other than Remedial Action) as a result of exposure to Hazardous Substances. 
 “Environmental Permits” means all permits, licenses, certificates, concessions, franchises, approvals or authorizations issued by a Governmental Authority pursuant to an Environmental Law. 
 “Equipment” has the meaning set forth in Section 2.1(b) hereof. 
 “Escrow Agreement” means that certain escrow agreement executed on February 16, 2006 by and between the Sellers, APP and
Fifth Third Bank, as escrow agent. 
 “Excluded Assets” has the meaning set forth in Section 2.3 hereof. 
 “Excluded Environmental Liabilities” means any Third Party Claims for: 
  

	 	(i)	Environmental Liabilities for Remedial Action to the extent a Release from the Facility had occurred prior to the Closing Date; 

  

	 	(ii)	Environmental Liabilities as defined in clauses (i) or (ii) of the definition of Environmental Liabilities that constitute fines or penalties imposed by Governmental
Authorities and that result from the failure of the Selling LLC to comply with any requirement of Environmental Law prior to the Closing Date or the failure of the Selling LLC, Pharmacia Corporation, and/or Searle Ltd. of Puerto Rico to obtain or
comply with any required Environmental Permit prior to the Closing Date; 

  

	 	(iii)	Environmental Liabilities resulting from the off-site transportation, storage, disposal, treatment or recycling of Hazardous Substances generated by or taken off-site by or on
behalf of the Selling LLC, Pharmacia Corporation, and/or Searle Ltd. of Puerto Rico prior to the Closing Date; 

  

	 	(iv)	Environmental Liabilities for on-site exposure to Hazardous Substances used, stored, or otherwise handled by the Selling LLC, Pharmacia Corporation, and/or Searle Ltd. of Puerto
Rico at the Facility prior to the Closing Date; and 

  

	 	(v)	Environmental Liabilities for off-site exposure to Hazardous Substances used, stored, or otherwise handled by the Selling LLC, Pharmacia Corporation, and/or Searle Ltd. of Puerto
Rico at the Facility prior to the Closing Date; and 

 Notwithstanding anything to the contrary set forth in this Agreement, capital and other
costs of environmental-related compliance with Environmental Laws in the ordinary course of operating 

  

 4 

 
the Purchased Assets after the Closing Date (including closure and post-closure expenditures incurred after the Closing Date) shall not be deemed to be
Excluded Environmental Liabilities; provided, however, that the foregoing does not limit (i) above. 
 “Excluded
Permits” shall have the meaning set forth in Section 2.3(k). 
 “Facility” means the Drug Product Building,
API Building, Support Facilities, waste water treatment plant, buildings, structures, improvements, fixtures (located at and affixed to the improvements) and betterments theron and appurtenance thereto located on the Land commonly known as Cruce
Dávila, Barceloneta, Puerto Rico excluding the API Equipment. 
 “Fire Protection Tanks Project” means the project
described in Section 7.7 
 “Governmental Authority” means any federal, state, Commonwealth, municipal or local judicial,
legislative or regulatory authority. 
 “Governmental Authorizations” means all licenses, permits, certificates concessions,
franchises or other authorizations or approvals under the applicable Laws of any Governmental Authority. 
 “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, determination, notification or award entered by or into with any Governmental Authority, including any statutory extension, modification
or re-enactment of the same. 
 “Hazardous Substances” means any substance, pollutant or contaminant that is regulated as a
hazardous waste or hazardous substance under any Environmental Law. For purposes of this Agreement, the foregoing includes petroleum products and their derivatives. 
 “Indemnified Party” has the meaning set forth in Section 8.3(a) hereof. 
 “Indemnifying Party” has the meaning set forth in Section 8.3(a) hereof. 
 “IRS” means the Internal Revenue Service of the United States of America. 
 “Intellectual Property” shall mean all intellectual property owned or licensed (as licensor or licensee) by Seller in which Seller has a
proprietary interest including: 
  

	 	(i)	the “Pfizer”, “Warner-Lambert”, “Parke-Davis”, “Searle” and “Pharmacia” names and logos, all assumed fictional business names,
trade names, registered and unregistered trademarks, service marks and applications (collectively “Marks”); 

  

	 	(ii)	all patents, patent applications and inventions and discoveries that may be patentable (collectively “Patents”); 

  

	 	(iii)	all registered and unregistered copyrights in both published works and unpublished works (collectively “Copyrights”); 

  

 5 

	 	(iv)	all rights in mask works; 

  

	 	(v)	all know how, trade secrets, confidential or proprietary information, customer lists, software, technical information, date, process technology, plans, drawings and blueprints
(collectively “Trade Secrets”); and 

  

	 	(vi)	all rights in internet domain names presently used by Seller (collectively “Net Names”). 

 “Inventory” shall mean all inventory, including, but not limited to, raw materials, packaging materials, work-in-process, maintenance
and operating supplies, fuels and maintenance store items owned by the Sellers at the Closing Date in connection with the operation of the Facility and warehoused at the Facility. 
 “Knowledge of Pfizer” means the actual knowledge of any of the individuals listed on Schedule 1.1(a). 
 “Land” means the real property more particularly described on Exhibit D hereto, together with all easements, covenants and other rights
appurtenant thereto. 
 “Laws” shall include law, common law, statute, ordinance, rule, regulation, permit, order, code,
injunction, judgment, decree or Governmental Order of any federal, state (including the Commonwealth), local, municipal or other Governmental Authority. 
 “Lease Agreement” means a document substantially in the form of Exhibit E hereto. 
 “Liabilities” means any and all debts, liabilities and obligations, whether accrued or fixed, known or unknown, absolute or contingent, matured or unmatured or determined or determinable. 
 “License” means that certain Use and Occupancy License Agreement executed prior to the date hereof between APP and Selling LLC.

 “Liens” means any lien, security interest, mortgage, deed to secure debt, charge or similar encumbrance. 
 “Loss” or “Losses” has the meaning set forth in Section 8.1(a) hereof. 
 “Material Adverse Effect” means an effect that is materially adverse to the physical or financial condition of the Purchased Assets
taken as a whole in excess of Three Hundred Thousand Dollars ($300,000.00), but shall exclude any effect resulting from (i) general economic conditions, (ii) any occurrence or condition generally affecting the pharmaceutical industry that
does not disproportionately affect the Facility, (iii) acts of terrorism or war (whether or not threatened, pending or declared), (iv) the public announcement of this Agreement or the transactions contemplated hereby and (v) the acts
or omissions of, or circumstances affecting, Purchaser or any of its Affiliates. 
 “Material Contracts” has the meaning set
forth in Section 5.11 hereof. 
  

 6 

 “Permits” has the meaning set forth in Section 5.5 hereof. 
 “Permitted Encumbrances” means (i) all Liens approved in writing by Purchaser; (ii) statutory Liens arising out of operation
of Law with respect to a Liability incurred in the ordinary course of business and which are not yet due or delinquent; (iii) Liens for real property taxes assessed for any period after the Closing Date; (iv) restrictive covenants and
easements which appear on records affecting the Land and/or the Facility; (v) zoning, use and other restrictions imposed by any Governmental Authority; and (vi) all those matters that appear in the Survey. 
 “Person” means an individual, a corporation, a partnership, a limited liability company, an association, a trust or other entity or
organization, including a governmental or political subdivision or an agency or instrumentality thereof. 
 “Pfizer” has the
meaning set forth in the preamble hereof. 
 “Plot Plan” means that certain Plot Plan attached hereto as Exhibit I.

 “PRIRC” means the Commonwealth’s Internal Revenue Code of 1994, as amended. 
 “Proceeding” has the meaning set forth in Section 10.11(b) hereof. 
 “Purchased Assets” has the meaning set forth in Section 2.1 hereof, it being understood that the Purchased Assets do not include
the Excluded Assets. 
 “Purchase Price” has the meaning set forth in Section 2.6 hereof. 
 “Purchaser Group” means, collectively, ABS and the Purchasing Entity. 
 “Purchasing Entity” has the meaning set forth in the preamble hereof. 
 “Real Property” means the Land and the Facility. 
 “Release” means any spilling, leaking, pumping, pouring, emitting, emptying, injecting, depositing, disposing, discharging, dispersal, escaping, dumping, or leaching of a Hazardous Substance
into the environment including surface water, soil, or groundwater (including the abandonment or discarding of barrels, containers, and other receptacles containing Hazardous Substances) or as otherwise defined under Environmental Laws.

 “Remedial Action” shall mean action required by Governmental Authority or Governmental Order pursuant to Environmental
Law to clean up soil, surface water, or groundwater in response to a Release of Hazardous Substances, including associated action taken to investigate, monitor, assess and evaluate the extent and severity of any such Release; action taken to
remediate any such Release; post-remediation monitoring of any such Release; and preparation of all reports, studies, analyses or other documents relating to the above. Remedial Action also shall refer to any judicial, administrative or other
proceeding relating to any of the above, including the negotiation and execution of judicial or administrative consent decrees; responding to information requests by any Governmental Authority; or defending claims brought by any Governmental
Authority or any other Person, whether such claims are equitable or legal 

  

 7 

 
in nature, relating to the cleanup of the environment, including soil, surface water, and groundwater in response to a Release of Hazardous Substances and
associated actions. Remedial Action shall not include (i) the capital, operation and maintenance costs incurred by the Purchaser Group to continue to operate the Purchased Assets which as of the Closing Date are being operated by Selling LLC in
compliance with Environmental Laws; or (ii) closure and post-closure expenditures related to the Purchased Assets. 
 “Required
Governmental Report” means any written notice, report or other filing by any party hereto that is required by Environmental Law, or by Governmental Authority. 
 “Retained API Equipment” means equipment, fixtures, furniture and machineries described in Exhibit J attached hereto and made a part hereof, whose title shall be retained by Pfizer on the
expiration or earlier termination of the Lease Agreement. 
 “Retained Liabilities” has the meaning set forth in
Section 2.5 hereof. 
 “Retained Tax Liabilities” has the meaning set forth in Section 2.5(a) hereof. 

“Sellers” or the “Seller Group” shall mean Pfizer and the Selling LLC. 
 “Selling LLC” shall mean Pfizer Pharmaceuticals L.L.C. 
 “Shared Facilities” shall mean the Cafeteria (#19 on the Plot Plan”) and the Gym (#17 on the Plot Plan). 
 “Storm Water UIC Project” means the project described in Section 7.6. 
 “Straddle Period” means any Tax period that begins before and ends after the Closing Date. 
 “Subsidiary” means an entity as to which Pfizer or ABS or any other relevant entity, as the case may be, owns directly or indirectly 50% or more of the voting power or other similar interests. 
 “Support Facilities” means the amenities building (#18 on the Plot Plan), warehouse space for storage of API ingredients (#14 and 63 on
the Plot Plan), the tank farms (#12, 47 and 65 on the Plot Plan), power plant generator (#42 on Plot Plan), therminol “chiller” (#10 on the Plot Plan), cooling tower (#25 on the Plot Plan), liquid nitrogen for API (#30 on the Plot Plan),
chemical plant sampling room (#33 on the Plot Plan), electrical sub-station (#36 on the Plot Plan), chemical plant HVAC chiller (#49 on the Plot Plan), scrubbers and water conservation tank (#50 on the Plot Plan), chemical area parking lot (#60 on
the Plot Plan), the guard house (#24 on the Plot Plan), ESH building (#52 on the Plot Plan), Celecoxib warehouse (#63 on the Plot Plan), the staging area bulk solvents (#66 on the Plot Plan), the maintenance shop in the Maintenance and Utilities I
Building (#13 on the Plot Plan), the combustible drum storage area and a new hazardous waste storage area to be agreed upon by the parties. 
  

 8 

 “Survey” means that certain as-built and survey plan dated June 1998 prepared by
Marcelino Díaz Declet, license number 7195, and certified by him on February 10, 2006 in connection with the Real Property. 
 “Tax” or “Taxes” means all taxes, charges, duties, fees, levies or other assessments, including, but not limited to, income, excise, property, sales, value added, profits, license, gross receipts,
withholding (with respect to compensation or otherwise), payroll, employment, net worth, capital gains, transfer, stamp, social security, environmental, occupation and franchise taxes, imposed by any Governmental Authority, and including any
interest, penalties, charges and additions attributable thereto. 
 “Tax Return” means any return, report, declaration,
information return, statement or other document filed or required to be filed with any Governmental Authority, in connection with the determination, assessment or collection of any Tax, the establishment of any plan or the administration of any Laws
relating to any Tax including any amendment thereto. 
 “Third Party Claim” has the meaning set forth in Section 8.4(a)
hereof, including, but not limited to, any claim, action, suit or proceeding from third parties or any governmental authority or agency. 
 “Transaction Agreements” means this Agreement and the agreements, documents and instruments listed on Exhibit F and Exhibit G hereto. 
 “Treasury” means the Commonwealth’s Department of the Treasury. 
 “WARN” means the Worker Adjustment and Retraining Notification Act of 1988, as amended. 
 “Waste Water
Treatment Plant Liner Replacement Project” means the project described in Section 7.9 
 “Where Is” means the
location of the Purchased Assets on the Closing Date. 
 Section 1.2. Other Definitional Provisions. 
  

	 	(a)	The words “hereof”, “herein”, “hereto” and “hereunder” and words of similar import, when used in this Agreement, shall refer to this
Agreement as a whole and not to any particular provision of this Agreement. 

  

	 	(b)	The terms defined in the singular have a comparable meaning when used in the plural, and vice versa. 

  

	 	(c)	The terms “dollars” and “US$” means United States dollars. 

  

	 	(d)	References to one gender include all genders. 

  

 9 

	 	(e)	The term “including” is not limited, but is inclusive. 

  

	 	(f)	The article, section, subsection, Exhibit and Schedule references are to this Agreement unless otherwise specified. 

  

	 	(g)	Reference to any agreement (including this Agreement), document or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in
accordance with the terms thereof and, if applicable, the terms hereof. 

 ARTICLE II 
 PURCHASE AND SALE 
 Section 2.1.
Purchase and Sale of Assets of the Facility. Upon the terms and subject to the conditions set forth herein (including Sections 2.2 and 2.3), at the Closing, the Seller Group shall sell, convey, assign, transfer, and deliver to the Purchaser
Group and the Purchaser Group shall purchase, acquire and accept from the Seller Group on an “As Is” “Where Is” basis, free and clear of all Liens, other than Permitted Encumbrances, all the rights, title and interests in and to
the following assets, properties and rights owned by the Seller Group on the Closing Date (collectively, the “Purchased Assets”): 
  

	 	(a)	the Real Property on an “As Is” “Where Is” basis; 

  

	 	(b)	the furniture, equipment, machinery, drug product and utility spare parts, vehicles, tools and other tangible property located at or otherwise used solely in connection with the
Facility and necessary to conduct operations at the Facility as conducted as of December 31, 2005, including the items set forth on Schedule 2.1(b), but excluding (i) the Retained API Equipment; (ii) the API Equipment; and
(iii) the cooling tower removed prior to the date hereof (the “Equipment”), on an “As Is” “Where Is” basis; 

  

	 	(c)	all rights under the contracts, licenses, and agreements solely related to the Facility (other than the API Building and the Support Facilities) and Equipment and set forth on
Schedule 2.1(c), to the extent that they are assignable or consent to assignment has been obtained (the “Assumed Contracts”); 

  

	 	(d)	transferable Governmental Authorizations (but not including Environmental Permits that can not be transferred to the Purchaser Group for any reason) owned, utilized or licensed
(subject to the terms of such licenses) by the Selling LLC that are solely required in the operation of the Facility (other than the API Building and the Support Facilities) as it was operated as of December 31, 2005; 

 

	 	(e)	all transferable rights of the Selling LLC under or pursuant to all warranties, representations and guarantees made by suppliers, manufacturers and contractors to the extent
affecting the Purchased Assets (other than the API Building and the Support Facilities); 

  

 10 

	 	(f)	all vendor lists to the extent solely relating to the Facility (other than the API Building and the Support Facilities), and all files and documents (including credit information)
to the extent solely relating to vendors of the Facility (other than the API Building and the Support Facilities), and other business and financial records, files, books and documents, including without limitation, permit applications, equipment
maintenance records, records concerning materials used, and compliance audits, including all correspondence, redacted to remove any proprietary (product or process related) information, with the Food and Drug Administration or any foreign
equivalent, and all Governmental Authorities, and all standard operating procedures for the Facility (other than the API Building and the Support Facilities), whether in hard copy or computer format, to the extent solely relating to the Facility
(other than the API Building and the Support Facilities); 

  

	 	(g)	(i) the databases and software programs, source codes and user manuals owned, used, leased by or licensed to the Selling LLC (in the case of leases or licenses, to the extent
that they are assignable or consent to assignment has been obtained), and used solely at the Facility (other than the API Building and the Support Facilities); and (ii) the computer hardware used solely at the Facility (other than the API
Building and the Support Facilities and except the API process control software and hardware as provided in Schedule 2.3(j) (these would be listed on the retained equipment list)); and 

  

	 	(h)	all other assets used solely in connection with the Facility and located at the Facility as of December 31, 2005. 

 Section 2.2. Consents. 
  

	 	(a)	There shall be excluded from the Purchased Assets transferred at the Closing any contract, agreement, Governmental Authorization, Permit, Environmental Permit, lease, license,
commitment or right that is not assignable or transferable without the consent of any Person, other than Selling LLC, any Pfizer Subsidiary, ABS or Purchaser, to the extent that such consent shall not have been given prior to the Closing, Selling
LLC shall use its Best Efforts (but without any payment of money by Sellers or their Subsidiaries) to obtain all such consents during the 90-day period following the Closing and, upon receipt of any such consent during such period, the relevant
contract, agreement, Governmental Authorization, Permit, Environmental Permit, lease, license, commitment or right shall then be included in the Purchased Assets. If any such consent shall not have been obtained on expiration of such 90-day period,
the relevant contract, agreement, Governmental Authorization, Permit, Environmental Permit, lease, license, commitment or right shall be an Excluded Asset. 

  

	 	(b)	 Purchaser agrees that no representation, warranty or covenant of the Seller Group contained herein shall be breached or deemed breached and no condition of
Purchaser shall be deemed not to be satisfied as a result of the failure to obtain 

  

 11 

	 	 
any consent referred to in Section 2.2(a) provided that the Selling LLC has used its Best Efforts as provided pursuant to Section 2.2(a) to obtain
such consents. 

 Section 2.3. Excluded Assets. Notwithstanding any other provision in this Agreement, the
Selling LLC or any Affiliate thereof shall retain, the following (the “Excluded Assets”): 
  

	 	(a)	Cash Equivalents; 

  

	 	(b)	all accounts and notes receivable; 

  

	 	(c)	all Inventory, except spare parts, change parts, maintenance and operating supplies, fuels and maintenance store items used directly or indirectly in connection with the API
Equipment, the API Building, the Support Facilities or relating to the API Operations; 

  

	 	(d)	all intercompany receivables, contracts, agreements and arrangements; 

  

	 	(e)	all Tax losses, Tax loss carry forwards and rights to receive refunds, credits and credit carry forwards with respect to any and all Taxes, to the extent attributable to a taxable
period (or portion thereof) ending on or prior to the Closing Date including, without limitation, interest thereon, whether or not the foregoing is derived from the operation of the Facility; 

  

	 	(f)	the corporate books and records of the Selling LLC or Pfizer; 

  

	 	(g)	all current and prior insurance policies and all rights of any nature with respect thereto, including all insurance recoveries and unearned premiums thereunder and rights to assert
claims with respect to any such insurance recoveries; 

  

	 	(h)	all Intellectual Property, except as specifically identified as part of the Purchased Assets or in Section 2.1 ; 

  

	 	(i)	all inventories of finished goods; 

  

	 	(j)	API Equipment; 

  

	 	(k)	Selling LLC’s or any Affiliates licenses, permits, certifications and other governmental authorizations and deposits that are not assignable or are not solely used in
connection with the Purchased Assets (collectively, the “Excluded Permits”), including, without limitation, any applications for Excluded Permits or for renewal of any of the Excluded Permits for which action by Governmental Authorities is
pending as of the Closing Date, except that, with respect to any Environmental Permits used in the conduct of the operation of the Purchased Assets which are not assignable to Purchaser, Excluded Permits shall not include documentation necessary for
Purchaser to apply for such Excluded Permits; 

  

	 	(l)	The cooling tower removed prior to the date hereof; 

  

 12 

	 	(m)	Retained API Equipment; and 

  

	 	(n)	All assets not expressly included in the Purchased Assets. 

 Section 2.4. Assumption of Certain Liabilities. Upon the terms and subject to the conditions of this Agreement, the Purchaser Group agrees, effective at the Closing, to assume the following Liabilities (collectively, the
“Assumed Liabilities”): 
  

	 	(a)	all lawsuits commenced and claims made after the Closing (including claims of patent or other intellectual property infringement) to the extent resulting from the operation of the
Real Property or the ownership of the Purchased Assets after the Closing, except for any claims or lawsuits related to the API Operations conducted by the Sellers; 

  

	 	(b)	all Liabilities resulting from a claim by a third party for money or other compensation (beyond the cost of a particular product) in respect of injury allegedly due and owing as a
result of the operation of the Facility after the Closing, including, without limitation, warranty obligations and irrespective of the legal theory asserted, except for any Liabilities related to the API Operations conducted by the Sellers;

  

	 	(c)	all Liabilities arising after the Closing under any contracts, agreements, leases, licenses or commitments that are assigned to Purchaser pursuant to Section 2.1 or 2.2 at or
subsequent to the Closing; 

  

	 	(d)	all Liabilities to suppliers for materials and services relating to the operation of the Facility (excluding the API Operations) ordered in the ordinary course of business prior to
the Closing, but scheduled to be delivered or provided after the Closing as set forth on Schedule 2.4(d), which schedule shall be mutually agreed to by the parties and provided five (5) days prior to Closing, except for any Liabilities
related to the API Operations conducted by the Sellers; and 

  

	 	(e)	except as provided in Section 2.5, all other Liabilities arising after the Closing relating to the ownership or operation of the Purchased Assets, except for any Liabilities
related to the API Operations conducted by the Sellers. 

 Section 2.5. Retained Liabilities. Notwithstanding any
other provision in this Agreement, the Sellers shall retain and be responsible for any Liabilities that are not Assumed Liabilities including, without limitation, the following (the “Retained Liabilities”): 
  

	 	(a)	 all Liabilities for Taxes of Selling LLC or taxes related to, imposed on, or arising from the Facility or the Purchased Assets (including the gain, if any, arising
to the Sellers from the sale of the Facility and the Purchased Assets to the Purchasing Entity) for any taxable period (or portion thereof) on or prior to the Closing, except for (w) any taxes payable by ABS pursuant to the License,
(x) Taxes attributable to actions taken or failures to act after the Closing by the Purchaser Group, any of its Affiliates or any transferee of Purchaser or any of its Affiliates (other than any such action expressly required or otherwise
expressly 

  

 13 

	 	 
contemplated by this Agreement or with the written consent of the Sellers), (y) as otherwise provided in Section 10.9, or (z) real and
personal property Taxes for the calendar year of the Closing attributable to the portion of the year during which the respective real or personal property of the Facility is owned by the Purchasing Entity, its Affiliates or any transferee of the
Purchasing Entity or its Affiliates (the “Retained Tax Liabilities”), provided that in the case of any real or personal property Tax for any Straddle Period, (A) the amount of such Tax attributable to the portion of such
Straddle Period ending on or prior to the Closing Date shall be the amount of such Tax for the entire Straddle Period multiplied by a fraction, the numerator of which is the number of days in such Straddle Period prior to and including the Closing
Date and the denominator of which is the total number of days in the entire Straddle Period and (B) the amount of such Tax attributable to the portion of such Straddle Period beginning after the Closing Date shall be the amount of such Tax for
the entire Straddle Period minus the amount of such Tax determined under clause (A) of this proviso and that in the case of all other Taxes, such Taxes shall be apportioned on the basis of an interim closing of the books at the end of the
Closing Date; 

  

	 	(b)	Liabilities exclusively associated with the Excluded Assets. 

  

	 	(c)	Excluded Environmental Liabilities. 

 Section 2.6.
Purchase Price. In consideration of the sale and transfer of the Purchased Assets, ABS, as agent for the Purchasing Entity shall pay to Pfizer, as agent for the Selling LLC, on the Closing Date, the amount of THIRTY TWO MILLION FIVE HUNDRED
THOUSAND DOLLARS (US$32,500,000) (the “Purchase Price”), in immediately available funds, by wire transfer in accordance with the written instructions attached hereto as Exhibit H or given by Pfizer to Purchaser not less than two
(2) Business Days prior to the Closing which consideration shall be allocated as provided in Section 2.8. Such payments shall be made free of any withholdings, including, without limitation, withholding of income taxes under the PRIRC.

 Section 2.7. Deposit. In consideration for Sellers’ covenant to sell the Purchased Asset in accordance with the terms and
conditions contained herein, ABS delivered to Sellers the amount of THREE MILLION DOLLARS ($3,000,000.00) (the “Deposit”) pursuant to the terms of the Escrow Agreement. The Deposit shall be held in escrow and disbursed in accordance with
the terms and conditions of the Escrow Agreement. At Closing, all amounts held in the escrow account, including any accrued interest on the Deposit, as per the Escrow Agreement, shall be credited to the Purchase Price. 
 Section 2.8. Allocation of the Purchase Price. The parties shall negotiate in good faith and agree prior to Closing on the allocation of the
Purchase Price among the Purchased Assets (the “Allocation”). In the event that ABS chooses an independent appraisal firm to perform an appraisal to support the Allocation, the cost of such appraisal firm shall be borne by ABS.
Pfizer shall be provided with a copy of the appraiser’s report within fifteen (15) Business Days following the delivery of such report to ABS and, provided that Pfizer consents to the report, the Allocation shall be made as specified in
the report. If Pfizer does not consent to the appraiser’s report, Pfizer and ABS shall use their best efforts to mutually agree on any changes to be made 

  

 14 

 
to the report and the Allocation shall be made as specified in the report so changed. The Sellers, on the one hand, and the Purchaser Group, on the other,
shall (i) be bound by the Allocation for purposes of determining any Taxes, (ii) prepare and file, and cause its Affiliates to prepare and file, its Tax Returns, including, without limitation, Internal Revenue Service Form 8594, on a basis
consistent with the Allocation, and (iii) take no position, and cause its Affiliates to take no position, inconsistent with the Allocation on any applicable Tax Return or in any proceeding before any taxing authority or otherwise. Any
post-Closing adjustment, if any, to the Purchase Price shall be allocated to each Purchased Asset to which the adjustment relates, and the Purchase Price allocation to such Purchased Asset shall be correspondingly increased or decreased. 

Section 2.9. Risk of Loss. Until the Closing, any loss of or damage to the Purchased Assets from fire, casualty or any other occurrence
shall be the sole responsibility of Pfizer or its Affiliates, as the case may be. At the Closing, title to the Purchased Assets shall be transferred to the Purchasing Entity, except for those Purchased Assets which transfer of title is conditioned
on the transfer or approval of a Permit after the Closing. The Purchasing Entity shall bear all risks of loss associated with the Purchased Assets after Closing; provided, however, that the Purchasing Entity shall not bear the risk of loss of any
Purchased Asset until title to such Purchased Asset has been transferred, except if the Purchasing Entity is controlling, supervising, operating or using the Purchased Asset. 
 ARTICLE III 
 CLOSING 
 Section 3.1. Closing. 
  

	 	(a)	The Closing shall take place at the offices of Pfizer, 235 E. 42nd Street, New York, New York, at 10:00 A.M., New York time, upon the meeting of all conditions to Closing set forth
in Article IV or such other time as the parties may agree, but not later than December 31, 2006. The date on which the Closing occurs is called the “Closing Date.” The Closing shall be deemed to occur and be effective as of
11:59 P.M., New York City time, on the Closing Date. 

  

	 	(b)	At the Closing, Pfizer shall deliver or cause to be delivered to the Purchasing Entity the instruments and documents set forth in Exhibit F hereto, in each case, in a form
reasonably acceptable to the Purchaser Group. 

  

	 	(c)	 At the Closing, ABS shall deliver to Pfizer, the following: (i) the Purchase Price, less the amounts held in escrow in accordance with the Escrow Agreement
described in Section 2.7 above, by wire transfer in immediately available funds to one or more accounts set forth on Exhibit H or as otherwise specified in writing by Pfizer at least two (2) Business Days prior to the Closing Date, free of
any withholdings, including, without limitation, withholding of income taxes under the Puerto Rico Internal Revenue Code of 1994, as amended, and (ii) the 

  

 15 

	 	 
instruments and documents set forth in Exhibit G hereto, in each case, in a form reasonably acceptable to Pfizer. 

 ARTICLE IV 
 CONDITIONS TO CLOSING

 Section 4.1. Conditions to the Obligations of ABS and Pfizer. The respective obligations of each of the parties to
consummate the transactions contemplated by this Agreement shall be subject to the satisfaction of the following conditions precedent: 
  

	 	(a)	There shall not be in effect any Law or Governmental Order that makes illegal or enjoins, prevents or modifies in any respect the consummation of the transactions contemplated by
this Agreement; 

  

	 	(b)	There shall not have been commenced and be continuing, or threatened in writing, any action or proceeding by any Governmental Authority which seeks to prevent or enjoin in any
respect the transactions contemplated by this Agreement; 

  

	 	(c)	Any approval or action of any Governmental Authority that is necessary to lawfully consummate the transactions contemplated hereby shall have been obtained or taken, and any
investigation opened or otherwise commenced by such Governmental Authority shall have been closed; and 

  

	 	(d)	The parties shall also execute at the Closing, a Bill of Sale, an Assumption Agreement, the Deed and the Lease Agreement referenced herein, which accurately reflect and take into
account the purchase and sale of the Purchased Assets contemplated under this Agreement. 

  

	 	(e)	The parties shall also negotiate and prepare, in form and content mutually acceptable to both parties, the Allocation. 

  

	 	(f)	The parties shall also prepare Schedule 2.4(d) which shall be mutually acceptable to both parties. 

 Section 4.2. Conditions to the Obligations of ABS. The obligation of ABS to consummate the transactions contemplated by this Agreement shall
be subject to the satisfaction of the following conditions precedent: 
  

	 	(a)	 (i) Pfizer, the Selling LLC and any Pfizer Affiliate obligated under the Agreement shall have performed in all material respects its agreements and obligations
contained in this Agreement required to be performed by it at or before the Closing, and (ii) the representations and warranties of Pfizer or the Seller LLC contained herein (A) that are qualified by materiality or Material Adverse Effect
shall be true and correct as of the Closing as if made as of such date, and (B) that are not qualified by materiality or Material Adverse Effect shall be true and correct in all material respects at and as of the Closing as if made at and as of
such time. Purchaser shall have received a certificate of Pfizer, dated as of the Closing 

  

 16 

	 	 
Date and signed by an officer of Pfizer, certifying as to the fulfillment of the foregoing; 

  

	 	(b)	Pfizer shall have made or caused to be made delivery to the Purchasing Entity of the items required by Section 3.1(b); 

  

	 	(c)	ABS shall have obtained the consents to transfer or have successfully been transferred (or, with respect to the EPA Hazardous Waste Generator Number, been issued) the Permits
(including the Environmental Permits) and contracts set forth in Schedule 4.2(c). 

  

	 	(d)	The Selling LLC shall pay the recording fees required by the Registrar of property of the Commonwealth and shall use Best Efforts to cure any written deficiency notice received from
the Registrar of Property of the Commonwealth by Selling LLC and, if such deficiencies are not cured by the Closing Date, Selling LLC shall use Best Efforts after the Closing Date to cure such deficiencies. 

  

	 	(e)	Purchaser Entity shall have received from one or more title companies authorized to do business in the Commonwealth, selected by Purchaser Entity, and reasonably acceptable to
Sellers, standard 1992 ALTA Form B owner’s (with respect to the Land) title insurance policies obtained at Purchaser Entity’s expense. Such policy shall: (i) be dated as of the Closing Date; (ii) be accompanied by copies of all
documents referenced as exceptions to title; (iii) insure good, valid and marketable fee simple title to the Land in Purchaser Entity subject only to Permitted Encumbrances; and (iv) contain an access endorsement, same land as survey
endorsement, separate tax lot endorsement and a waiver of subrogation endorsement in favor of Sellers. Pfizer agrees to execute such reasonable affidavits and other documents, consistent with local practice, as are necessary to induce Purchaser
Entity’s title company to issue the policies and endorsements in the manner set forth above. 

 Section 4.3.
Conditions to the Obligations of Pfizer. The obligation of Pfizer to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction of the following conditions precedent: 
  

	 	(a)	(i) ABS shall have performed in all material respects its agreements and obligations contained in this Agreement required to be performed by it at or before the Closing, and
(ii) the representations and warranties of ABS contained herein (A) that are qualified by materiality shall be true and correct as of the Closing as if made as of such date, and (B) that are not qualified by materiality shall be true
and correct in all material respects at and as of the Closing as if made at and as of such time. Pfizer shall have received a certificate of ABS, dated as of the Closing Date and signed by an officer of ABS, certifying as to the fulfillment of the
foregoing; and 

  

	 	(b)	ABS shall have made or caused to be made delivery to Pfizer of the items required by Section 3.1(c). 

  

 17 

 Section 4.4. Reasonable Efforts. To the extent not otherwise specified herein, each party to
this Agreement shall use its diligent and reasonable efforts in good faith to satisfy those conditions precedent to its or to the other party’s obligation to consummate the transactions contemplated by this Agreement to the extent that such
satisfaction requires action by such party. 
 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES OF PFIZER 
 Pfizer hereby represents and warrants to ABS as follows:

 Section 5.1. Organization. Pfizer is a corporation duly organized, validly existing and in good standing under the Laws of the
State of Delaware. The Selling LLC is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware and duly authorized to do business under the Laws of the Commonwealth. 
 Section 5.2. Authority; Binding Effect. 
  

	 	(a)	Each of the Sellers has all requisite corporate power and authority to carry on its business as it is now being conducted and to execute, deliver and perform each Transaction
Agreement to which it is a party. The execution, delivery and performance by each Seller of each Transaction Agreement to which it is a party has been or will have been at the Closing duly authorized by all requisite corporate action on the part of
Pfizer or the Selling LLC, as the case may be. 

  

	 	(b)	This Agreement constitutes and, when executed and delivered in accordance with its terms, each other Transaction Agreement will constitute, a valid and binding obligation of the
Sellers, enforceable against the Sellers that are a party thereto, in accordance with its terms, except, as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally
or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). 

 Section 5.3. Non-Contravention. The execution, delivery and performance by each Seller of each Transaction Agreement to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and
will not (i) violate any provision of the certificate of incorporation, bylaws or other comparable organizational documents of any Seller; (ii) subject to obtaining the consents or other actions referred to in Schedule 5.4, result in a
breach of, or default under (whether after the giving of notice or the lapse of time or both), or right to accelerate with respect to, or result in the termination of any contract, commitment or other obligation to which any Seller or any of its
Affiliates is a party or is subject relating to a Purchased Asset, or result in the creation of any Lien on any Purchased Asset; or (iii) assuming compliance with the matters set forth in Sections 5.4 and 6.4, conflict with, violate or result
in a breach of or constitute a default under any Law or other restriction of any Governmental Authority to which any Seller is subject with respect to the Facility, except, with respect to clauses (ii) and (iii) above, for any breaches,
defaults or Liens as would no be reasonably be expected to have, individually or in aggregate, a Material Adverse Effect. 
  

 18 

 Section 5.4. Consents. Except with respect to Environmental Permits, Schedule 5.4 sets
forth each agreement, contract or other instrument binding upon Sellers, other than any Governmental Authorizations, that are related to the operation of the Facility (a) requiring a consent or other action by any Person or (b) pursuant to
which obligations would be accelerated or rights would be terminated, as a result of the execution, delivery and performance of this Agreement (the “Consents”). 
 Section 5.5. Licenses and Permits. Except with respect to Environmental Permits, Schedule 5.5 describes each material license, permit,
certificate, approval or other similar Governmental Authorizations required to operate the Facility (the “Permits”), together with the name of the Governmental Authority issuing such Permit. Except as set forth on Schedule 5.5, to
the Knowledge of Pfizer, (i) the Permits are valid and in full force and effect, and (ii) Seller is not in default, and no condition exists that with notice or lapse of time or both would constitute a default, under the Permits.

 Section 5.6. Governmental Authorization. Other than as set forth in Schedule 5.6, the execution, delivery and performance by
any of the Sellers of each Transaction Agreement does not require any consent or approval of any Governmental Authority except for such consents or approvals, the failure of which to obtain, would not reasonably be expected to have, individually or
in aggregate, a Material Adverse Effect. 
 Section 5.7. Conduct of Business. Since January 1, 2006, except to the extent
set forth in Schedule 5.7, the operations of the Facility have been conducted in the normal course of business consistent with past practices and there has not been: 
  

	 	(a)	any event, occurrence, development or state of circumstances or facts which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse
Effect; 

  

	 	(b)	any creation or other incurrence of any Lien on any Purchased Asset other than Permitted Encumbrances; 

  

	 	(c)	any damage, destruction or other casualty loss (whether or not covered by insurance) affecting the Facility or any Purchased Asset which, individually or in the aggregate, has had
or would reasonably be expected to have a Material Adverse Effect; 

  

	 	(d)	any transaction or commitment made, or any contract or agreement entered into, by any Seller relating to the Facility or any other Purchased Asset (including the acquisition or
disposition of any assets) or any relinquishment by any Seller of any contract or other right, in either case, material to the Facility or operation of the Facility, other than (i) transactions and commitments in the ordinary course of business
consistent with past practices and (ii) those contemplated by this Agreement; or 

  

	 	(e)	 any capital expenditure, or commitment for a capital expenditure, for additions or improvements to property, plant and equipment, other than any capital
expenditures or commitments which have been budgeted, including the (i) capital 

  

 19 

	 	 
project to improve the management of storm water flows at the Facility, known as the “Storm Water UIC Project”, (ii) the capital project to
improve the roof of the fire protection system storage tanks, known as the “Fire Protection Tanks Project” (iii) the API Building pipe rack sprinkler installation, known as the “API Building Pipe Rack Sprinkler Project” and
(iv) the replacement of the waste water treatment plant liner, known as the “Waster Water Treatment Plant Liner Replacement Project”. 

 Section 5.8. No Litigation. 
  

	 	(a)	To the Knowledge of Pfizer, as of the date hereof, no litigation, preliminary or permanent injunction, cease or desist order, investigation or proceeding by or before any court or
Governmental Authority or arbitrator is pending against or threatened in writing against any of the Sellers, concerning the Facility, its operations or employees, except as set forth in Schedule 5.8(a). 

  

	 	(b)	There are no outstanding orders, injunctions or decrees of any Governmental Authority that apply to any of the Purchased Assets that restrict the ownership, disposition or use of
the Purchased Assets, which restriction or restrictions have had or would reasonably be expected to have, individually or in aggregate, a Material Adverse Effect. 

 Section 5.9. Compliance with Laws. Except with respect to Environmental Matters (which are the subject of Section 5.10), and except as
to matters otherwise set forth in this Agreement or set forth in Schedule 5.9: 
  

	 	(a)	To the Knowledge of Pfizer, the Selling LLC is in compliance in all respects with all Laws applicable to the ownership or operation of the Purchased Assets, except to the extent
that the failure to comply therewith has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; and 

  

	 	(b)	The Selling LLC possesses all Governmental Authorizations necessary for the operation of the Facility as it is currently conducted, except where the failure to possess any such
Governmental Authorization would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

 Section 5.10. Environmental Matters. To the Knowledge of Pfizer, and except as set forth on Schedule 5.10: 
  

	 	(a)	the Purchased Assets are in substantial compliance with all applicable Environmental Laws and/or Environmental Permits, in each case, in effect as of the Closing Date; and
(ii) the Selling LLC is not undertaking, nor has Selling LLC received written notice that it is subject to, a Remedial Action or enforcement action under any applicable Environmental Laws and/or Environmental Permits with respect to the
Purchased Assets, in each case, in effect as of the Closing Date, except for such compliance, Remedial Actions or enforcement actions that would not have a Material Adverse Effect 

  

 20 

	 	(b)	the Selling LLC has obtained all Environmental Permits required under all applicable Environmental Laws, in effect as of the Closing Date, in relation to the Purchased Assets,
except for such failure to obtain as would not have a Material Adverse Effect; 

  

	 	(c)	no written claims have been made that could reasonably be expected to result, as of the Closing Date, in Environmental Liability arising from or as a result of (i) on-site
exposures to Hazardous Substances from the Real Property; (ii) Releases of Hazardous Substances at or from the Real Property; or (iii) off-site treatment, storage or disposal of Hazardous Substances transported from the Purchased Assets;

  

	 	(d)	the underground wastewater lines associated with the Facility, as of the Closing Date, have been inspected and maintained consistent with the Selling LLC’s Process Safety
Management Mechanical Integrity Compliance Guidelines (February 2003), and procedure #22.796.00 (October 2002) which procedures and guidelines have been disclosed to the Purchaser Group; 

  

	 	(e)	all Equipment and pipelines associated with the Facility has been taken out of service, as of the Closing Date, consistent with the Selling LLC’s procedures #45.565.04 (July
2004), #63.009.06 (September 2005), #63.005.03 (October 2003), #60.540.12 (September 2005), and #63.006.17 (September 2005) which procedures have been disclosed to the Purchaser Group; 

  

	 	(f)	asbestos-containing materials have been removed from certain areas of the Facility, as of the Closing Date, as has been disclosed to the Purchaser Group in Section 4.10.1 of
the Detailed Divestiture Environmental Site Assessment report prepared by Golder Associates and dated October 2005; 

  

	 	(g)	lead based paint has been removed from certain areas of the Facility, as of the Closing Date, as has been disclosed to the Purchaser Group in Section 4.10.4 of the Detailed
Divestiture Environmental Site Assessment report prepared by Golder Associates and dated October 2005; and 

  

	 	(h)	there are no underground storage tanks located on the Real Property, as of the Closing Date. 

 Notwithstanding any other provision of this Agreement, the representations and warranties contained in this Section 5.10 are the sole
representations and warranties of the Sellers relating to Environmental Laws, Environmental Permits, and/or environmental matters. 
 The
Purchaser Group acknowledges that the Sellers have granted access to the Purchaser Group and its employees, agents and representatives to the Purchased Assets for such inspections as the Purchaser Group has deemed necessary or desirable in the
conduct of an environmental due diligence assessment (and copies of the Detailed Divestiture Environmental Site Assessment Report dated October 2005 and the Data Summary Report for the November 2005 Groundwater Sampling prepared by Golder Associates
have been provided to the Purchaser Group by Sellers) prior to the date of the execution of this Agreement. The Purchaser Group also acknowledges 

  

 21 

 
that it has had the opportunity to interview certain current agents, representatives and employees with managerial responsibility for environmental matters
with regard to the Purchased Assets. 
 Section 5.11. Material Contracts. 
  

	 	(a)	Except for intercompany agreements, agreements entered into after the date hereof in accordance with Section 7.2 or as set forth on Schedule 5.11 (the “Material
Contracts”), Sellers are not parties to or bound by any of the following solely related to the Facility: 

  

	 	(i)	any contract, agreement or other arrangement for the purchase of materials, supplies, goods, services, equipment or other assets or other personal property with any supplier or for
the furnishing of services solely related to the Facility, in each case, extending beyond one year from the date hereof or the terms of which provide for financial commitments in excess of US$10,000; 

  

	 	(ii)	any contract, agreement or other arrangement for the furnishing of services by the Facility, in each case, with firm commitments in excess of three years from the date hereof;

  

	 	(iii)	any lease, sublease or other agreement granting rights of occupancy or use of real property solely related to the Facility, other than the License; or 

  

	 	(iv)	any contract, agreement or other arrangement which provide for financial commitments in excess of US$10,000 solely related to the Facility. 

  

	 	(b)	Except as disclosed in Schedule 5.11, (i) each Material Contract and each Assumed Contract is valid and binding on the Sellers that are a party to such contract and, to
the Knowledge of Pfizer, on the other party thereto, and is in full force and effect and (ii) Sellers are not, or to the Knowledge of Pfizer, no other party thereto is, in breach of, or in default under, any Material Contract or any Assumed
Contract, in any material respect. 

 Section 5.12. Real Property. 
  

	 	(a)	Exhibit D sets forth a legal description of the Land. 

  

	 	(b)	Except for the License and the Lease, the Selling LLC is not a party to any lease, sublease, license or other similar arrangement to occupy (whether as landlord, sublandlord,
tenant, subtenant or other occupancy arrangement) any real property or interest in real property that is used or held for use in connection with the operation and use of the Facility as it is currently operated and used. 

  

	 	(c)	The Selling LLC is the sole owner of fee simple title (“pleno dominio”) to the Real Property, free and clear of any Liens other than the Permitted Encumbrances.

  

 22 

	 	(d)	To the Knowledge of Pfizer, there are no special assessment, condemnation, eminent domain or similar proceeding existing or pending, or, to the Knowledge of Pfizer threatened in
writing, relating to any component of the Real Property or any portion thereof. 

  

	 	(e)	Except as set forth on Schedule 5.12(e), to the Knowledge of Pfizer, as of the Closing no default or breach exists under any of the covenants, restrictions, conditions,
rights of way or easements, if any, affecting all or any portion of the Real Property which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. 

 Section 5.13. INTENTIONALLY OMITTED 
 Section 5.14. Taxes. To the Knowledge of Pfizer, there are no material Liens for Taxes upon any of the Purchased Assets, except for Liens for Taxes not yet due and payable or being contested in good faith. 
 Section 5.15. Title or Ownership to the Purchased Assets. Sellers own or have good and marketable title to all of the Purchased Assets free
and clear of any Liens except for Permitted Encumbrances. 
 Section 5.16. Brokers. Except as set forth on Schedule 5.16,
no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Sellers. Sellers
shall be responsible for the payment of any brokerage, finder’s or other fee or commission due, if any, to the Persons listed in Schedule 5.16 in connection with the transactions contemplated by this Agreement. 
 Section 5.17 Disclaimer. Purchaser and its representatives and agents have had and have exercised, prior to the date hereof, the right to
make all inspections and investigations of the Facility and the Purchased Assets deemed necessary or desirable by Purchaser. Purchaser is purchasing the Purchased Assets based on the results of its inspections and investigations and this Agreement
and therefore, except as expressly set forth in this Agreement, Purchaser is acquiring the Purchased Assets in an “As Is” “Where Is” basis. All warranties of habitability, merchantability and fitness for any particular purpose,
and all other warranties arising under the Uniform Commercial Code (or similar Commonwealth Laws, including without limitations the Civil Code of the Commonwealth and the laws of the State of New York), are hereby disclaimed by Seller and waived by
Purchaser. Purchaser further represents that neither Pfizer nor any other Person has made any representation or warranty, express or implied, as to the accuracy or completeness of any information regarding the Facility, any of the Purchased Assets
or the Assumed Liabilities other than as expressly set forth in this Agreement. Except as otherwise provided in this Agreement, neither Pfizer nor any other Person (including without limitation Pfizer’s agents or contractors), will have or be
subject to any Liability to Purchaser or any other Person resulting from the distribution to Purchaser or its representatives or agents (except to the extent such actions involved fraud or willful misconduct) or Purchaser’s use of, any such
information or any other documents or information provided to Purchaser or its representatives or agents in connection with the sale of the Purchase Assets. 
  

 23 

 ARTICLE VI 
 REPRESENTATIONS AND WARRANTIES OF ABS 
 ABS represents and warrants to Pfizer as follows: 

Section 6.1. Organization. ABS is duly organized, validly existing and in good standing under the Laws of the State of Delaware.

 Section 6.2. Authority; Binding Effect. 
  

	 	(a)	The Purchaser Group has all requisite corporate power and authority to carry on its business as it is now being conducted and to execute, deliver and perform each Transaction
Agreement to which it is a party. The execution, delivery and performance by the Purchasing Entity and/or ABS of each Transaction Agreement to which it is a party has been or will have been at the Closing duly authorized by all requisite corporate
action on the part of the Purchasing Entity and/or ABS, as the case may be. 

  

	 	(b)	This Agreement constitutes and each other Transaction Agreement, when executed and delivered in accordance with its terms will constitute, a valid and legally binding obligation of
ABS or the Purchasing Entity, as the case may be, enforceable against ABS or the Purchasing Entity, as the case may be, in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). 

 Section 6.3. Non-Contravention. The execution, delivery and performance by the Purchasing Entity and/or ABS of each Transaction Agreement,
and the consummation of the transactions contemplated hereby and thereby, do not and will not (i) violate any provision of the certificate of incorporation, bylaws or other comparable organizational documents of the Purchasing Entity and/or
ABS, as the case may be; (ii) result in a breach of, or default under, or right to accelerate with respect to, any term or provision of any contract, commitment or other obligation to which ABS or any of its Affiliates is a party or is subject;
or (iii) assuming compliance with the matters set forth in Sections 5.4 and 6.4, conflict with, violate or result in a breach of or constitute a default under any Law or other restriction of any Governmental Authority to which the Purchasing
Entity or ABS is subject, except with respect to clauses (ii) and (iii) above, for any breaches or defaults as would reasonably be expected to have, individually or in aggregate, a Material Adverse Effect. 
 Section 6.4. Governmental Authorization. The execution, delivery and performance by the Purchasing Entity and/or ABS of each Transaction
Agreement does not require any consent or approval of any Governmental Authority, except for those consents or approvals, the failure of which to obtain, would not reasonably be expected to have, individually or in aggregate, a Material Adverse
Effect. 
  

 24 

 Section 6.5. Litigation. There is no action, order, writ, injunction, judgment or decree
outstanding, or suit, litigation, proceeding, labor dispute (other than routine grievance procedures), arbitration, investigation or reported claim, pending, or to ABS’s knowledge, threatened, before any Governmental Authority, which seeks to
delay or prevent the consummation of the transactions contemplated by this Agreement or would, if successful, materially and adversely affect the ability of the ABS to consummate the transactions contemplated by this Agreement. 
 Section 6.6. Financial Capability. Purchaser has funds sufficient for the Purchase Price to be paid by it under the terms of this Agreement.

 Section 6.7. Brokers. Except as set forth on Schedule 6.7, no broker, finder or investment banker is entitled to any
brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Purchaser Group. Purchaser Group shall be responsible for the payment of any
brokerage, finder’s or other fee or commission due, if any, to the Persons listed in Schedule 6.7 in connection with the transactions contemplated by this Agreement. 
 ARTICLE VII 
 COVENANTS 
 Section 7.1. Information and Documents; Confidentiality. 
  

	 	(a)	From the date hereof until the Closing Date, upon reasonable advance notice, Pfizer shall permit ABS and its representatives to have access, during regular business hours and upon
reasonable notice, to the facilities, assets, employees, books and records of the Sellers relating to the Purchased Assets, and shall furnish, or cause to be furnished, to ABS such financial, tax and operating data and other available information
with respect to the Purchased Assets as ABS and its representatives shall from time to time reasonably request; provided that no such access shall unreasonably interfere with Pfizer or the Selling LLC’s operation of its businesses, including,
without limitation, the Facility. 

  

	 	(b)	INTENTIONALLY OMITTED. 

 Section 7.2. Conduct of
Business. From the date hereof until the Closing Date, Pfizer shall maintain the operating systems and equipment of the Facility in good condition in accordance with its standard operating procedures for a closed facility; provided, however,
that the temperature and humidity control and pressure differential shall be maintained in the aseptic core area in accordance with Selling LLC’s standard operating procedures. From the date hereof until the Closing Date, except as otherwise
specifically contemplated by this Agreement or as ABS shall otherwise consent in writing, Pfizer shall cause the Selling LLC to, with respect to the Purchased Assets: 
  

	 	(a)	not incur, create or assume any Lien with respect to any Purchased Asset other than Permitted Encumbrances; 

  

 25 

	 	(b)	not acquire any assets or lease or license any Purchased Asset outside of the ordinary course of business consistent with past practice or dispose of any Purchased Assets;

  

	 	(c)	not enter into, amend any material term of, or waive any material right under, any Material Contract; 

  

	 	(d)	not agree to take any of the foregoing actions; and 

  

	 	(e)	not engage in any conduct or action that would result in a Material Adverse Effect on the Purchased Assets. 

 Section 7.3. Reasonable Best Efforts; Certain Governmental Matters. 
  

	 	(a)	Upon the terms and subject to the conditions herein provided (including, without limitation, Section 2.2 hereof), each of the parties hereto agrees to use its reasonable Best
Efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Laws to consummate and make effective the transactions contemplated by the Transaction Agreements, including, without
limitation, (i) to comply promptly with all legal requirements which may be imposed on it with respect to the Transaction Agreements and the transactions contemplated thereby (which actions shall include, without limitation, furnishing all
information required by applicable Law in connection with approvals of or filings with any Governmental Authority); (ii) to satisfy the conditions precedent to the obligations of such party hereto; (iii) to obtain any consent,
authorization, order or approval of, or any exemption by, any Governmental Authority or other public or private third party required to be obtained or made by the Purchaser Group or the Sellers in connection with the transactions contemplated by the
Transaction Agreements; and (iv) to take any action reasonably necessary to vigorously defend, lift, mitigate or rescind the effect of any litigation or administrative proceeding adversely affecting the consummation of the transactions
contemplated by the Transaction Agreements, including promptly appealing any adverse court or administrative decision. 

  

	 	(b)	Subject to appropriate confidentiality protections and applicable Law, each of the parties hereto will furnish to the other party such necessary information and reasonable
assistance as such other party may reasonably request in connection with the foregoing and will provide the other party with copies of all filings made by such party with any Governmental Authority and, upon request, any other information supplied
by such party to a Governmental Authority in connection with the Transaction Agreements and the transactions contemplated thereby. 

  

	 	(c)	 Each of the parties hereto agrees to use its Best Efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary for it to
do to effect all registrations, filings and transfers of all Permits, including 

  

 26 

	 	 
Environmental Permits, necessary for the operation of the Purchased Assets and required under applicable Laws. 

 Section 7.4. Tax Matters. 
  

	 	(a)	Preparation and Filing of Tax Returns. The Sellers shall be responsible for the preparation and timely filing of all Tax Returns in respect of the Retained Tax Liabilities
that are required by Law to be filed by the Sellers (including any Puerto Rico and/or United States income, gross receipts, or municipal license tax returns). ABS shall cause the Purchasing Entity to prepare and timely file all Tax Returns that are
required to be filed after the Closing Date with respect to periods on or after the Closing Date in respect of the Purchased Assets. 

  

	 	(b)	Payment of Taxes. Except as provided in the License, the Sellers shall be responsible for the payment of all Taxes due with respect to Tax Returns for which the Sellers are
responsible pursuant to Section 7.4(a) (including any Puerto Rico and/or United States income, gross receipts, or municipal license taxes), other than real and personal property Taxes for the calendar year of the Closing attributable to the
portion of the year that the respective real or personal property of the Purchased Assets is owned by Purchasing Entity, as calculated pursuant to Section 2.5. The Purchasing Entity shall be responsible for the payment of all Taxes due with
respect to Tax Returns for which the Purchasing Entity is responsible pursuant to Section 7.4(a), provided that the Sellers shall pay to the Purchasing Entity the amount of any Retained Tax Liabilities required to be reported on any Tax Return
which is required to be prepared and filed by the Purchasing Entity pursuant to Section 7.4(a). 

  

	 	(c)	Tax Cooperation. Each of the Purchaser Group, on the one hand, and the Sellers, on the other hand, shall provide the other party with such information and records and make
such of its officers, directors, employees and agents available as may reasonably be requested by such other party in connection with the preparation of any Tax Return or any audit or other proceeding that relates to the Facility. This Tax
cooperation does not include payment of attorneys, accountants or other professional advisors in connection with such cooperation. 

  

	 	(d)	Refunds. In the case of any refunds or credits with respect to real or personal property Taxes for any Straddle Period, the Sellers shall be entitled to receive payment
(promptly after receipt or entitlement thereto) of the amount of such refunds or credits multiplied by the fraction described in Section 2.5 for such Straddle Period. 

  

	 	(e)	Tax Indemnification. 

  

	 	(i)	 The Sellers shall pay for, indemnify, defend and hold the Purchaser Group and its Affiliates harmless from and against all Retained Tax Liabilities. Further, the
Sellers’ obligations pursuant to this Section 7.4(e)(i) shall 

  

 27 

	 	 
terminate effective 60 days after the expiration of the applicable statute of limitations (including extensions) in respect of each such Liability.

  

	 	(ii)	The Purchaser Group shall pay for, indemnify, defend and hold the Sellers and their respective Affiliates harmless from and against all Liabilities for Taxes related to the
Purchased Assets and the Facility that are not Retained Tax Liabilities. The Purchaser Group’s obligations pursuant to this Section 7.4(e)(ii) shall terminate effective 60 days after the expiration of the applicable statute of limitations
(including extensions) in respect of each such Liability. 

  

	 	(iii)	Any indemnity payment required to be made pursuant to this Section 7.4(e) shall be paid within 30 days after the indemnified party makes written demand upon the indemnifying
party. 

  

	 	(iv)	Amounts paid to, by or on behalf of the Purchaser Group as indemnification shall be treated as adjustments to the Purchase Price. 

  

	 	(f)	Tax Contests. 

  

	 	(i)	If a claim shall be made by any taxing authority (a “Tax Claim”) which, if successful, might result in an indemnity payment pursuant to Section 7.4(e), the
party receiving notice of such claim shall promptly notify the other party of such Tax Claim; provided that the failure by an indemnified party to provide prompt notification shall not relieve the indemnifying party of its indemnification
obligations hereunder except to the extent that the indemnifying party is materially prejudiced thereby in defending such Tax Claim. 

  

	 	(ii)	Except as otherwise provided in Section 7.4(f)(iii), the Sellers shall control all proceedings relating to any Tax Claim with respect to a Retained Tax Liability and make all
decisions in connection with such Tax Claim (including, without limitation, selection of counsel) and, without limiting the foregoing, may in their sole discretion pursue or forego any and all administrative appeals, proceedings, hearings and
conferences with any taxing authority with respect thereto, and may, in their sole discretion, either pay the Tax claimed and sue for a refund (where applicable law permits such refund suits) or contest the Tax Claim in any permissible manner;
provided the Sellers shall not take any position, unless required by Law, that could reasonably be expected to have a Material Adverse Effect on the Purchaser Group without consulting with the Purchaser Group regarding such position. The Purchaser
Group shall be entitled to be informed of such Tax Claim within a reasonable time after such Tax Claim is asserted and the developments with respect to such Tax Claim at any administrative meeting, conference, hearing or other proceeding.

  

 28 

	 	(iii)	Subject to the Lease and except as otherwise provided in Section 7.4(f)(ii), the Purchaser Group shall control all proceedings with respect to Taxes related to the Purchased
Assets and the Facility for any taxable period beginning after the Closing Date. 

  

	 	(iv)	The Sellers and the Purchaser Group shall jointly control any proceedings with respect to real and personal property Taxes relating to the Purchased Assets for any Straddle Period.

  

	 	(v)	The Purchaser Group and its Affiliates, on the one hand, and the Sellers and their respective Affiliates, on the other, shall cooperate in contesting any Tax Claim, which
cooperation shall include the retention and (upon request) the provision to the requesting party of records and information which are reasonably relevant to such Tax Claim, and making employees available on a mutually convenient basis to provide
additional information or explanation of any material provided hereunder or to testify at proceedings relating to such Tax Claim. 

 Section 7.5. Employees. 
  

	 	(a)	Employees relating to the API Building and related facilities. Pfizer shall be responsible for all personnel needed to operate the API Building, who shall remain employees or
contractors of Pfizer, including any severance related costs at such time as any such employees are no longer required by Pfizer. 

  

	 	(b)	Other Site Employees. Pfizer will be responsible for any severance related costs for any utility, facility and maintenance staff terminated by Pfizer.

  

	 	(c)	Upon closing of the API Building, Pfizer will be responsible for the termination of all employees and for any statutory or severance payment due to such employees. Pfizer and not
the Purchaser Group, shall be solely responsible for payment of any salary, wages, bonuses and benefits (including vacation and sick pay) of Pfizer’s employees, accrued and owed as of the Closing. 

 Section 7.6. Storm Water UIC Project- Sellers agree to complete the development and implementation of the Storm Water UIC Project which
project will be developed and implemented by the Sellers or any qualified contractor, according to the plans, drawings and specifications developed by Sellers as of the date hereof, or as amended from time to time by Sellers in good faith
consultation with the Purchasing Entity. The Sellers shall not be required to guarantee that the completed Storm Water UIC Project will result in achieving regulatory compliance with any Environmental Law or Environmental Permit, however, the
risks associated with the construction work on this project shall remain with the Sellers. The Purchaser Group shall provide Sellers with any and all easements necessary or required to complete the Storm Water UIC Project and hereby agree not to
engage in any action or inaction which may have the effect of interfering with, delaying or increasing the cost of, the completion of this project. 
  

 29 

 Section 7.7. Fire Protection Tanks. Sellers agree to complete the development and
implementation of the Fire Protection Tanks Project which project will be developed and implemented by the Sellers or any qualified contractor, substantially in accordance with the plans, drawings and specifications developed by Sellers as of the
date hereof, or as amended from time to time by Sellers in good faith consultation with the Purchasing Entity. 
 Section 7.8. API
Building Pipe Rack Sprinklers. Sellers agree to complete the development and implementation of the API Building Pipe Rack Sprinklers Project which project will be developed and implemented by the Sellers or any qualified contractor substantially
in accordance with the plans, drawings and specifications developed by Sellers as of the date hereof, or as amended from time to time by Sellers in good faith consultation with the Purchasing Entity. 
 Section 7.9. Waste Water Treatment Plant Liner. Sellers agree to complete the development and implementation of the Waste Water Treatment
Plant Liner Replacement Project which project will be developed and implemented by the Sellers or any qualified contractor, substantially in accordance with the plans, drawings and specifications developed by Sellers as of the date hereof, or as
amended from time to time by Sellers in good faith consultation with the Purchasing Entity. 
 Section 7.10. Insurance. As of the
Closing Date, the coverage under all insurance policies related to the Facility shall continue in force only for the benefit of the Sellers and their Affiliates and not for the benefit of the Purchaser Group. Except as provided in the Lease
Agreement and the License, the Purchaser Group agrees to arrange for its own insurance policies with respect to the Purchased Assets covering all periods after the Closing Date and agrees not to seek, through any means, to benefit from any of
Sellers’ or their Affiliates’ insurance policies which may provide coverage for claims relating in any way to the Facility on or prior to the Closing Date. 
 Section 7.11. Notification of Certain Matters. Pfizer shall give prompt notice to ABS, and ABS shall give prompt notice to Pfizer, of the occurrence, or non-occurrence, of any event the occurrence or
non-occurrence of which would be reasonably likely to cause (i) any representation or warranty of Pfizer or ABS, as the case may be, contained in this Agreement to be untrue or inaccurate in any material respect at or prior to the Closing or
(ii) Pfizer or ABS, as the case may be, to fail to comply with or satisfy in any material respect any covenant, condition or agreement to be complied with or satisfied by it hereunder; provided however, that the delivery of any notice pursuant
to this Section 7.8 shall not limit or otherwise affect the remedies available hereunder to the party receiving such notice. 
 Section 7.12. Bulk Transfer Laws. The Purchaser Group acknowledges that the Sellers have not taken, and do not intend to take, any action required to comply with any applicable bulk sale or bulk transfer laws or similar laws.
Pfizer agrees to indemnify the Purchaser Group for any loss resulting from Sellers’ failure to comply with any applicable bulk sale or bulk transfer laws or similar laws. 
 Section 7.13 Intentionally Omitted. 
  

 30 

 Section 7.14. Lease Agreement. At the Closing, the Purchasing Entity and Pfizer shall enter
into, execute and deliver the Lease Agreement. 
 Section 7.15. Compliance with WARN, Etc. With respect to WARN or other similar
Laws of any jurisdiction, the parties hereto will timely give any notices and take any other actions as may be required thereunder. 
 Section 7.16. Further Assurances and Cooperation. Subject to the terms and conditions of this Agreement, at any time and from time to time after the Closing, at a party’s reasonable request, the other party shall execute
and deliver such other instruments of sale, transfer, conveyance, assignment and confirmation, and assumption, and provide such materials and information and take such other actions as the requesting party may reasonably deem necessary or desirable
in order to more effectively transfer, convey and assign to the Purchasing Entity all of the Assumed Liabilities, Purchased Assets and contracts set forth in Schedule 2.2(a). This reasonable cooperation does not include payment of attorneys,
accountants or other professional advisors in connection with such cooperation. 
 Section 7.17. Post-Closing Access. In
connection with any matter relating to any period before, or any period ending on, the Closing Date, the Purchasing Entity will, upon reasonable notice of the Sellers, permit the Sellers and its representatives access at all reasonable times to the
books and records of the Facility (including for example, equipment records) that shall have been transferred to the Purchaser provided that Purchaser’s business shall not be unreasonably interfered with. The Purchaser Group acknowledges that,
due to regulatory requirements requiring responses to inquiries from certain Governmental Authorities to be received within seventy-two (72) hours, Sellers may require access to such books and records urgently. Accordingly, if so requested by
the Sellers, the Purchasing Entity shall permit Sellers to have access to such books and records within twenty-four (24) hours of the Purchasing Entity’s receipt of Sellers’ request, which may be made orally or by facsimile
transmission. The Purchasing Entity shall not dispose of such books and records during the seven (7) year period beginning with the Closing Date without the Sellers’ written consent. Following expiration of such seven (7) year period,
the Purchasing Entity may dispose of such books and records at any time; provided, however, the Purchasing Entity shall notify the Sellers of its intention to dispose of its books and records and upon Sellers’ request, and at Sellers’
expense, shall provide a copy of the same. 
 Section 7.18. Return of Excluded Assets. In the event, through inadvertence,
mistake or otherwise, any Excluded Assets are transferred to the Purchasing Entity, the Purchaser Group agrees to promptly transfer and deliver the same to Sellers. 
 ARTICLE VIII 
 INDEMNIFICATION 
 Section 8.1. Indemnification by Sellers. 
  

	 	(a)	 Subject to the provisions of this Article VIII, Sellers agree to defend, indemnify, release and hold harmless the Purchaser Group and its Affiliates and, its
directors, officers, agents, employees, successors and assigns from and against any and all 

  

 31 

	 	 
claims, actions, causes of action, judgments, awards, liabilities, losses, costs (including reasonable attorney’s fees) or damages (each, a
“Loss” and collectively, the “Losses”) claimed or arising from (i) any Retained Liability, (ii) any breach by the Sellers of any of its covenants or agreements contained in this Agreement or in any other
Transaction Agreement other than the Lease and License; (iii) any breach of any representation or warranty of the Sellers contained in this Agreement or in any other Transaction Agreement other than the Lease Agreement and License.

  

	 	(b)	The Purchaser Group hereby waives compliance by the Sellers with any applicable bulk sales or similar law, or any statute or regulation of any Governmental Authority regarding tax
clearance procedures which may be applicable to or by reason of the sale and transfer of the Purchased Assets. The Sellers shall indemnify and hold the Purchaser Group harmless from and against any and all Loss suffered or incurred by the Purchaser
Group by reason of any failure of the Sellers to comply with any such Law and such indemnification shall not be subject to the limitations set forth in Section 8.6. 

  

	 	(c)	The Purchaser Group acknowledges and agrees that the Sellers shall not have any liability under any provision of this Agreement for any Loss to the extent that such Loss results
from any action taken by the Purchaser Group or its Affiliates after the Closing Date. The Purchaser Group shall take and shall cause its Affiliates to take all reasonable actions to mitigate any Loss upon becoming aware of any event which would
reasonably be expected to, or does, give rise thereto. 

  

	 	(d)	Nothing in this Section 8.1 shall be construed to impose liabilities with respect to Taxes. 

  

	 	(e)	Sellers, and not the Purchaser Group, shall be responsible and will hold harmless and indemnify the Purchaser Group and assume all litigation costs for any and all claims, actions,
damages, and liabilities or expenses incurred by or threatened against the Purchaser Group by any employee or former employee of Sellers, filed before any local or federal court or government agencies which relates to acts or omissions of Sellers
during their employment with Sellers. 

 Section 8.2. Indemnification by Purchaser Group. 
  

	 	(a)	 Subject to the provisions of this Article VIII, Purchaser Group agrees to defend, indemnify and hold harmless the Sellers and their respective Affiliates and, if
applicable, their respective directors, officers, agents, employees, successors and assigns from and against any and all Losses claimed or arising directly from (i) any Assumed Liability, (ii) any breach by Purchaser Group of any of its
covenants or agreements contained in this Agreement or in any other Transaction Agreement other than the Lease Agreement and License, (iii) any breach of any representation or warranty of Purchaser Group contained in this Agreement or in any
other Transaction Agreement other than the Lease Agreement and License; 

  

 32 

	 	 
and (iv) events occurring after the Closing Date in connection with the Purchased Assets (including, without limitation, the use, ownership, possession,
operation or occupancy of the Purchased Assets from and after the Closing Date, but excluding the API Operations), provided, however, that nothing in this Section 8.2(a) is intended to limit the scope of Sellers indemnification
obligations under Section 8.1. 

  

	 	(b)	Sellers shall take and shall cause its Affiliates to take all reasonable actions to mitigate any Loss upon becoming aware of any event which would reasonably be expected to, or
does, give rise thereto. 

  

	 	(c)	Nothing in this Section 8.2 shall be construed to impose liabilities with respect to Taxes. 

  

	 	(d)	Nothing in this Section 8.2 shall be construed to impose liabilities with respect to matters for which the liabilities are set forth in the Lease Agreement.

 Section 8.3. Notice of Claims. 
  

	 	(a)	If any of the Persons to be indemnified under this Article VIII (each, an “Indemnified Party”) has suffered or incurred any Loss, the Indemnified Party shall so
notify the party from whom indemnification is sought (the “Indemnifying Party”) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of
computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement or any other agreement, instrument or certificate delivered pursuant hereto in respect of which such Loss shall have occurred.
If any action at law or suit in equity is instituted by or against a third party with respect to which the Indemnified Party intends to seek indemnification under this Article VIII, the Indemnified Party shall promptly notify the Indemnifying Party
of such action or suit and permit the Indemnifying Party to participate in and control the defense of such action or suit. A failure to give such notice in a timely manner pursuant to this Section 8.3 shall not limit the obligation of the
Indemnifying Party under this Article VIII, except (i) to the extent such Indemnifying Party is prejudiced thereby, (ii) to the extent expenses are incurred during the period in which notice was not provided or (iii) as provided by
Section 8.5 below. 

  

	 	(b)	 Except when a notice, report or other filing must be filed immediately pursuant to an express requirement of Environmental Laws, the Indemnified Party will provide
notice and an opportunity to comment to the Indemnifying Party before the Indemnified Party files any Required Governmental Report or any other report, notification or filing with any Governmental Authority or third party in connection with an event
that would be reasonably likely to result in a Loss subject to the indemnification provisions of this Article VIII. In the event the Indemnified Party is required to file a Required Governmental Report or any other report, notification or filing
immediately, the Indemnified Party will provide 

  

 33 

	 	 
simultaneous notice to the Indemnifying Party when it files such report with the Governmental Authority. 

 Section 8.4. Third Party Claims. 
  

	 	(a)	The Indemnifying Party under this Article VIII shall have the right, but not the obligation, to conduct and control, through counsel of its choosing, any third party claim, action,
suit or proceeding (a “Third Party Claim”), and the Indemnifying Party may compromise or settle the same; provided that the Indemnifying Party shall give the Indemnified Party advance notice of any proposed compromise or settlement.
No Indemnified Party may compromise or settle any Third Party Claim for which it is seeking indemnification hereunder without the consent of the Indemnifying Party. The Indemnifying Party shall permit the Indemnified Party to participate in the
defense of any such action or suit through counsel chosen by the Indemnified Party; provided that the fees and expenses of such counsel shall be borne by the Indemnified Party. If the Indemnifying Party elects not to control or conduct the defense
or prosecution of a Third Party Claim, the Indemnifying Party shall still have the right to participate in the defense or prosecution of any Third Party Claim and, at its own expense, to employ counsel of its own choosing for such purpose.

  

	 	(b)	The parties hereto shall cooperate in the defense or prosecution of any Third Party Claim, with such cooperation to include (i) the retention and the provision of the
Indemnifying Party records and information that are reasonably relevant to such Third Party Claim and (ii) the making available of employees on a mutually convenient basis for providing additional information and explanation of any material
provided hereunder. 

 Section 8.5. Expiration. 
  

	 	(a)	Notwithstanding anything in this Agreement to the contrary, and except for (i) the Sellers’ existence and authority as per Sections 5.1 and 5.2 hereof which shall survive
indefinitely, and (ii) environmental matters as per Section 5.10 and Excluded Environmental Liabilities which are discussed below in Section 8.5(b), if the Closing shall have occurred, all covenants, agreements, representations and
warranties made herein or in any certificate delivered pursuant hereto shall survive the Closing, but all representations and warranties made herein or in any certificate delivered pursuant hereto, and all indemnification obligations under Sections
8.1. and 8.2 with respect to any such representation or warranty shall terminate and expire on, and no action or proceeding seeking damages or other relief for breach, misrepresentation or inaccuracy with respect thereto shall be commenced after the
second anniversary of the Closing Date, with respect to all claims of any party (including any Indemnified Party) which shall not have been previously asserted with reasonable specificity by written notice given under Section 8.3.

  

 34 

	 	(b)	Notwithstanding anything in this Agreement to the contrary, (i) all indemnification obligations with respect to clause (i) of the definition of Excluded Environmental
Liabilities shall terminate and expire on, and no action or proceeding seeking damages or other relief with respect thereto shall be commenced after the fifth anniversary of the expiration or earlier termination of the Lease Agreement to be entered
into by the parties on the Closing Date with respect to all claims of Purchaser Group which shall not have been previously asserted with reasonable specificity, by written notice given under Section 8.3; (ii) all indemnification
obligations with respect to the breach of representations and warranties set forth in Section 5.10 shall terminate and expire on and no action or proceeding seeking damages or other relief with respect thereto shall be commenced after the fifth
anniversary of the Closing Date with respect to all claims of Purchaser Group which shall not have been previously asserted, with reasonable specificity, by written notice given under Section 8.3; and (iii) all indemnification obligations
with respect to clauses (ii), (iii) and (iv) of the definition of Excluded Environmental Liabilities shall survive the Closing; and (iv) all indemnification obligations with respect to clause (v) of the definition of Excluded
Environmental Liabilities shall terminate and expire on and no action or proceeding seeking damages or other relief with respect thereto shall be commenced after the fifth anniversary of the expiration or earlier termination of the Lease Agreement
to be entered into by the parties on the Closing Date with respect to all claims of Purchaser Group which shall not have been previously asserted, with reasonable specificity, by written notice given under Section 8.3. 

Section 8.6. Certain Limitations. 
 Sellers shall not have any indemnification obligation under Section 8.1(a)(i) with respect to clauses (i) and (v) of the definition of Excluded Environmental Liabilities and Section 8.1(a)(iii) for Losses with respect to any
breach of any representation or warranty of Seller in this Agreement, except with respect to breaches of Sections 5.1, or 5.2, unless each Loss exceeds US$100,000 or the aggregate of all such Losses for which Sellers would, but for this provision,
be liable exceeds on a cumulative basis US$250,000 (but these thresholds shall be deemed satisfied to the extent such losses arise out of a breach of a representation or warranty constituting a Material Adverse Effect). At such point, Sellers shall
be required to pay the full amount of such Losses; provided however, that Sellers shall have no indemnification obligation under Section 8.1(a)(i) with respect to clauses (i) and (v) of the definition of Excluded Environmental
Liabilities and Section 8.1(a)(iii), except with respect to breaches of Sections 5.1, or 5.2, for Losses which in the aggregate are in excess of Seven Million Five Hundred Thousand Dollars ($7,500,000). 
 Section 8.7. Losses Net of Insurance, Other Indemnities, Etc. The amount of any Loss for which indemnification is provided under
Section 8.1 or 8.2 shall be net of (i) any amounts recovered by the Indemnified Party pursuant to any indemnification by or indemnification agreement with any third party, (ii) any insurance proceeds or other cash receipts or sources
of reimbursement received as an offset against such Loss including without limitation any Loss covered by the title insurance policy described in Section 4.2(d) hereof (each Person named in clauses (i) and (ii), a “Collateral
Source”), and (iii) an amount equal to the present value of the 

  

 35 

 
tax benefit, if any, attributable to such Loss. If the amount to be netted hereunder from any payment required under Section 8.1 or 8.2 is determined
after payment by the Indemnifying Party of any amount otherwise required to be paid to an Indemnified Party to this Article VIII, the Indemnified Party shall repay to the Indemnifying Party, promptly after such determination, any amount that the
Indemnifying Party would not have had to pay pursuant to this Article VIII had such determination been made at the time of such payment. 
 With respect to any Loss insured by the title insurance policy described in Section 4.2(d) hereof, the Purchaser Group shall use their Best Efforts to recover from its title insurer prior to seeking indemnification from the Seller
Group. Notwithstanding anything to the contrary in this Agreement, and subject to the previous sentence, the Indemnified Party shall not be obligated to seek recovery from a Collateral Source prior to seeking indemnification from the Indemnifying
Party. 
 Section 8.8. Other Limitations. No claim for breach of representation or warranty shall be made by Purchaser under
Section 8.1(a)(iii) if (a) such claim is based on a fact or an event occurring prior to Closing (whether or not also occurring prior to the date of this Agreement), and (b) such fact or event was disclosed by any Seller prior to the
Closing and included as a Schedule to this Agreement. 
 Section 8.9. Sole/Remedy/Waiver. The parties hereto acknowledge and
agree that the remedies provided for in this Agreement shall be the parties’ sole and exclusive remedy with respect to the subject matter of this Agreement, except for claims based on fraud or willful misconduct. In furtherance of the
foregoing, each party hereby waives, to the fullest extent permitted by applicable Law, any and all other rights, claims and causes of action with respect to the subject matter of this Agreement, (including rights of contribution, if any) known or
unknown, foreseen or unforeseen, which exist or may arise in the future, that it may have against the Sellers or any of the Affiliates, or Purchaser or any of its Affiliates, as the case may be, arising under or based upon any federal, state or
local Law (including, without limitation, any such Law relating to the environmental matters or arising under or based upon any common law or otherwise), except to the extent such rights, claims and causes of action are based on fraud or willful
misconduct. 
 Section 8.10. Indemnification Procedures for Remedial Actions on Purchased Assets. 
  

	 	(a)	 Sellers shall have the right but not the obligation to conduct and control the management of a Remedial Action that is subject to indemnification pursuant to this
Agreement. Sellers must notify the Purchaser Group, within 30 days of receipt of notice of the Purchaser Group’s claim for indemnification for such matter, that (i) it intends to undertake said responsibility or (ii) that more
information is needed from the Purchaser Group before Sellers can reasonably determine that the Purchaser Group’s claim is subject to indemnification pursuant to this Agreement. The Purchaser shall promptly respond to such requests for
information (to the extent such information is reasonably available to the Purchaser Group) and, within 30 days of receipt of such information, Sellers shall notify the Purchaser Group as to whether it shall undertake the Remedial Action. Prior to a
determination by Sellers that it will undertake a Remedial Action 

  

 36 

	 	 
pursuant to this Section 8.10, the Purchaser Group shall take only those actions necessary to comply with applicable Environmental Laws or address
conditions that pose an imminent threat to the environment or public health (unless additional actions are approved by Sellers). 

  

	 	(b)	 In undertaking a Remedial Action pursuant to this Section 8.10, Sellers shall retain a qualified independent environmental consultant, which consultant shall
be subject to the Purchaser Group’s approval (such approval not to be unreasonably delayed or withheld). Sellers shall (i) undertake such Remedial Action to meet the Applicable Remedial Action Standards in a prompt and expeditious fashion,
provided that Sellers may exercise its rights, including its due process right, to contest any requirement imposed or determination made by Governmental Authority with respect to the contemplated Remedial Action; and (ii) not cause, through its
own inaction, any undue delay in obtaining written notice from the appropriate Governmental Authority that no further investigation or remediation is necessary with respect to the matter that is the subject of the indemnification claim to meet the
Applicable Remedial Action Standards or, if no Governmental Authority is involved in such matter, a good faith determination from its environmental consultant that no further investigation or remediation is required to bring the applicable property
into conformance with Applicable Remedial Action Standards. When a Governmental Authority is involved with a Remedial Action, the Sellers shall use its best efforts to obtain written notice from the appropriate Governmental Authority that no further
investigation or remediation is necessary with respect to the matter that is the subject of the indemnification claim to meet the Applicable Remedial Action Standards. Sellers shall comply with all applicable Laws, including all applicable
Environmental Laws and any other requirements that may be imposed by a Governmental Authority, pertaining to Sellers’ performance of Remedial Action pursuant to this Section 8.10; provided however, that Sellers reserve the right to contest
or modify any requirements imposed by a Governmental Authority as provided for under applicable Environmental Laws and Environmental Permits with respect to Sellers’ performance of a Remedial Action. Sellers shall provide copies to the
Purchaser Group of all written notices, final submissions, final work plans, and final reports and shall give the Purchaser Group a reasonable opportunity given the circumstances (at the Purchaser Group’s own expense) to comment on any
submissions Sellers intends to deliver or submit to the appropriate Governmental Authority prior to said submission. The Purchaser Group may, at its own expense, hire its own consultants, attorneys or other professionals to monitor the Remedial
Action, including any field work undertaken by Sellers, and the Purchaser Group shall provide Sellers with the results of all such monitoring. Notwithstanding the above, the Purchaser Group shall not take any actions that shall unreasonably
interfere with, or unreasonably delay, Sellers performance of the Remedial Action. Sellers shall undertake any such work required herein in a manner designed to minimize any disruption, to the greatest extent possible, with the conduct of operations
at the assets. The Purchaser Group shall allow Sellers reasonable access to conduct any of the work contemplated herein and shall cooperate with Sellers in the performance of the Remedial Action, including 

  

 37 

	 	 
providing Sellers with reasonable access to employees and documents as necessary. 

  

	 	(c)	If Sellers decline to undertake the performance of a Remedial Action as provided in Section 8.10, the Purchaser Group shall be entitled to undertake the Remedial Action to meet
the Applicable Remedial Action Standards. The Purchaser Group shall retain a qualified independent environmental consultant, which consultant shall be subject to Sellers’ approval (such approval not to be unreasonably delayed or withheld,
however, if there should be a conflict of interest as a result of the Purchaser Group’s choice of environmental consultant, then the Sellers will use their best efforts to clear any such conflicts if possible and if any conflicts can not be
cleared then the Purchaser Group will retain another independent environmental consultant). The Purchaser Group shall promptly provide copies to Sellers of all notices, correspondence, draft reports, submissions, work plans, and final reports and
shall give Sellers a reasonable opportunity (at Sellers’ own expense) to comment on any submissions the Purchaser Group intends to deliver or submit to any appropriate Governmental Authority prior to said submission. Sellers may, at its own
expense, hire its own consultants, attorneys or other professionals to monitor the Remedial Action, including any field work undertaken by the Purchaser Group, and the Purchaser Group shall provide to Sellers the results of all such field work.
Notwithstanding the above, Sellers shall not take any actions that shall unreasonably interfere with, or unreasonably delay, the Purchaser Group’s performance of the Remedial Action. Sellers’ decision to not to undertake Remedial Action
hereunder shall not limit or affect Sellers’ obligation to indemnify the Purchaser Group for said Remedial Action to the Applicable Remedial Action Standards as otherwise provided in this Agreement. 

 Section 8.11. Limitation on Indemnification for Third Party Claims for Remedial Action. Notwithstanding anything to the contrary in this
Agreement, Sellers’ indemnification obligations under Section 8.1(a) hereof in respect of subsection (i) of the definition of Excluded Environmental Liabilities are subject to the provisions of this Section 8.11. Sellers shall be
responsible for the cost of such Remedial Action only to the extent necessary to meet the Applicable Remedial Action Standard and any other requirements that may be imposed by a Governmental Authority pertaining to Sellers’ performance of a
Remedial Action pursuant to Section 8.10. Sellers shall not be responsible for those costs incurred in connection with a Remedial Action to the extent such costs arise from or are exacerbated by actions of the Purchaser Group, including the
initiation of Remedial Action by the Purchaser Group or at the request of a third party in the absence of a requirement of Environmental Law after the Closing Date, except for those actions that are necessary to address conditions that pose an
imminent threat to the environment or public health. Sellers shall not be responsible for those costs incurred in connection with a Remedial Action to the extent such costs are caused by: (i) a Release of Hazardous Substances in connection with
the Purchaser Group’s operation of the Purchased Assets, or (ii) the Purchaser Group’s negligent, knowing or reckless action resulting in the exacerbation of environmental conditions otherwise subject to the indemnification pursuant
to this Agreement, or (iii) the Purchaser Group’s initiation of Remedial Action in the absence of a requirement of Environmental Law. 
  

 38 

 Section 8.12. No Consequential Damages. EXCEPT WITH RESPECT TO A PARTY’S INDEMNIFICATION
OBLIGATIONS HEREUNDER WITH RESPECT TO THIRD PARTY CLAIMS, NO PARTY TO THIS AGREEMENT SHALL BE LIABLE TO OR OTHERWISE RESPONSIBLE TO ANY OTHER PARTY HERETO OR ANY AFFILIATE OF ANY OTHER PARTY HERETO FOR SPECIAL, CONSEQUENTIAL, INCIDENTAL OR PUNITIVE
DAMAGES OR FOR DIMINUTION IN VALUE OR LOST PROFITS THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OR ANY LIABILITY RETAINED OR ASSUMED HEREUNDER. 
 ARTICLE IX 
 TERMINATION 
 Section 9.1. Termination. This Agreement may be terminated at any time prior to the Closing: 
  

	 	(a)	by written agreement of ABS and Pfizer; 

  

	 	(b)	by either ABS or Pfizer, by giving written notice of such termination to the other party, if the Closing shall not have occurred on or prior to December 31, 2006; or

  

	 	(c)	by either Pfizer or ABS, by giving written notice of such termination to the other party, if any court of competent jurisdiction or other competent Governmental Authority shall have
issued a Governmental Order or taken any other action permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement and such Governmental Order or other action shall have become final and nonappealable;
or 

  

	 	(d)	by either Pfizer or ABS, unilaterally, in accordance with Section 10.10 hereof. 

 Section 9.2. Effect of Termination. 
  

	 	(a)	In the event of the termination of this Agreement in accordance with Section 9.1 hereof, this Agreement shall thereafter become void and have no effect, and no party hereto
shall have any liability to the other parties hereto or their respective Affiliates, directors, officers or employees, except for the obligations of the parties hereto contained in this Section 9.2 and in Sections, 10.1, 10.7, 10.8, 10.9 and
10.11 hereof. 

  

	 	(b)	Notwithstanding anything to the contrary in Section 9.2(a), in the event this Agreement shall be terminated and at such time any party is in material breach of or default under
any term or provision hereof, such termination shall be without prejudice to, and shall not affect, any and all rights to damages that the other party may have hereunder or otherwise under applicable Law. The damages recoverable by the
non-defaulting party shall include, without limiting the generality of the immediately preceding sentence, all attorneys’ fees reasonably incurred by such parties in connection with the transactions contemplated hereby.

  

 39 

 ARTICLE X 
 MISCELLANEOUS 
 Section 10.1. Notices. All notices, requests, consents and other
communications hereunder shall be deemed given: (i) when delivered if delivered personally (including by courier); (ii) on the third day after mailing, if mailed, postage prepaid, by registered or certified mail (return receipt requested);
(iii) on the day after mailing if sent by a nationally recognized overnight delivery service which maintains records of the time, place, and recipient of delivery; or (iv) upon receipt of a confirmed transmission, if sent by telex,
telecopy or facsimile transmission with the original delivered via one of the preceding methods, in each case to the parties at the following addresses or to other such addresses as may be furnished in writing by one party to the others: 

If to any Seller, to: 
 PFIZER INC.

 235 East 42nd Street 
 New
York, NY 10017 
 Telephone: 212-733-4935 
 Facsimile: 212-808-8924 

	 	Attn:	Senior Vice President & 

	 	    	General Counsel 

 with a copy to: 
 FIDDLER, GONZÁLEZ & RODRÍGUEZ, P.S.C. 
 254 Muñoz Rivera Avenue, 6th Floor 
 Hato Rey, Puerto Rico 00918 
 Facsimile No.: (787) 759-3123 

	 	Attention:	Roberto B. Suárez, Esq. 

	 	    	  José Julián Álvarez-Maldonado, Esq. 

 If to the Purchaser Group, to: 
 ABRAXIS BIOSCIENCE, INC. 
 1501 E. Woodfield Rd., Suite 300 
 Schaumberg,
IL 60175-5837 
 Facsimile: (847) 413-2670 
 Attn: CEO 
 With copies to: 
 ABRAXIS BIOSCIENCE, INC. 
 11777 San Vicente Boulevard, Suite 550 
 Los Angeles, CA 90049 
 Facsimile:
(310) 826-8525 
 Attn: General Counsel 
  

 40 

 MARTÍNEZ ODELL & CALABRIA 
 281 Muñoz Rivera Avenue, 16th Floor 
 Hato Rey, Puerto Rico 00918 
 Telephone: (787) 753-8914 
 Facsimile: (787) 753-8402 

	 	Attn:	Lawrence Odell, Esq. 

	 	    	Rogelio Carrasquillo, Esq. 

 Section 10.2.
Amendment; Waiver. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the parties hereto, or in the case of a waiver, by the party
against whom the waiver is to be effective. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any other right, power or privilege. 
 Section 10.3. Assignment. Except as otherwise
provided in Section 10.5, no party to this Agreement may assign any of its rights or obligations under this Agreement without the prior written consent of the other party hereto, except that ABS may transfer or assign, in whole or from time to
time in part, to one or more of its Affiliates, the right to purchase all or a portion of the Purchased Assets, but no such transfer or assignment will relieve ABS of its obligations hereunder. 
 Section 10.4. Entire Agreement. This Agreement (including all Schedules and Exhibits hereto) and the other Transaction Agreements constitute
the entire agreement between the parties hereto with respect to the subject matter hereof and thereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, other than any written agreement of the
parties that expressly provides that it is not superseded by the Transaction Agreements. In the event of any conflict between the terms and conditions of this Agreement and the terms and conditions of the other Transaction Agreements, the terms and
conditions of this Agreement shall prevail. 
 Section 10.5. Fulfillment of Obligations. Any obligation of any party to any other
party under this Agreement, which obligation is performed, satisfied or fulfilled by an Affiliate of such party, shall be deemed to have been performed, satisfied or fulfilled by such party. 
 Section 10.6. Parties in Interest. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and permitted assigns. Nothing in this Agreement, express or implied, is intended to confer upon any Person other than the Purchaser Group, Sellers, or their successors or permitted assigns, any rights or remedies under or by reason of
this Agreement. 
 Section 10.7. Public Disclosure. On or prior to the Closing, the parties agree to obtain the consent of the
other party, which consent shall not be unreasonably withheld, before issuing any press release or making any public statement with respect to this Agreement or the 

  

 41 

 
transactions contemplated hereby and will not issue any such press release or make any such public statement prior to obtaining such consent; provided,
however, that the parties agree to consult with each other with respect to any press releases and public statements the making of which may be required by applicable Law or any listing agreement with any national securities exchange, and will not
issue such press release or make any such public statement prior to such consultation. 
 Section 10.8. Return of Information. If
for any reason whatsoever the transactions contemplated by the Transaction Agreements are not consummated, ABS shall promptly return to Pfizer all books and records furnished by any Seller or any of its respective Affiliates, agents, employees, or
representatives (including all copies, summaries and abstracts, if any, thereof) in accordance with the terms of the Confidentiality Agreement. After the Closing, the provisions of the Confidentiality Agreement shall be of no effect with respect to
any information provided regarding the Purchased Assets. 
 Section 10.9. Expenses. The documentary and stamp Taxes, including
without limitation the internal revenues stamps of the Commonwealth and the stamps of the Public Defendant of the Commonwealth to be affixed and cancelled on the original of the deed of purchase and sale as well as the notarial fees and expenses
relating thereto, and the documentary and stamp Taxes, including without limitation the internal revenues stamps of the Commonwealth and the stamps of the Public Defendant of the Commonwealth to be affixed and cancelled on any certified copy of the
deed of purchase and sale as well as all other charges for filing and recording documents in connection with the transfer of the Purchased Assets, including, but not limited to, those related to the transfer of the Real Property, will be paid by the
Purchaser Group. Except as otherwise expressly provided in this Agreement, whether the transactions contemplated by this Agreement are ever consummated, all costs and expenses incurred in connection with this Agreement and the transactions
contemplated hereby shall be borne by the party incurring such expenses. 
 Section 10.10. Schedules; Supplemental Disclosure.
The disclosure of any matter in any one Schedule shall be deemed to be a disclosure for all purposes of this Agreement, but shall expressly not be deemed to constitute an admission by Pfizer, the Selling LLC, the Purchasing Entity or ABS, or to
otherwise imply, that any such matter is material for the purposes of this Agreement. 
 If between the date of this Agreement and the
Closing Date, either party becomes aware of any fact or condition that causes or constitutes a breach of any of its representations and warranties as of the date of this Agreement, or if either party becomes aware of the occurrence after the date of
this Agreement of any fact or condition that would (except as expressly contemplated by this Agreement) cause or constitute a breach of any such representation or warranty had such representation or warranty been made as of the time of occurrence or
discovery of such fact or condition, then such party will promptly deliver to the other party, prior to the Closing Date, a supplement to the Schedules to this Agreement specifying such fact or condition. During the same period, each party will
promptly notify the other party of the occurrence of any breach of any of its covenants or of the occurrence of any event that may make the satisfaction of the conditions in Article IV of this Agreement impossible or unlikely. Any such disclosure by
a party shall be deemed to cure any breach of the applicable representations, 

  

 42 

 
warranties or covenants made under this Agreement and the other party shall have no claim under this Agreement on the basis of such disclosure(s) except as
set forth in the following paragraphs. 
 Notwithstanding the generality of the foregoing, it is hereby agreed to by the parties that if any
fact or condition disclosed by the Sellers to the Purchaser Group prior to the Closing pursuant to this Section 10.10 has a Material Adverse Effect, then in the Purchaser Group’s sole discretion, the Purchaser Group may elect to terminate
this Agreement unilaterally. 
 Likewise, if any fact or condition is disclosed by the Purchaser Group to the Sellers prior to the Closing
pursuant to this Section 10.10 and has a Material Adverse Effect, then in the Sellers’ sole discretion, the Sellers may elect to terminate this Agreement unilaterally. 
 Section 10.11. Governing Law; Jurisdiction. 
  

	 	(a)	This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to the conflicts of law rules of such state.

  

	 	(b)	With respect to any suit, action or proceeding relating to this Agreement (each, a “Proceeding”), each party hereto irrevocably (i) agrees and consents to be
subject to the jurisdiction of the United States District Court for the Southern District of New York or any New York State court sitting in New York City and (ii) waives any objection which it may have at any time to the laying of venue of any
Proceeding brought in any such court, waives any claim that such Proceeding has been brought in an inconvenient forum and further waives the right to object, with respect to such Proceeding, that such court does not have any jurisdiction over such
party. 

 Section 10.12. Counterparts. This Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, and all of which shall constitute one and the same agreement. Any such counterpart may be executed by facsimile signature with only verbal confirmation, and when so executed and delivered shall be deemed an original and
such counterpart(s) together shall constitute only one original. 
 Section 10.13. Headings. The heading references herein and
the table of contents hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 
 Section 10.14. Severability. Each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under
applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this
Agreement. 
 Section 10.15. No Joint Venture or Partnership. The parties agree that nothing contained herein shall be construed
as making the parties joint ventures or partners. 
 [Remainder of the Page Intentionally Left Blank] 
  

 43 

 IN WITNESS WHEREOF, the parties have executed or caused this Agreement to be executed as of the date
first written above. 
  

			
	 PFIZER INC.

		
	 By:
	 	 /s/ Natale S. Ricciardi

	 Name:
	 	 Natale S. Ricciardi

	 Title:
	 	 Senior Vice President

	
	 ABRAXIS BIOSCIENCE, INC.

		
	 By:
	 	 /s/ Bruce Wendel

	 Name:
	 	 Bruce Wendel

	 Title:
	 	 VP Corporate Development

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]